{
  "1AD.AX": {
    "city": "Bundoora",
    "country": "Australia",
    "currency": "AUD",
    "exchange": "ASX",
    "industry": "Biotechnology",
    "long_name": "AdAlta Limited",
    "market": "au_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "ADALTA FPO",
    "state": "VIC",
    "summary": "AdAlta Limited, a clinical stage biotechnology company, discovers and develops protein therapeutics in Australia. The company's lead i-body drug candidate includes AD-214, which is in Phase I clinical trials for the treatment of idiopathic pulmonary fibrosis and other fibrotic diseases. It has a collaborative partnership with GE Healthcare to discover i-bodies against granzyme B for use as a molecular imaging agent. AdAlta Limited was incorporated in 2006 and is based in Bundoora, Australia.",
    "website": "http://adalta.com.au",
    "zipcode": "3083"
  },
  "1I4.F": {
    "city": "Sydney",
    "country": "Australia",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Medical Devices",
    "long_name": "HeraMED Limited",
    "market": "dr_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "HERAMEDLTD",
    "state": "NSW",
    "summary": "HeraMED Limited, together with its subsidiaries, develops, manufactures, and sells foetal heart beat monitors and other pregnancy monitoring solutions for home use in Australia, Europe, and Israel. The company provides HeraBEAT, a fetal heart rate monitor principally for use by an expectant mother to monitor their fetus' heartbeat. It is also involved in developing EchoBEAT, the next generation of its home-oriented pregnancy monitoring devices; and Orion, an artificial intelligence powered pregnancy monitoring system for pregnancy monitoring analysis. The company has a collaboration agreement with Mayo Clinic for the development of its HeraCARE pregnancy management platform. HeraMED Limited was incorporated in 2011 and is based in Sydney, Australia.",
    "website": "http://www.hera-med.com",
    "zipcode": "2000"
  },
  "1X8.F": {
    "city": "Nedlands",
    "country": "Australia",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Drug Manufacturers - Specialty & Generic",
    "long_name": "Creso Pharma Limited",
    "market": "dr_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "CRESO PHARMA LTD",
    "state": "WA",
    "summary": "Creso Pharma Limited develops, registers, and commercializes pharmaceutical-grade cannabis, and hemp-based nutraceutical products and treatments for human and animal health in Europe, the Middle East, North America, and the Asia Pacific. The company develops and commercializes therapeutic products; and cultivates and harvests cannabis plants, as well as supplies dried cannabis plant retail products. Its products include anibidiol, a complementary feed product for companion animals; cannaQIX, a nutraceutical product containing hemp oil extract, and vitamins and zinc that reduces stress and supports psychological and nervous functions in humans; and topical and skin care products, which include cannaDOL, a CBD-based topical gel associated with a mixture of cooling and warming essential oils. The company also offers nutraceutical products, such as cannaQIX, a hemp oil-derived food supplement under the Cannamics brand. Creso Pharma Limited was incorporated in 2015 and is headquartered in Nedlands, Australia.",
    "website": "http://www.cresopharma.com",
    "zipcode": "6009"
  },
  "26E.F": {
    "city": "Sydney",
    "country": "Australia",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Medical Care Facilities",
    "long_name": "Estia Health Limited",
    "market": "dr_market",
    "market_cap": "Small Cap",
    "sector": "Healthcare",
    "short_name": "ESTIA HEALTH LTD",
    "state": "NSW",
    "summary": "Estia Health Limited operates residential aged care homes in Australia. As of June 30, 2020, it had 69 homes, which include 6,182 resident places in New South Wales, Queensland, South Australia, and Victoria. The company was founded in 2005 and is based in Sydney, Australia.",
    "website": "http://www.estiahealth.com.au",
    "zipcode": "2000"
  },
  "39I.F": {
    "city": "Pinkenba",
    "country": "Australia",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Medical Devices",
    "long_name": "ImpediMed Limited",
    "market": "dr_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "IMPEDIMED LTD",
    "state": "QLD",
    "summary": "ImpediMed Limited, a medical software technology company, together with its subsidiaries, develops, manufactures, and sells bioimpedance spectroscopy (BIS) devices and software services in Australia, North America, and internationally. It offers SOZO, a noninvasive bioimpedance spectroscopy device for the detection of lymphedema and fluid status monitoring of heart failure patients; SFB7, a single-channel, tetrapolar BIS device to analyze body composition in healthy individuals; and ImpediVET, a single-channel, tetrapolar (BIS) device that measures fluid status and tissue composition for veterinary applications. The company sells its devices to hospitals and clinics. ImpediMed Limited was founded in 1999 and is headquartered in Pinkenba, Australia.",
    "website": "http://www.impedimed.com",
    "zipcode": "4008"
  },
  "3AC.F": {
    "city": "Sydney",
    "country": "Australia",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Biotechnology",
    "long_name": "Actinogen Medical Limited",
    "market": "dr_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "ACTINOGEN MEDICAL LTD.",
    "state": "NSW",
    "summary": "Actinogen Medical Limited, a biotechnology company, develops therapies for cognitive impairment associated with chronic neurological, psychiatric, and metabolic diseases in Australia. The company is developing Xanamem, a therapy for Alzheimer's disease, and cognitive impairment associated with schizophrenia, diabetes, and other disorders; and XanADu, which has completed Phase II clinical trials is a double-blind, randomized, and placebo-controlled study to assess the safety, tolerability, and efficacy of Xanamem in subjects with mild Alzheimer's disease. It is also developing XanaHES, a single blinded, central reader blinded, placebo-controlled, and dose escalation study of Xanamem to assess safety and tolerability in healthy elderly subjects. The company was formerly known as Actinogen Limited and changed its name to Actinogen Medical Limited in November 2015. Actinogen Medical Limited was incorporated in 1999 and is headquartered in Sydney, Australia.",
    "website": "http://www.actinogen.com.au",
    "zipcode": "2000"
  },
  "51S.F": {
    "city": "Carlton",
    "country": "Australia",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Biotechnology",
    "long_name": "Cynata Therapeutics Limited",
    "market": "dr_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "CYNATA THERAPEUTICS",
    "state": "VIC",
    "summary": "Cynata Therapeutics Limited, together with its subsidiaries, develops and commercializes a proprietary mesenchymal stem cell technology under the Cymerus brand for human therapeutic use in Australia. The company's lead therapeutic product candidate is CYP-001, which has completed Phase I clinical trial for the treatment of graft versus host disease. It also develops products for the treatment of asthma, heart attack, diabetic wounds, coronary artery disease, acute respiratory distress syndrome, brain cancer, melanoma, sepsis, osteoarthritis, and critical limb ischemia, which are in a preclinical model. The company has a partnership with Monash University, University of Sydney, the Cooperative Research Centre for Cell Therapy Manufacturing, University of New South Wales, Critical Care Research Group, Massachusetts General Hospital, and the Royal College of Surgeons in Ireland to develop stem cell therapies. It also has a strategic partnership with Fujifilm Corporation of Japan for the development and research of Cymerus technology. The company was formerly known as Eco Quest Limited and changed its name to Cynata Therapeutics Limited in October 2013. Cynata Therapeutics Limited was founded in 2011 and is based in Carlton, Australia.",
    "website": "http://www.cynata.com",
    "zipcode": "3053"
  },
  "7JH.F": {
    "city": "Southbank",
    "country": "Australia",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Medical Care Facilities",
    "long_name": "Japara Healthcare Limited",
    "market": "dr_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "JAPARA HEALTH CARE LTD",
    "state": "VIC",
    "summary": "Japara Healthcare Limited, together with its subsidiaries, owns, develops, and operates residential aged care homes in Australia. It operates approximately 4,400 resident places across 51 homes located in Victoria, New South Wales, Queensland, South Australia, and Tasmania; and 180 independent living units across 5 retirement villages. The company was founded in 2005 and is based in Southbank, Australia.",
    "website": "http://japara.com.au",
    "zipcode": "3006"
  },
  "A4B.F": {
    "city": "Mascot",
    "country": "Australia",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Health Information Services",
    "long_name": "ImExHS Limited",
    "market": "dr_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "IMEXHS LTD",
    "state": "NSW",
    "summary": "ImExHS Limited operates as an imaging software as a service and ancillary service provider in Australia and internationally. It is involved in developing and selling Hiruko software platform that comprises radiology information system, which manages the workflow management system with a patient data and image distribution system, as well as picture archiving and communication system that allows healthcare organization to capture, store, view, and share radiology images. The company was founded in 2012 and is headquartered in Mascot, Australia.",
    "website": "http://www.imexhs.com",
    "zipcode": "2020"
  },
  "AC8.AX": {
    "city": "West Perth",
    "country": "Australia",
    "currency": "AUD",
    "exchange": "ASX",
    "industry": "Drug Manufacturers - Specialty & Generic",
    "long_name": "AusCann Group Holdings Ltd",
    "market": "au_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "AUSCANN FPO",
    "state": "WA",
    "summary": "AusCann Group Holdings Ltd, a pharmaceutical company, researches, develops, cultivates, produces, and distributes cannabinoid-based pharmaceuticals in Australia and internationally. It offers hard-shell capsules using Neuvis technology for the treatment of chronic neuropathic pain. The company is based in West Perth, Australia.",
    "website": "http://auscann.com.au",
    "zipcode": "6005"
  },
  "ACNNF": {
    "city": "West Perth",
    "country": "Australia",
    "currency": "USD",
    "exchange": "PNK",
    "industry": "Drug Manufacturers - Specialty & Generic",
    "long_name": "AusCann Group Holdings Ltd",
    "market": "us_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "AUSCANN GROUP HOLDINGS LTD",
    "state": "WA",
    "summary": "AusCann Group Holdings Ltd, a pharmaceutical company, researches, develops, cultivates, produces, and distributes cannabinoid-based pharmaceuticals in Australia and internationally. It offers hard-shell capsules using Neuvis technology for the treatment of chronic neuropathic pain. The company is based in West Perth, Australia.",
    "website": "http://auscann.com.au",
    "zipcode": "6005"
  },
  "ACR.AX": {
    "city": "West Melbourne",
    "country": "Australia",
    "currency": "AUD",
    "exchange": "ASX",
    "industry": "Biotechnology",
    "long_name": "Acrux Limited",
    "market": "au_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "ACRUX FPO",
    "state": "VIC",
    "summary": "Acrux Limited, together with its subsidiaries, develops and commercializes generic and specialty topical pharmaceuticals in Australia, Germany, the United States, and internationally. The company offers testosterone solutions, such as oral tablets, buccal tablets, subcutaneous pellets, transdermal patches, injections, and topical gels for treatment of adult males who have low or no testosterone. It also provides estradiol sprays for women under the Evamist and Lenzetto brand names for the treatment of flushes associated with menopause. Acrux Limited was founded in 1998 and is based in West Melbourne, Australia.",
    "website": "http://www.acrux.com.au",
    "zipcode": "3003"
  },
  "ACW.AX": {
    "city": "Sydney",
    "country": "Australia",
    "currency": "AUD",
    "exchange": "ASX",
    "industry": "Biotechnology",
    "long_name": "Actinogen Medical Limited",
    "market": "au_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "ACTINOGEN FPO",
    "state": "NSW",
    "summary": "Actinogen Medical Limited, a biotechnology company, develops therapies for cognitive impairment associated with chronic neurological, psychiatric, and metabolic diseases in Australia. The company is developing Xanamem, a therapy for Alzheimer's disease, and cognitive impairment associated with schizophrenia, diabetes, and other disorders; and XanADu, which has completed Phase II clinical trials is a double-blind, randomized, and placebo-controlled study to assess the safety, tolerability, and efficacy of Xanamem in subjects with mild Alzheimer's disease. It is also developing XanaHES, a single blinded, central reader blinded, placebo-controlled, and dose escalation study of Xanamem to assess safety and tolerability in healthy elderly subjects. The company was formerly known as Actinogen Limited and changed its name to Actinogen Medical Limited in November 2015. Actinogen Medical Limited was incorporated in 1999 and is headquartered in Sydney, Australia.",
    "website": "http://www.actinogen.com.au",
    "zipcode": "2000"
  },
  "ADO.AX": {
    "city": "Eight Mile Plains",
    "country": "Australia",
    "currency": "AUD",
    "exchange": "ASX",
    "industry": "Biotechnology",
    "long_name": "AnteoTech Limited",
    "market": "au_market",
    "market_cap": "Small Cap",
    "sector": "Healthcare",
    "short_name": "ANTEO TECH FPO",
    "state": "QLD",
    "summary": "AnteoTech Limited engages in developing, commercializing, manufacturing, and distributing products for the life sciences research, vitro diagnostics, energy, and medical device markets primarily in Australia. Its principal technology products include AnteoCoat, which is applicable to the energy sector in lithium-ion batteries; AnteoBind that is applicable to point of care, in vitro, and life science diagnostic sectors. The company also manufactures and sells COVID-19 antigen testing kits. AnteoTech Limited has collaboration agreements with Axxin for for COVID-19 anigen test. The company was formerly known as Anteo Diagnostics Limited and changed its name to AnteoTech Limited in November 2019. AnteoTech Limited was incorporated in 1995 and is headquartered in Eight Mile Plains, Australia.",
    "website": "http://www.anteotech.com",
    "zipcode": "4113"
  },
  "AGH.AX": {
    "city": "Melbourne",
    "country": "Australia",
    "currency": "AUD",
    "exchange": "ASX",
    "industry": "Drug Manufacturers - Specialty & Generic",
    "long_name": "Althea Group Holdings Limited",
    "market": "au_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "ALTHEA FPO",
    "state": "VIC",
    "summary": "Althea Group Holdings Limited cultivates, produces, supplies, imports, and exports pharmaceutical grade medicinal cannabis in Australia, the United Kingdom, and Canada. It also offers a range of education, access, and management services to support eligible patients, healthcare professionals, and pharmacies in navigating medicinal cannabis treatment pathways through Concierge, an online service, as well as Medic, an online education. Althea Group Holdings Limited was founded in 2017 and is based in Melbourne, Australia.",
    "website": "http://www.althea.life",
    "zipcode": "3000"
  },
  "AHC.AX": {
    "city": "Port Melbourne",
    "country": "Australia",
    "currency": "AUD",
    "exchange": "ASX",
    "industry": "Medical Instruments & Supplies",
    "long_name": "Austco Healthcare Limited",
    "market": "au_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "AUS HEALTH FPO",
    "state": "VIC",
    "summary": "Austco Healthcare Limited, together with its subsidiaries, provides communication and clinical workflow management solutions in Australia, New Zealand, Canada, the United Kingdom, the United States, Asia, and the Middle East. The company offers Tacera, an IP based nurse call system for hospitals, and aged care and acute care facilities. It also develops software. The company was formerly known as Azure Healthcare Limited and changed its name to Austco Healthcare Limited in November 2020. Austco Healthcare Limited was incorporated in 2004 and is based in Port Melbourne, Australia.",
    "website": "http://www.austcohealthcare.com",
    "zipcode": "3207"
  },
  "ALC.AX": {
    "city": "South Yarra",
    "country": "Australia",
    "currency": "AUD",
    "exchange": "ASX",
    "industry": "Health Information Services",
    "long_name": "Alcidion Group Limited",
    "market": "au_market",
    "market_cap": "Small Cap",
    "sector": "Healthcare",
    "short_name": "ALCIDION FPO",
    "state": "VIC",
    "summary": "Alcidion Group Limited, together with its subsidiaries, engages in the development and licensing of healthcare software products in Australia, New Zealand, and the United Kingdom. The company offers Miya Precision that combines artificial intelligence, clinical decision support, and mobile alerts in clinical dashboard; Patientrack, a patient safety and communication system; and Smartpage, a messaging and task management platform, which enables hospital staff to communicate and collaborate. It also provides project management, data and analytics, implementation consulting, and integration and support services for digital health projects. The company was formerly known as Alcidion Corporation Pty Ltd and changed its name to Alcidion Group Limited in December 2015. The company was founded in 2000 and is headquartered in South Yarra, Australia.",
    "website": "http://www.alcidion.com",
    "zipcode": "3141"
  },
  "ALT.AX": {
    "city": "Brisbane",
    "country": "Australia",
    "currency": "AUD",
    "exchange": "ASX",
    "industry": "Medical Devices",
    "long_name": "Analytica Limited",
    "market": "au_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "ANALYTICA FPO",
    "state": "QLD",
    "summary": "Analytica Limited designs, develops, and supplies medical devices in Australia, the United Kingdom, and the United States. The company's lead product is PeriCoach system, an e-health treatment system for women used in treatment of stress urinary incontinence. Its PeriCoach comprises a device, Web portal, and smartphone app for evaluating activity in pelvic floor muscles. The company also provides Autostart Burette Infusion System for monitoring and refilling of burettes in intravenous fluid infusion. Analytica Limited was incorporated in 1985 and is based in Brisbane, Australia.",
    "website": "http://www.analyticamedical.com",
    "zipcode": "4000"
  },
  "AMEUF": {
    "city": "Toowong",
    "country": "Australia",
    "currency": "USD",
    "exchange": "PNK",
    "industry": "Medical Devices",
    "long_name": "Anteris Technologies Ltd",
    "market": "us_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "ANTERIS TECHNOLOGIES LTD",
    "state": "QLD",
    "summary": "Anteris Technologies Ltd operates as a structural heart company. The company offers ADAPT technology, which re-engineers xenograft tissue into a pure collagen scaffold; and develops DurAVRTM, a 3D single piece aortic valve for the treatment of aortic stenosis. It also researches and develops regenerative medicine and immunotherapies. The company was formerly known as Admedus Limited and changed its name to Anteris Technologies Ltd in May 2020. Anteris Technologies Ltd was incorporated in 1999 and is based in Toowong, Australia.",
    "website": "http://www.anteristech.com",
    "zipcode": "4066"
  },
  "AMT.AX": {
    "city": "Lane Cove West",
    "country": "Australia",
    "currency": "AUD",
    "exchange": "ASX",
    "industry": "Medical Devices",
    "long_name": "Allegra Orthopaedics Limited",
    "market": "au_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "ALLEGRA FPO",
    "state": "NSW",
    "summary": "Allegra Orthopaedics Limited designs, sells, and distributes orthopaedic implant products in Australia and New Zealand. The company operates through Orthopaedics Division and Innovation Division segments. It offers adult and adolescent clavicle fixation systems; shoulder implants; ulna heads, compression screws, distal radius systems, and hand fracture systems; reconstruction prosthesis, modular tumor and revision systems, partial pelvis replacement, cementless stems, cups, and ceramic prosthesis heads for hips; and knee replacement systems and knee distal first instruments. The company also provides foot and ankle products, such as total ankle replacement systems, toe products, A-curve handles, screws, staples, and foot systems; surgical screws, sawblades, and kirschner wires and pins; NanoFx, a solution for microfracture; and face shields and mask strap holders. The company was formerly known as Advanced Surgical Design & Manufacture Limited and changed its name to Allegra Orthopaedics Limited in November 2014. Allegra Orthopaedics Limited was founded in 1994 and is based in Lane Cove West, Australia.",
    "website": "http://www.allegraorthopaedics.com",
    "zipcode": "2066"
  },
  "ANN.AX": {
    "city": "Richmond",
    "country": "Australia",
    "currency": "AUD",
    "exchange": "ASX",
    "industry": "Medical Instruments & Supplies",
    "long_name": "Ansell Limited",
    "market": "au_market",
    "market_cap": "Mid Cap",
    "sector": "Healthcare",
    "short_name": "ANSELL FPO",
    "state": "VIC",
    "summary": "Ansell Limited designs, develops, and manufactures protection solutions in the Asia Pacific, Europe, the Middle East, Africa, Latin America, Caribbean, and North America. It operates in two segments, Healthcare and Industrial. The Healthcare segment manufactures and markets solutions comprising surgical gloves, single use and examination gloves, and clean and sterile gloves and garments, as well as consumables used by healthcare, life sciences, and industrial workers for a range of customers, including hospitals, surgical centers, dental surgeries, veterinary clinics, first responders, manufacturers, auto repair shops, chemical plants, laboratories, and pharmaceutical companies. The Industrial segment manufactures and markets high-performance hand and chemical protective clothing solutions for a range of industrial applications, including automotive, chemical, metal fabrication, machinery and equipment, food, construction, mining, oil and gas, and first responders. The company was formerly known as Pacific Dunlop Limited and changed its name to Ansell Limited in 2002. Ansell Limited was founded in 1893 and is based in Richmond, Australia.",
    "website": "http://www.ansell.com",
    "zipcode": "3121"
  },
  "ANP.AX": {
    "city": "Toorak",
    "country": "Australia",
    "currency": "AUD",
    "exchange": "ASX",
    "industry": "Drug Manufacturers - Specialty & Generic",
    "long_name": "Antisense Therapeutics Limited",
    "market": "au_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "ANTISENSE FPO",
    "state": "VIC",
    "summary": "Antisense Therapeutics Limited, a biopharmaceutical company, engages in the research and development of novel antisense pharmaceuticals in Australia. Its product pipeline comprises ATL1102, an antisense inhibitor of CD49d that has completed Phase IIa for the treatment of multiple sclerosis, Duchennes Muscular Dystrophy, multiple sclerosis, asthma, and other inflammatory indications. The company's product pipeline also includes ATL1103, a second generation antisense drug designed to block growth hormone receptor expression thereby reducing levels of the hormone insulin-like growth factor-I in the blood, as well as to treat diseases associated with excessive growth hormone action that has completed Phase II clinical trial. Antisense Therapeutics Limited is based in Toorak, Australia.",
    "website": "http://www.antisense.com.au",
    "zipcode": "3142"
  },
  "ANR.AX": {
    "city": "Carlton",
    "country": "Australia",
    "currency": "AUD",
    "exchange": "ASX",
    "industry": "Biotechnology",
    "long_name": "Anatara Lifesciences Limited",
    "market": "au_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "ANATARA LS FPO",
    "state": "VIC",
    "summary": "Anatara Lifesciences Limited engages in the research and development of non-antibiotic oral solutions for gastrointestinal diseases in animals and humans in Australia. Its lead product candidate includes Detach, a non-antibiotic therapy that prevents and treats diarrhea disease in piglets. The company is also developing bromelain formulations for gastrointestinal health in humans, as well as for piglets and poultry. Anatara Lifesciences Limited was incorporated in 2010 and is based in Carlton, Australia.",
    "website": "http://www.anataralifesciences.com",
    "zipcode": "3053"
  },
  "ANSLF": {
    "city": "Richmond",
    "country": "Australia",
    "currency": "USD",
    "exchange": "PNK",
    "industry": "Medical Instruments & Supplies",
    "long_name": "Ansell Limited",
    "market": "us_market",
    "market_cap": "Mid Cap",
    "sector": "Healthcare",
    "short_name": "ANSELL",
    "state": "VIC",
    "summary": "Ansell Limited designs, develops, and manufactures protection solutions in the Asia Pacific, Europe, the Middle East, Africa, Latin America, Caribbean, and North America. It operates in two segments, Healthcare and Industrial. The Healthcare segment manufactures and markets solutions comprising surgical gloves, single use and examination gloves, and clean and sterile gloves and garments, as well as consumables used by healthcare, life sciences, and industrial workers for a range of customers, including hospitals, surgical centers, dental surgeries, veterinary clinics, first responders, manufacturers, auto repair shops, chemical plants, laboratories, and pharmaceutical companies. The Industrial segment manufactures and markets high-performance hand and chemical protective clothing solutions for a range of industrial applications, including automotive, chemical, metal fabrication, machinery and equipment, food, construction, mining, oil and gas, and first responders. The company was formerly known as Pacific Dunlop Limited and changed its name to Ansell Limited in 2002. Ansell Limited was founded in 1893 and is based in Richmond, Australia.",
    "website": "http://www.ansell.com",
    "zipcode": "3121"
  },
  "ANSLY": {
    "city": "Richmond",
    "country": "Australia",
    "currency": "USD",
    "exchange": "PNK",
    "industry": "Medical Instruments & Supplies",
    "long_name": "Ansell Limited",
    "market": "us_market",
    "market_cap": "Mid Cap",
    "sector": "Healthcare",
    "short_name": "ANSELL",
    "state": "VIC",
    "summary": "Ansell Limited designs, develops, and manufactures protection solutions in the Asia Pacific, Europe, the Middle East, Africa, Latin America, Caribbean, and North America. It operates in two segments, Healthcare and Industrial. The Healthcare segment manufactures and markets solutions comprising surgical gloves, single use and examination gloves, and clean and sterile gloves and garments, as well as consumables used by healthcare, life sciences, and industrial workers for a range of customers, including hospitals, surgical centers, dental surgeries, veterinary clinics, first responders, manufacturers, auto repair shops, chemical plants, laboratories, and pharmaceutical companies. The Industrial segment manufactures and markets high-performance hand and chemical protective clothing solutions for a range of industrial applications, including automotive, chemical, metal fabrication, machinery and equipment, food, construction, mining, oil and gas, and first responders. The company was formerly known as Pacific Dunlop Limited and changed its name to Ansell Limited in 2002. Ansell Limited was founded in 1893 and is based in Richmond, Australia.",
    "website": "http://www.ansell.com",
    "zipcode": "3121"
  },
  "ANW.F": {
    "city": "Carlton",
    "country": "Australia",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Biotechnology",
    "long_name": "Immuron Limited",
    "market": "dr_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "IMMURON LTD",
    "state": "VIC",
    "summary": "Immuron Limited, a biopharmaceutical company, researches and develops oral immunotherapy polyclonal antibodies for the treatment and prevention of infectious and immune modulated diseases in Australia, the United States, and internationally. The company operates through two segments, Research and Development, and Hyperimmune Products. The company markets Travelan and Protectyn for the prevention of travellers' diarrhea. Its lead product candidates include IMM-124E that is in Phase II clinical trials for non-alcoholic steatohepatitis, severe alcoholic hepatitis, and non-alcoholic fatty liver disease, as well as used in antiviral activity against the COVID-19 virus in laboratory studies; and IMM-529, a clinical stage product for clostridium difficile infections. Immuron Limited was founded in 1994 and is based in Carlton, Australia.",
    "website": "http://www.immuron.com.au",
    "zipcode": "3053"
  },
  "ANWA.F": {
    "city": "Carlton",
    "country": "Australia",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Biotechnology",
    "long_name": "Immuron Limited",
    "market": "dr_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "IMMURON LTD SPON.ADR 40",
    "state": "VIC",
    "summary": "Immuron Limited, a biopharmaceutical company, researches and develops oral immunotherapy polyclonal antibodies for the treatment and prevention of infectious and immune modulated diseases in Australia, the United States, and internationally. The company operates through two segments, Research and Development, and Hyperimmune Products. The company markets Travelan and Protectyn for the prevention of travellers' diarrhea. Its lead product candidates include IMM-124E that is in Phase II clinical trials for non-alcoholic steatohepatitis, severe alcoholic hepatitis, and non-alcoholic fatty liver disease, as well as used in antiviral activity against the COVID-19 virus in laboratory studies; and IMM-529, a clinical stage product for clostridium difficile infections. Immuron Limited was founded in 1994 and is based in Carlton, Australia.",
    "website": "http://www.immuron.com.au",
    "zipcode": "3053"
  },
  "APH.AX": {
    "city": "Geelong",
    "country": "Australia",
    "currency": "AUD",
    "exchange": "ASX",
    "industry": "Drug Manufacturers - Specialty & Generic",
    "long_name": "Australian Primary Hemp Limited",
    "market": "au_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "APHEMP FPO",
    "state": "VIC",
    "summary": "Australian Primary Hemp Limited manufactures and distributes hemp products under the Australian Primary Hemp brand to retail, wholesale, and white label customers in Australia. The company offers hemp seeds, cold pressed hemp oil, hemp fiber powder, hemp flour, hemp protein powder, hemp and bush balm mint hand sanitizers, hemp boost, hemp balance, and hemp and honey nut bars. It is also involved in the cultivation and production of hemp; handling various areas of hemp seed selection, farming, processing, and distribution; hemp contract packaging; and bulk and retail sale of edible hemp products. The company was founded in 2016 and is headquartered in Geelong, Australia.",
    "website": "http://www.ausprimaryhemp.com.au",
    "zipcode": "3220"
  },
  "API.AX": {
    "city": "Camberwell",
    "country": "Australia",
    "currency": "AUD",
    "exchange": "ASX",
    "industry": "Medical Distribution",
    "long_name": "Australian Pharmaceutical Industries Limited",
    "market": "au_market",
    "market_cap": "Small Cap",
    "sector": "Healthcare",
    "short_name": "AUST PHARM FPO",
    "state": "VIC",
    "summary": "Australian Pharmaceutical Industries Limited engages in the wholesale distribution of pharmaceutical, medical, health, beauty, and lifestyle products to pharmacies primarily in Australia. It also retails health and beauty products to consumers through a network of Priceline and Priceline Pharmacy franchise stores, and company owned Priceline stores in Australia; sells beauty products through Clear Skincare network of clinics in Australia and New Zealand; and manufactures and distributes pharmaceutical and toiletry goods to New Zealand, Australian, and Asian markets, as well as provides cosmetic products and non-invasive aesthetic beauty services. The company was founded in 1910 and is based in Camberwell, Australia.",
    "website": "http://www.api.net.au",
    "zipcode": "3124"
  },
  "ARPC": {
    "city": "Melbourne",
    "country": "Australia",
    "currency": "USD",
    "exchange": "PNK",
    "industry": "Medical Care Facilities",
    "long_name": "Arem Pacific Corporation",
    "market": "us_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "AREM PACIFIC CORPORATION",
    "state": "VIC",
    "summary": "Arem Pacific Corporation operates a wellness center in Victoria State, Australia. The company's wellness center provides various services, including acupressure/reflexology; neck, shoulder, back, legs, and full body massages; foot massages; cupping; and deep tissue and hot oil massage. Arem Pacific Corporation is based in Melbourne, Australia.",
    "website": "http://www.arempac.com",
    "zipcode": "3000"
  },
  "ARUXF": {
    "city": "West Melbourne",
    "country": "Australia",
    "currency": "USD",
    "exchange": "PNK",
    "industry": "Biotechnology",
    "long_name": "Acrux Limited",
    "market": "us_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "ACRUX",
    "state": "VIC",
    "summary": "Acrux Limited, together with its subsidiaries, develops and commercializes generic and specialty topical pharmaceuticals in Australia, Germany, the United States, and internationally. The company offers testosterone solutions, such as oral tablets, buccal tablets, subcutaneous pellets, transdermal patches, injections, and topical gels for treatment of adult males who have low or no testosterone. It also provides estradiol sprays for women under the Evamist and Lenzetto brand names for the treatment of flushes associated with menopause. Acrux Limited was founded in 1998 and is based in West Melbourne, Australia.",
    "website": "http://www.acrux.com.au",
    "zipcode": "3003"
  },
  "AT1.AX": {
    "city": "Leichhardt",
    "country": "Australia",
    "currency": "AUD",
    "exchange": "ASX",
    "industry": "Medical Devices",
    "long_name": "Atomo Diagnostics Limited",
    "market": "au_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "ATOMO DIAG FPO",
    "state": "NSW",
    "summary": "Atomo Diagnostics Limited researches, designs, develops, manufactures, and sells medical devices for blood-based rapid testing for professional use and self-testing. The company offers AtomoRapid RDT platforms to suit various blood-based lateral flow test assays and are appropriate for a range of applications, including screening for chronic conditions and detection of infectious diseases. Its rapid test devices are used by healthcare professionals and by consumers to screen for a range of diseases and medical conditions, including HIV infection. The company has operations in Europe, Asia, Africa, and Central and South America. Atomo Diagnostics Limited was founded in 2010 and is headquartered in Leichhardt, Australia.",
    "website": "http://atomodiagnostics.com",
    "zipcode": "2040"
  },
  "ATH.AX": {
    "city": "Melbourne",
    "country": "Australia",
    "currency": "AUD",
    "exchange": "ASX",
    "industry": "Biotechnology",
    "long_name": "Alterity Therapeutics Limited",
    "market": "au_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "ALTERITY FPO",
    "state": "VIC",
    "summary": "Alterity Therapeutics Limited researches and develops therapeutic drugs for the treatment of Parkinsonian's disease and other neurodegenerative diseases in Australia. The company's lead drug candidates is ATH434 that has completed Phase I clinical trial for the treatment of Parkinson's disease. It is also developing PBT2 for used as an antimicrobial agent. The company was formerly known as Prana Biotechnology Limited and changed its name to Alterity Therapeutics Limited in April 2019. The company was founded in 1997 and is based in Melbourne, Australia.",
    "website": "http://www.alteritytherapeutics.com",
    "zipcode": "3000"
  },
  "ATHE": {
    "city": "Melbourne",
    "country": "Australia",
    "currency": "USD",
    "exchange": "NCM",
    "industry": "Biotechnology",
    "long_name": "Alterity Therapeutics Limited",
    "market": "us_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "Alterity Therapeutics Limited",
    "state": "VIC",
    "summary": "Alterity Therapeutics Limited researches and develops therapeutic drugs for the treatment of Parkinsonian's disease and other neurodegenerative diseases in Australia. The company's lead drug candidates is ATH434 that has completed Phase I clinical trial for the treatment of Parkinson's disease. It is also developing PBT2 for used as an antimicrobial agent. The company was formerly known as Prana Biotechnology Limited and changed its name to Alterity Therapeutics Limited in April 2019. The company was founded in 1997 and is based in Melbourne, Australia.",
    "website": "http://www.alteritytherapeutics.com",
    "zipcode": "3000"
  },
  "ATHJF": {
    "city": "Toorak",
    "country": "Australia",
    "currency": "USD",
    "exchange": "PNK",
    "industry": "Drug Manufacturers - Specialty & Generic",
    "long_name": "Antisense Therapeutics Limited",
    "market": "us_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "ANTISENSE THERAPEUTICS",
    "state": "VIC",
    "summary": "Antisense Therapeutics Limited, a biopharmaceutical company, engages in the research and development of novel antisense pharmaceuticals in Australia. Its product pipeline comprises ATL1102, an antisense inhibitor of CD49d that has completed Phase IIa for the treatment of multiple sclerosis, Duchennes Muscular Dystrophy, multiple sclerosis, asthma, and other inflammatory indications. The company's product pipeline also includes ATL1103, a second generation antisense drug designed to block growth hormone receptor expression thereby reducing levels of the hormone insulin-like growth factor-I in the blood, as well as to treat diseases associated with excessive growth hormone action that has completed Phase II clinical trial. Antisense Therapeutics Limited is based in Toorak, Australia.",
    "website": "http://www.antisense.com.au",
    "zipcode": "3142"
  },
  "ATX.AX": {
    "city": "Melbourne",
    "country": "Australia",
    "currency": "AUD",
    "exchange": "ASX",
    "industry": "Biotechnology",
    "long_name": "Amplia Therapeutics Limited",
    "market": "au_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "AMPLIA FPO",
    "state": "VIC",
    "summary": "Amplia Therapeutics Limited, a pharmaceutical company, focuses on advancing a pipeline of focal adhesion kinase (FAK) inhibitors for cancer and fibrosis in Australia. The company's clinical development pipeline comprises two lead molecules, AMP945 and AMP886 that inhibits (FAK). It has a collaboration agreement with the Garvan Institute of Media Research in Sydney. The company was formerly known as Innate Immunotherapeutics Limited and changed its name to Amplia Therapeutics Limited in September 2018. Amplia Therapeutics Limited was incorporated in 2000 and is based in Melbourne, Australia.",
    "website": "http://www.ampliatx.com",
    "zipcode": "3000"
  },
  "AVE.AX": {
    "city": "Clayton",
    "country": "Australia",
    "currency": "AUD",
    "exchange": "ASX",
    "industry": "Biotechnology",
    "long_name": "Avecho Biotechnology Limited",
    "market": "au_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "AVECHO FPO",
    "state": "VIC",
    "summary": "Avecho Biotechnology Limited, a biotechnology company, develops, produces, sells, and licenses products using its patented platform technology, Targeted Penetration Matrix (TPM) drug delivery system for the pharmaceutical, animal health, and nutrition industries in Australia and internationally. The company operates through Production, Human Health, and Other segments. It offers TPM and Vital ET products for use in drug delivery and cosmetic formulations; and develops TPM/Oxymorphone and TPM/Oxycodone. The company's human health portfolio covers delivery of pharmaceutical products through gels, injectables, and patches. It provides non-antibiotic feed additive products to enhance feed efficiency and the health of livestock animals. The company was formerly known as Phosphagenics Limited and changed its name to Avecho Biotechnology Limited in May 2019. Avecho Biotechnology Limited was incorporated in 1992 is based in Clayton, Australia.",
    "website": "http://avecho.com.au",
    "zipcode": "3168"
  },
  "AVR.AX": {
    "city": "Toowong",
    "country": "Australia",
    "currency": "AUD",
    "exchange": "ASX",
    "industry": "Medical Devices",
    "long_name": "Anteris Technologies Ltd",
    "market": "au_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "ANTERIS FPO",
    "state": "QLD",
    "summary": "Anteris Technologies Ltd operates as a structural heart company. The company offers ADAPT technology, which re-engineers xenograft tissue into a pure collagen scaffold; and develops DurAVRTM, a 3D single piece aortic valve for the treatment of aortic stenosis. It also researches and develops regenerative medicine and immunotherapies. The company was formerly known as Admedus Limited and changed its name to Anteris Technologies Ltd in May 2020. Anteris Technologies Ltd was incorporated in 1999 and is based in Toowong, Australia.",
    "website": "http://www.anteristech.com",
    "zipcode": "4066"
  },
  "AWY.F": {
    "city": "Toorak",
    "country": "Australia",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Drug Manufacturers - Specialty & Generic",
    "long_name": "Antisense Therapeutics Limited",
    "market": "dr_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "ANTISENSE THERAPEUTICS",
    "state": "VIC",
    "summary": "Antisense Therapeutics Limited, a biopharmaceutical company, engages in the research and development of novel antisense pharmaceuticals in Australia. Its product pipeline comprises ATL1102, an antisense inhibitor of CD49d that has completed Phase IIa for the treatment of multiple sclerosis, Duchennes Muscular Dystrophy, multiple sclerosis, asthma, and other inflammatory indications. The company's product pipeline also includes ATL1103, a second generation antisense drug designed to block growth hormone receptor expression thereby reducing levels of the hormone insulin-like growth factor-I in the blood, as well as to treat diseases associated with excessive growth hormone action that has completed Phase II clinical trial. Antisense Therapeutics Limited is based in Toorak, Australia.",
    "website": "http://www.antisense.com.au",
    "zipcode": "3142"
  },
  "B1N.F": {
    "city": "Thebarton",
    "country": "Australia",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Biotechnology",
    "long_name": "Bionomics Limited",
    "market": "dr_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "BIONOMICS LTD.",
    "state": "SA",
    "summary": "Bionomics Limited, a clinical-stage biopharmaceutical company, discovers and develops novel drug candidates for the treatment of central nervous system disorders and cancers in Australia and the United States. The company's lead drug candidate includes BNC210, a negative allosteric modulator of the a7 nicotinic acetylcholine receptor, which has completed phase 2 clinical trial for the treatment of anxiety, panic, agitation, and post-traumatic stress disorder. It also develops BNC375, a small molecule therapeutics for the treatment of cognitive impairment in Alzheimer's disease; BNC101, a monoclonal antibody that has completed phase 1 clinical trial targets cancer stem cells; and BNC105, a vascular disrupting agent, which is in phase 2 clinical trial for the treatment of refractory colorectal cancer, and phase 1 clinical trial for the treatment of patients with relapsed/refractory chronic lymphocytic leukemia. In addition, the company offers ionX, an integrated platform of genomics discoveries and technologies. Bionomics Limited has a strategic partnership with Merck & Co., Inc. The company was incorporated in 1996 and is based in Thebarton, Australia.",
    "website": "http://www.bionomics.com.au",
    "zipcode": "5031"
  },
  "BD1.AX": {
    "city": "South Perth",
    "country": "Australia",
    "currency": "AUD",
    "exchange": "ASX",
    "industry": "Diagnostics & Research",
    "long_name": "BARD1 Life Sciences Limited",
    "market": "au_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "BARD1 LIFE FPO",
    "state": "WA",
    "summary": "BARD1 Life Sciences Limited engages in the research and development of non-invasive diagnostic tests for early detection of cancer in Australia. The company offers hTERT test for diagnosis of bladder cancer, with the development-stage BARD1 autoantibody test for early detection of ovarian, breast and lung cancers; hTERT ICC test, an antibody-based immunocytochemistry stain that detects a component of telomerase; EXO-NET, a technology to capture and isolation of exosomes from any liquid biopsy sample; and BARD1 autoantibodies test to evaluate autoantibody panels and algorithms for detection of ovarian, breast and lung cancers. BARD1 Life Sciences Limited was incorporated in 1983 and is headquartered in South Perth, Australia.",
    "website": "http://www.bard1.com",
    "zipcode": "3168"
  },
  "BGT.AX": {
    "city": "Melbourne",
    "country": "Australia",
    "currency": "AUD",
    "exchange": "ASX",
    "industry": "Biotechnology",
    "long_name": "Bio-Gene Technology Limited",
    "market": "au_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "BIOGENETEC FPO",
    "state": "VIC",
    "summary": "Bio-Gene Technology Limited, a biotechnology company, engages in developing insecticides/pesticides for animal health, crop protection, public health, and consumer applications in Australia. It is involved in developing Flavocide, a beta-triketone insecticide product; and Qcide, a natural oil extracted from the leaves of rare eucalyptus trees. The company has a research collaboration agreement with James Cook University for the development of a tissue culture system to support the expansion of tree plantations and scale-up of future Qcide oil production. It also has collaborations with Pacific Discovery Services for studying Flavocide's mode of action; and the Queensland Department of Agriculture and Fisheries for assessing activity against grain storage pests. Bio-Gene Technology Limited was incorporated in 1995 and is based in Melbourne, Australia.",
    "website": "http://www.bio-gene.com.au",
    "zipcode": "3000"
  },
  "BIT.AX": {
    "city": "North Ryde",
    "country": "Australia",
    "currency": "AUD",
    "exchange": "ASX",
    "industry": "Biotechnology",
    "long_name": "Biotron Limited",
    "market": "au_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "BIOTRON FPO",
    "state": "NSW",
    "summary": "Biotron Limited, a biotechnology company, engages in the developing and commercializing small molecule products to treat various viral diseases in Australia. Its lead antiviral drug is BIT225, which is in Phase II clinical trials for the treatment of HIV-1 and hepatitis C virus infections. The company also develops a portfolio of preclinical antiviral drugs. Biotron Limited was incorporated in 1999 and is based in North Ryde, Australia.",
    "website": "http://www.biotron.com.au",
    "zipcode": "2113"
  },
  "BITRF": {
    "city": "North Ryde",
    "country": "Australia",
    "currency": "USD",
    "exchange": "PNK",
    "industry": "Biotechnology",
    "long_name": "Biotron Limited",
    "market": "us_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "BIOTRON",
    "state": "NSW",
    "summary": "Biotron Limited, a biotechnology company, engages in the developing and commercializing small molecule products to treat various viral diseases in Australia. Its lead antiviral drug is BIT225, which is in Phase II clinical trials for the treatment of HIV-1 and hepatitis C virus infections. The company also develops a portfolio of preclinical antiviral drugs. Biotron Limited was incorporated in 1999 and is based in North Ryde, Australia.",
    "website": "http://www.biotron.com.au",
    "zipcode": "2113"
  },
  "BNO.AX": {
    "city": "Thebarton",
    "country": "Australia",
    "currency": "AUD",
    "exchange": "ASX",
    "industry": "Biotechnology",
    "long_name": "Bionomics Limited",
    "market": "au_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "BIONOMICS FPO",
    "state": "SA",
    "summary": "Bionomics Limited, a clinical-stage biopharmaceutical company, discovers and develops novel drug candidates for the treatment of central nervous system disorders and cancers in Australia and the United States. The company's lead drug candidate includes BNC210, a negative allosteric modulator of the a7 nicotinic acetylcholine receptor, which has completed phase 2 clinical trial for the treatment of anxiety, panic, agitation, and post-traumatic stress disorder. It also develops BNC375, a small molecule therapeutics for the treatment of cognitive impairment in Alzheimer's disease; BNC101, a monoclonal antibody that has completed phase 1 clinical trial targets cancer stem cells; and BNC105, a vascular disrupting agent, which is in phase 2 clinical trial for the treatment of refractory colorectal cancer, and phase 1 clinical trial for the treatment of patients with relapsed/refractory chronic lymphocytic leukemia. In addition, the company offers ionX, an integrated platform of genomics discoveries and technologies. Bionomics Limited has a strategic partnership with Merck & Co., Inc. The company was incorporated in 1996 and is based in Thebarton, Australia.",
    "website": "http://www.bionomics.com.au",
    "zipcode": "5031"
  },
  "BNOEF": {
    "city": "Thebarton",
    "country": "Australia",
    "currency": "USD",
    "exchange": "PNK",
    "industry": "Biotechnology",
    "long_name": "Bionomics Limited",
    "market": "us_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "BIONOMICS LTD",
    "state": "SA",
    "summary": "Bionomics Limited, a clinical-stage biopharmaceutical company, discovers and develops novel drug candidates for the treatment of central nervous system disorders and cancers in Australia and the United States. The company's lead drug candidate includes BNC210, a negative allosteric modulator of the a7 nicotinic acetylcholine receptor, which has completed phase 2 clinical trial for the treatment of anxiety, panic, agitation, and post-traumatic stress disorder. It also develops BNC375, a small molecule therapeutics for the treatment of cognitive impairment in Alzheimer's disease; BNC101, a monoclonal antibody that has completed phase 1 clinical trial targets cancer stem cells; and BNC105, a vascular disrupting agent, which is in phase 2 clinical trial for the treatment of refractory colorectal cancer, and phase 1 clinical trial for the treatment of patients with relapsed/refractory chronic lymphocytic leukemia. In addition, the company offers ionX, an integrated platform of genomics discoveries and technologies. Bionomics Limited has a strategic partnership with Merck & Co., Inc. The company was incorporated in 1996 and is based in Thebarton, Australia.",
    "website": "http://www.bionomics.com.au",
    "zipcode": "5031"
  },
  "BOT.AX": {
    "city": "North Perth",
    "country": "Australia",
    "currency": "AUD",
    "exchange": "ASX",
    "industry": "Biotechnology",
    "long_name": "Botanix Pharmaceuticals Limited",
    "market": "au_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "BOTANIX FPO",
    "state": "WA",
    "summary": "Botanix Pharmaceuticals Limited, a clinical stage synthetic cannabinoid pharmaceutical company, engages in the research and development of dermatology and antimicrobial products in Australia. It offers BTX 1503, a transdermal gel formulation for the treatment of serious acne in adults and teenagers that has completed Phase II clinical trials; BTX 1801, which is in Phase IIa clinical trials for the treatment of staphylococcus aureus and methicillin resistant staphylococcus aureus; and BTX 1702 that is in Phase II clinical trials for the treatment of papulopustular rosacea. The company was incorporated in 1984 and is based in North Perth, Australia.",
    "website": "http://www.botanixpharma.com",
    "zipcode": "6006"
  },
  "BPN.F": {
    "city": "Melbourne",
    "country": "Australia",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Health Information Services",
    "long_name": "Medibio Limited",
    "market": "dr_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "MEDIBIO LTD",
    "state": "VIC",
    "summary": "Medibio Limited, a health technology company, researches, develops, and commercializes mental health technology to assist in the screening, diagnosing, monitoring, and management of depression and other mental health conditions in Australia and the United States. It offers mental well-being solutions for businesses through corporate health product; and develops products for healthcare provider market. Medibio Limited has a clinical trial agreement with MedBridge Healthcare LLC to support Medibio's sleep analysis of depressive burden (SADB) trial. The company was formerly known as BioProspect Limited and changed its name to Medibio Limited in November 2014. Medibio Limited was incorporated in 1987 and is based in Melbourne, Australia.",
    "website": "http://medibio.com.au",
    "zipcode": "3205"
  },
  "BTC.AX": {
    "city": "Camberwell",
    "country": "Australia",
    "currency": "AUD",
    "exchange": "ASX",
    "industry": "Biotechnology",
    "long_name": "BTC Health Limited",
    "market": "au_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "BTC HEALTH FPO",
    "state": "VIC",
    "summary": "BTC Health Limited is a Pooled Development Fund managed by LHC Capital Partners Pty Ltd specializing in seed/startup, early venture, mid venture, late venture, emerging growth and growth capital investments. It makes investments in the healthcare and biotechnology sector with a focus on post-genomics, stem cell biology, convergence, silicon biology, and nanomedicine. Within post-genomics, it invests in functional genomics, transcriptomics, proteomics, structural genomics, glycomics, and pharmacogenomics. In the stem cell biology sector, the fund focuses on stem cell therapies. Within convergent technologies, it invests in biomaterials, bionics, biosensors, tissue engineering, microfluidics, and moletronics. In the silicon biology sector, the fund focuses on structure-based drug design, virtual screening, computational library design, and in silico ADME/tox. It invests in companies based in Australia. The fund invests in both listed and unlisted companies.",
    "website": "http://www.btchealth.com.au/",
    "zipcode": "3124"
  },
  "BXN.AX": {
    "city": "Sydney",
    "country": "Australia",
    "currency": "AUD",
    "exchange": "ASX",
    "industry": "Biotechnology",
    "long_name": "Bioxyne Limited",
    "market": "au_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "BIOXYNE FPO",
    "state": "NSW",
    "summary": "Bioxyne Limited, a life sciences and health products company, researches, develops, manufactures, markets, and distributes consumer dietary supplements based on the proprietary probiotic strain of Lactobacillus Fermentum PCC. The company operates in two segments, Wholesale Sales and Direct Sales segments. It also engages in developing a range of functional foods and beauty products. The company's products portfolio include BK18, a dairy based food supplement; Allura, a beauty drink for women's weight management; Mustang, a nutritional shake for men's weight management; Mymana, a colostrum and fortified milk formula for nutrition and immune support; and BEssence, an anti-ageing serum. In addition, it offers its probiotic products under the Progastrim and proTract names. The company provides its products online, as well as through retail channels in Australia, the United States, New Zealand, and Asia. Bioxyne Limited was incorporated in 1998 and is headquartered in Sydney, Australia.",
    "website": "http://www.bioxyne.com",
    "zipcode": "2000"
  },
  "BXPHF": {
    "city": "North Perth",
    "country": "Australia",
    "currency": "USD",
    "exchange": "PNK",
    "industry": "Biotechnology",
    "long_name": "Botanix Pharmaceuticals Limited",
    "market": "us_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "BOTANIX PHARMACEUTICALS LTD",
    "state": "WA",
    "summary": "Botanix Pharmaceuticals Limited, a clinical stage synthetic cannabinoid pharmaceutical company, engages in the research and development of dermatology and antimicrobial products in Australia. It offers BTX 1503, a transdermal gel formulation for the treatment of serious acne in adults and teenagers that has completed Phase II clinical trials; BTX 1801, which is in Phase IIa clinical trials for the treatment of staphylococcus aureus and methicillin resistant staphylococcus aureus; and BTX 1702 that is in Phase II clinical trials for the treatment of papulopustular rosacea. The company was incorporated in 1984 and is based in North Perth, Australia.",
    "website": "http://www.botanixpharma.com",
    "zipcode": "6006"
  },
  "CAJ.AX": {
    "city": "East Melbourne",
    "country": "Australia",
    "currency": "AUD",
    "exchange": "ASX",
    "industry": "Medical Care Facilities",
    "long_name": "Capitol Health Limited",
    "market": "au_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "CAPITOL H FPO",
    "state": "VIC",
    "summary": "Capitol Health Limited provides diagnostic imaging and related services to the healthcare market in Australia. The company owns and operates clinics in Victoria, Tasmania, and Western Australia. It offers a range of diagnostic imaging services, including general x-ray, magnetic resonance imaging, ultrasound, mammography, Doppler, orthopantomogram, echocardiography, computed tomography, CT angiography, cone beam CT, nuclear medicine, bone densitometry, and fluoroscopy. The company was founded in 2005 and is headquartered in East Melbourne, Australia.",
    "website": "http://www.capitolhealth.com.au",
    "zipcode": "3002"
  },
  "CALZF": {
    "city": "Port Melbourne",
    "country": "Australia",
    "currency": "USD",
    "exchange": "PNK",
    "industry": "Biotechnology",
    "long_name": "PolyNovo Limited",
    "market": "us_market",
    "market_cap": "Small Cap",
    "sector": "Healthcare",
    "short_name": "POLYNOVO LIMITED",
    "state": "VIC",
    "summary": "Polynovo Limited develops medical devices in the United States, Australia, New Zealand, and internationally. The company offers NovoSorb Biodegradable Temporising Matrix, which is used in a fully debrided clean surgical wound to physiologically close the wound. It is also developing Syntrel hernia devices for hernia repair; breast devices in partnership with Establishment Labs; NovoSorb dermal beta cell implant in collaboration with BetaCell Technologies Pty Ltd; and NovoSorb drug elution depots. The company was formerly known as Calzada Limited and changed its name to Polynovo Limited in November 2014. Polynovo Limited was incorporated in 1998 and is based in Port Melbourne, Australia.",
    "website": "http://www.polynovo.com.au",
    "zipcode": "3207"
  },
  "CAN.AX": {
    "city": "Bundoora",
    "country": "Australia",
    "currency": "AUD",
    "exchange": "ASX",
    "industry": "Drug Manufacturers - Specialty & Generic",
    "long_name": "Cann Group Limited",
    "market": "au_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "CANN GROUP FPO",
    "state": "VIC",
    "summary": "Cann Group Limited engages in research and development, cultivation and production, manufacturing, clinical evaluation, processing, packaging, and distribution and supply of medicinal cannabis for various diseases and medical conditions in Australia. The company was founded in 2014 and is based in Bundoora, Australia.",
    "website": "http://www.canngrouplimited.com",
    "zipcode": "3083"
  },
  "CAU.AX": {
    "city": "South Yarra",
    "country": "Australia",
    "currency": "AUD",
    "exchange": "ASX",
    "industry": "Drug Manufacturers - Specialty & Generic",
    "long_name": "Cronos Australia Limited",
    "market": "au_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "CRONOS FPO",
    "state": "VIC",
    "summary": "Cronos Australia Limited operates as a medicinal cannabis company in Australia and Asia. The company operates through Medicinal Cannabis and Clinics segments. It distributes  PEACE NATURALS brand medicinal cannabis products; develops and sells medicinal cannabis products; and operates medicinal cannabis clinics. The company was incorporated in 2018 and is headquartered in South Yarra, Australia.",
    "website": "http://www.cronosaustralia.com",
    "zipcode": "3141"
  },
  "CBL.AX": {
    "city": "Surrey Hills",
    "country": "Australia",
    "currency": "AUD",
    "exchange": "ASX",
    "industry": "Medical Devices",
    "long_name": "Control Bionics Limited",
    "market": "au_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "CTRLBIONIC FPO",
    "state": "VIC",
    "summary": "Control Bionics Limited designs, manufactures, and sells wireless wearable electromyography based augmentative and alternative communication technologies that allow users to operate and communicate through a computer using their thoughts and neuroelectric signals. It offers Eye Control Duo, an integrated eye tracking device for those living with paralysis and loss of speech; NeuroNode Trilogy, a solution for those living with paralysis and loss of speech; and Control Bionics Complete Communication System, an out of the box solution for those living with paralysis and loss of speech. The company also provides support and warranty services. The company's products are used by people suffering from diseases, such as motor neuron diseases, amyotrophic lateral sclerosis, cerebral palsy, multiple sclerosis, and spinal cord injuries. It operates in Australia, the United States, Japan, and internationally. The company was formerly known as Control Bionics Holdings Pty Limited and changed its name to Control Bionics Limited in September 2020. Control Bionics Limited was incorporated in 2005 and is based in Surrey Hills, Australia.",
    "website": "http://www.controlbionics.com",
    "zipcode": "3127"
  },
  "CDX.AX": {
    "city": "Sydney",
    "country": "Australia",
    "currency": "AUD",
    "exchange": "ASX",
    "industry": "Medical Devices",
    "long_name": "CardieX Limited",
    "market": "au_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "CARDIEXLTD FPO",
    "state": "NSW",
    "summary": "CardieX Limited designs, manufactures, and markets medical devices for use in cardiovascular health management in the Americas, Europe, and the Asia Pacific. The company develops, markets, and distributes medical technologies that measure patient risk for hypertension, cardiovascular disease (CVD), and other related vascular disorders. It also provides TeleHealth Services, which provides digital, e-commerce, and mobile tools for patients to connect online with health coaches. The company offers its devices and services to hospitals, clinics, research institutions and pharmaceutical companies. CardieX Limited has a strategic collaboration with Blumio Inc. to develop wearable sensor; and a joint development agreement with inHealth to develop hypertension and cardiovascular programs for the products. The company was formerly known as AtCor Medical Holdings Limited and changed its name to CardieX Limited in June 2018. CardieX Limited was founded in 1994 and is headquartered in Sydney, Australia.",
    "website": "http://cardiex.com",
    "zipcode": "2000"
  },
  "CDY.AX": {
    "city": "Sydney",
    "country": "Australia",
    "currency": "AUD",
    "exchange": "ASX",
    "industry": "Biotechnology",
    "long_name": "Cellmid Limited",
    "market": "au_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "CELLMID FPO",
    "state": "NSW",
    "summary": "Cellmid Limited, a life sciences company, researches, develops, and commercializes diagnostic and therapeutic products for cancer and various chronic inflammatory conditions in Australia, the United States, and Japan. The company offers midkine, a driver and modulator of inflammatory diseases, including chronic inflammatory diseases and cancer; and focuses on blocking midkine, a protein for autoimmune disorders, chronic inflammation, osteoporosis, cardiovascular diseases, cancer, and neurodegenerative diseases. It also develops and sells over-the-counter products; and a range of FGF5 inhibitor hair growth products under the evolis, evolis Professional, Lexilis Hybrid, Jo-Ju RED, and Lexilis BLACK brands. In addition, the company sells SARS-CoV-2 antibody kits and PCR tests. It markets its products through retailers and wholesalers, as well as through a direct-to-consumer e-commerce platform. Cellmid Limited was incorporated in 2004 and is based in Sydney, Australia.",
    "website": "http://www.cellmid.com.au",
    "zipcode": "2000"
  },
  "CGB.AX": {
    "city": "Sydney",
    "country": "Australia",
    "currency": "AUD",
    "exchange": "ASX",
    "industry": "Drug Manufacturers - Specialty & Generic",
    "long_name": "Cann Global Limited",
    "market": "au_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "CANNGLOBAL FPO",
    "state": "NSW",
    "summary": "Cann Global Limited operates in medicinal cannabis and hemp food industries in Australia and internationally. The company operates through Hemp and Medical Cannabis Products, and Mining Exploration and Evaluation segments. It grows and cultivates hemp and medical cannabis products; and provides plant-based food and skin care products. The company also engages in the exploration and development of bauxite. In addition, it holds interests in the South Johnstone Project located in Queensland; and the New England Bauxite Project located in the New South Wales. The company was formerly known as Queensland Bauxite Limited and changed its name to Cann Global Limited in January 2019. Cann Global Limited was incorporated in 2007 and is based in Sydney, Australia.",
    "website": "http://www.canngloballimited.com",
    "zipcode": "2000"
  },
  "CGS.AX": {
    "city": "Fitzroy",
    "country": "Australia",
    "currency": "AUD",
    "exchange": "ASX",
    "industry": "Health Information Services",
    "long_name": "Cogstate Limited",
    "market": "au_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "COGSTATE FPO",
    "state": "VIC",
    "summary": "Cogstate Limited, a cognitive science company, provides computerized cognitive tests for clinical trials, academic research, healthcare, and brain health applications in Australia and internationally. The company's services include scientific consultancy, project management, data management, statistical analysis, and reporting. It operates in three segments: Clinical Trials, Academic Research, and Healthcare. The Clinical Trials segment provides technology and associated services that are used to quantify the effect of diseases and drugs, and devices or other interventions on human subjects participating in clinical trials primarily conducted by pharmaceutical and biotechnology companies. The Academic Research segment offers technology and associated services to support international research studies and academic collaborations across various indications, including Alzheimer's disease, HIV, multiple sclerosis, pediatric and adult oncology, Parkinson's disease, epilepsy, and schizophrenia. As of June 30, 2020, it had participated in approximately 1,800 academic research studies in approximately 200 indications. The Healthcare segment provides Cognigram, a system for regular and standardized testing to assist in the early detection of cognitive decline. The company serves biopharmaceutical companies, sporting organizations, military, physicians and patients, academic institutions, and public-private partnerships. Cogstate Limited was founded in 1999 and is based in Fitzroy, Australia.",
    "website": "http://www.cogstate.com",
    "zipcode": "3065"
  },
  "CHEOF": {
    "city": "Sydney",
    "country": "Australia",
    "currency": "USD",
    "exchange": "PNK",
    "industry": "Medical Devices",
    "long_name": "Cochlear Limited",
    "market": "us_market",
    "market_cap": "Large Cap",
    "sector": "Healthcare",
    "short_name": "COCHLEAR LTD",
    "state": "NSW",
    "summary": "Cochlear Limited provides implantable hearing solutions in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers cochlear implants, including Nucleus 7, Nucleus 6, Nucleus CP802, and Kanso sound processors; and Baha bone conduction implants, such as Baha attract system, Baha connect system, Baha softband, Baha soundarc, Baha 5 sound processor, and Baha sound processor. It also provides Cochlear true wireless accessories comprising mini microphones, phone clips, and TV streamers; Nucleus water-safe accessories; and training and development services. Cochlear Limited was founded in 1981 and is headquartered in Sydney, Australia.",
    "website": "http://www.cochlear.com",
    "zipcode": "2109"
  },
  "CHEOY": {
    "city": "Sydney",
    "country": "Australia",
    "currency": "USD",
    "exchange": "PNK",
    "industry": "Medical Devices",
    "long_name": "Cochlear Limited",
    "market": "us_market",
    "market_cap": "Large Cap",
    "sector": "Healthcare",
    "short_name": "COCHLEAR LTD",
    "state": "NSW",
    "summary": "Cochlear Limited provides implantable hearing solutions in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers cochlear implants, including Nucleus 7, Nucleus 6, Nucleus CP802, and Kanso sound processors; and Baha bone conduction implants, such as Baha attract system, Baha connect system, Baha softband, Baha soundarc, Baha 5 sound processor, and Baha sound processor. It also provides Cochlear true wireless accessories comprising mini microphones, phone clips, and TV streamers; Nucleus water-safe accessories; and training and development services. Cochlear Limited was founded in 1981 and is headquartered in Sydney, Australia.",
    "website": "http://www.cochlear.com",
    "zipcode": "2109"
  },
  "CHM.AX": {
    "city": "Carlton",
    "country": "Australia",
    "currency": "AUD",
    "exchange": "ASX",
    "industry": "Biotechnology",
    "long_name": "Chimeric Therapeutics Limited",
    "market": "au_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "CHIMERIC FPO",
    "state": "VIC",
    "summary": "Chimeric Therapeutics Limited, a biotechnology company, develops and commercializes chimeric antigen receptor T cell therapy drugs for solid tumors in Australia. It is developing CLTX-CAR T cell therapy that is Phase I clinical study in Glioblastoma. The company was incorporated in 2020 and is based in Carlton, Australia.",
    "website": "http://www.chimerictherapeutics.com",
    "zipcode": "3053"
  },
  "CLVLF": {
    "city": "Melbourne",
    "country": "Australia",
    "currency": "USD",
    "exchange": "PNK",
    "industry": "Biotechnology",
    "long_name": "Clinuvel Pharmaceuticals Limited",
    "market": "us_market",
    "market_cap": "Small Cap",
    "sector": "Healthcare",
    "short_name": "CLINUVEL PHARMACEUTICALS LTD",
    "state": "VIC",
    "summary": "Clinuvel Pharmaceuticals Limited, a biopharmaceutical company, focuses on developing and delivering drugs for the treatment of patients with severe genetic and skin disorders worldwide. Its lead drug candidate is SCENESSE, a photoprotective drug for the prevention of phototoxicity in adult patients with erythropoietic protoporphyria (EPP). The company's pipeline products include CUV9900, an alpha-melanocyte stimulating hormone analogue; Parvysmelanotide (VLRX001), an addition to the family of melanocortin analogues, which provoke increased and prolonged cellular activity; and PRNUMBRA, a liquid injectable formulation of afamelanotide. Clinuvel Pharmaceuticals Limited has a collaboration agreement with HK Winhealth Pharma Group Co. Limited for launching SCENESSE under a named patient program for the treatment of patients with EPP in the People's Republic of China. The company was founded in 1987 and is headquartered in Melbourne, Australia.",
    "website": "http://www.clinuvel.com",
    "zipcode": "3000"
  },
  "CLVLY": {
    "city": "Melbourne",
    "country": "Australia",
    "currency": "USD",
    "exchange": "PNK",
    "industry": "Biotechnology",
    "long_name": "Clinuvel Pharmaceuticals Limited",
    "market": "us_market",
    "market_cap": "Small Cap",
    "sector": "Healthcare",
    "short_name": "CLINUVEL PHARMACEUTICALS LTD",
    "state": "VIC",
    "summary": "Clinuvel Pharmaceuticals Limited, a biopharmaceutical company, focuses on developing and delivering drugs for the treatment of patients with severe genetic and skin disorders worldwide. Its lead drug candidate is SCENESSE, a photoprotective drug for the prevention of phototoxicity in adult patients with erythropoietic protoporphyria (EPP). The company's pipeline products include CUV9900, an alpha-melanocyte stimulating hormone analogue; Parvysmelanotide (VLRX001), an addition to the family of melanocortin analogues, which provoke increased and prolonged cellular activity; and PRNUMBRA, a liquid injectable formulation of afamelanotide. Clinuvel Pharmaceuticals Limited has a collaboration agreement with HK Winhealth Pharma Group Co. Limited for launching SCENESSE under a named patient program for the treatment of patients with EPP in the People's Republic of China. The company was founded in 1987 and is headquartered in Melbourne, Australia.",
    "website": "http://www.clinuvel.com",
    "zipcode": "3000"
  },
  "CMP.AX": {
    "city": "Abbotsford",
    "country": "Australia",
    "currency": "AUD",
    "exchange": "ASX",
    "industry": "Medical Devices",
    "long_name": "Compumedics Limited",
    "market": "au_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "COMPUMEDIC FPO",
    "state": "VIC",
    "summary": "Compumedics Limited researches, develops, manufactures, sells, and distributes medical devices in Australia, the Asia Pacific, the Americas, Europe, and the Middle East. It provides sleep diagnostics products, including Grael 4K PSG:EEG amplifiers; Somt PSG; Siesta 802, an ambulatory recording device; Grael PSG; and Somt, an investigative tool. The company also provides neurology diagnostics, such as ONsight A.V.S. for monitoring patient's home ambulatory studies; Grael 4K PSG:EEG amplifiers; Grael 4K-EEG amplifiers; Grael LT EEG System amplifiers; Neuvo 64-512 Channel LTM EEG monitoring systems; Xegis Forte EMG/EP; and Xegis G:NEO 2 Channel EMG/EP systems. In addition, it offers software products, such as Profusion Sleep software suite; Profusion EEG Software; ProFusion neXus 360, a Web-based patient data and lab management system that provides integrated hardware and software solutions for sleep and neurology clinics; Multi-Modal Neuroimaging Suite; Profusion neXus Laboratory Management System to optimize administrative and operational workflow needs of diagnostic and research laboratories; Profusion neXus Scheduler for planning for staff and time; and Digital Video, a plug-in software module to add synchronized digital video capabilities to sleep and EEG systems, as well as ECG Free, Profusion Plus, Siesta extended battery pack, and summit IP products. Further, the company provides magnetoencephalography systems; brain research technologies; pharmaceutical clinical trials and research services; accessories; and a range of consumables and supplies for diagnostic and research solutions. The company was founded in 1987 and is headquartered in Abbotsford, Australia. Compumedics Limited is a subsidiary of D & DJ Burton Holdings Pty Ltd.",
    "website": "http://www.compumedics.com.au",
    "zipcode": "3067"
  },
  "CMXHF": {
    "city": "Parkville",
    "country": "Australia",
    "currency": "USD",
    "exchange": "PNK",
    "industry": "Biotechnology",
    "long_name": "CSL Limited",
    "market": "us_market",
    "market_cap": "Large Cap",
    "sector": "Healthcare",
    "short_name": "CSL LTD",
    "state": "VIC",
    "summary": "CSL Limited researches, develops, manufactures, markets, and distributes biopharmaceutical and allied products in Australia, the United States, Germany, the United Kingdom, Switzerland, China, and internationally. The company operates through two segments, CSL Behring and Seqirus. The CSL Behring segment offers plasma therapies for the treatment of immunodeficiency, bleeding disorders, hereditary angioedema, Alpha-1 antitrypsin deficiency, and neurological disorders. This segment also conducts research on plasma and non-plasma therapies; and receives license and royalty from the commercialization of intellectual property. The Seqirus segment manufactures and distributes non-plasma biotherapeutic products; and develops influenza vaccines. CSL Limited was founded in 1916 and is headquartered in Parkville, Australia.",
    "website": "http://www.csl.com.au",
    "zipcode": "3052"
  },
  "CNGGF": {
    "city": "Bundoora",
    "country": "Australia",
    "currency": "USD",
    "exchange": "PNK",
    "industry": "Drug Manufacturers - Specialty & Generic",
    "long_name": "Cann Group Limited",
    "market": "us_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "CANN GROUP LTD",
    "state": "VIC",
    "summary": "Cann Group Limited engages in research and development, cultivation and production, manufacturing, clinical evaluation, processing, packaging, and distribution and supply of medicinal cannabis for various diseases and medical conditions in Australia. The company was founded in 2014 and is based in Bundoora, Australia.",
    "website": "http://www.canngrouplimited.com",
    "zipcode": "3083"
  },
  "COGZF": {
    "city": "Fitzroy",
    "country": "Australia",
    "currency": "USD",
    "exchange": "PNK",
    "industry": "Health Information Services",
    "long_name": "Cogstate Limited",
    "market": "us_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "COGSTATE",
    "state": "VIC",
    "summary": "Cogstate Limited, a cognitive science company, provides computerized cognitive tests for clinical trials, academic research, healthcare, and brain health applications in Australia and internationally. The company's services include scientific consultancy, project management, data management, statistical analysis, and reporting. It operates in three segments: Clinical Trials, Academic Research, and Healthcare. The Clinical Trials segment provides technology and associated services that are used to quantify the effect of diseases and drugs, and devices or other interventions on human subjects participating in clinical trials primarily conducted by pharmaceutical and biotechnology companies. The Academic Research segment offers technology and associated services to support international research studies and academic collaborations across various indications, including Alzheimer's disease, HIV, multiple sclerosis, pediatric and adult oncology, Parkinson's disease, epilepsy, and schizophrenia. As of June 30, 2020, it had participated in approximately 1,800 academic research studies in approximately 200 indications. The Healthcare segment provides Cognigram, a system for regular and standardized testing to assist in the early detection of cognitive decline. The company serves biopharmaceutical companies, sporting organizations, military, physicians and patients, academic institutions, and public-private partnerships. Cogstate Limited was founded in 1999 and is based in Fitzroy, Australia.",
    "website": "http://www.cogstate.com",
    "zipcode": "3065"
  },
  "COH.AX": {
    "city": "Sydney",
    "country": "Australia",
    "currency": "AUD",
    "exchange": "ASX",
    "industry": "Medical Devices",
    "long_name": "Cochlear Limited",
    "market": "au_market",
    "market_cap": "Large Cap",
    "sector": "Healthcare",
    "short_name": "COCHLEAR FPO",
    "state": "NSW",
    "summary": "Cochlear Limited provides implantable hearing solutions in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers cochlear implants, including Nucleus 7, Nucleus 6, Nucleus CP802, and Kanso sound processors; and Baha bone conduction implants, such as Baha attract system, Baha connect system, Baha softband, Baha soundarc, Baha 5 sound processor, and Baha sound processor. It also provides Cochlear true wireless accessories comprising mini microphones, phone clips, and TV streamers; Nucleus water-safe accessories; and training and development services. Cochlear Limited was founded in 1981 and is headquartered in Sydney, Australia.",
    "website": "http://www.cochlear.com",
    "zipcode": "2109"
  },
  "COO.AX": {
    "city": "Sydney",
    "country": "Australia",
    "currency": "AUD",
    "exchange": "ASX",
    "industry": "Health Information Services",
    "long_name": "Corum Group Limited",
    "market": "au_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "CORUM GRP FPO",
    "state": "NSW",
    "summary": "Corum Group Limited, together with its subsidiaries, operates as a technology and software development company in Australia. It operates through two segments, Health Services and eCommerce. The Health Services segment develops and distributes business software for the pharmacy industry, including point-of-sale and pharmaceutical dispensing software; multi-site retail management; and dispense solutions and computer hardware and support services. The eCommerce segment operates a payment gateway primarily for the real estate and pharmacy sectors. The company was formerly known as Cosmos Limited and changed its name to Corum Group Limited in November 2006. Corum Group Limited was incorporated in 1950 and is headquartered in Sydney, Australia.",
    "website": "http://www.corumgroup.com.au",
    "zipcode": "2000"
  },
  "COPHF": {
    "city": "Nedlands",
    "country": "Australia",
    "currency": "USD",
    "exchange": "PNK",
    "industry": "Drug Manufacturers - Specialty & Generic",
    "long_name": "Creso Pharma Limited",
    "market": "us_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "CRESO PHARMA LTD",
    "state": "WA",
    "summary": "Creso Pharma Limited develops, registers, and commercializes pharmaceutical-grade cannabis, and hemp-based nutraceutical products and treatments for human and animal health in Europe, the Middle East, North America, and the Asia Pacific. The company develops and commercializes therapeutic products; and cultivates and harvests cannabis plants, as well as supplies dried cannabis plant retail products. Its products include anibidiol, a complementary feed product for companion animals; cannaQIX, a nutraceutical product containing hemp oil extract, and vitamins and zinc that reduces stress and supports psychological and nervous functions in humans; and topical and skin care products, which include cannaDOL, a CBD-based topical gel associated with a mixture of cooling and warming essential oils. The company also offers nutraceutical products, such as cannaQIX, a hemp oil-derived food supplement under the Cannamics brand. Creso Pharma Limited was incorporated in 2015 and is headquartered in Nedlands, Australia.",
    "website": "http://www.cresopharma.com",
    "zipcode": "6009"
  },
  "CPH.AX": {
    "city": "Nedlands",
    "country": "Australia",
    "currency": "AUD",
    "exchange": "ASX",
    "industry": "Drug Manufacturers - Specialty & Generic",
    "long_name": "Creso Pharma Limited",
    "market": "au_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "CRESO FPO",
    "state": "WA",
    "summary": "Creso Pharma Limited develops, registers, and commercializes pharmaceutical-grade cannabis, and hemp-based nutraceutical products and treatments for human and animal health in Europe, the Middle East, North America, and the Asia Pacific. The company develops and commercializes therapeutic products; and cultivates and harvests cannabis plants, as well as supplies dried cannabis plant retail products. Its products include anibidiol, a complementary feed product for companion animals; cannaQIX, a nutraceutical product containing hemp oil extract, and vitamins and zinc that reduces stress and supports psychological and nervous functions in humans; and topical and skin care products, which include cannaDOL, a CBD-based topical gel associated with a mixture of cooling and warming essential oils. The company also offers nutraceutical products, such as cannaQIX, a hemp oil-derived food supplement under the Cannamics brand. Creso Pharma Limited was incorporated in 2015 and is headquartered in Nedlands, Australia.",
    "website": "http://www.cresopharma.com",
    "zipcode": "6009"
  },
  "CSJ.F": {
    "city": "Parkville",
    "country": "Australia",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Biotechnology",
    "long_name": "CSL Limited",
    "market": "dr_market",
    "market_cap": "Large Cap",
    "sector": "Healthcare",
    "short_name": "CSL LTD",
    "state": "VIC",
    "summary": "CSL Limited researches, develops, manufactures, markets, and distributes biopharmaceutical and allied products in Australia, the United States, Germany, the United Kingdom, Switzerland, China, and internationally. The company operates through two segments, CSL Behring and Seqirus. The CSL Behring segment offers plasma therapies for the treatment of immunodeficiency, bleeding disorders, hereditary angioedema, Alpha-1 antitrypsin deficiency, and neurological disorders. This segment also conducts research on plasma and non-plasma therapies; and receives license and royalty from the commercialization of intellectual property. The Seqirus segment manufactures and distributes non-plasma biotherapeutic products; and develops influenza vaccines. CSL Limited was founded in 1916 and is headquartered in Parkville, Australia.",
    "website": "http://www.csl.com.au",
    "zipcode": "3052"
  },
  "CSJA.F": {
    "city": "Parkville",
    "country": "Australia",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Biotechnology",
    "long_name": "CSL Limited",
    "market": "dr_market",
    "market_cap": "Large Cap",
    "sector": "Healthcare",
    "short_name": "CSL LTD  SPON.ADR 2",
    "state": "VIC",
    "summary": "CSL Limited researches, develops, manufactures, markets, and distributes biopharmaceutical and allied products in Australia, the United States, Germany, the United Kingdom, Switzerland, China, and internationally. The company operates through two segments, CSL Behring and Seqirus. The CSL Behring segment offers plasma therapies for the treatment of immunodeficiency, bleeding disorders, hereditary angioedema, Alpha-1 antitrypsin deficiency, and neurological disorders. This segment also conducts research on plasma and non-plasma therapies; and receives license and royalty from the commercialization of intellectual property. The Seqirus segment manufactures and distributes non-plasma biotherapeutic products; and develops influenza vaccines. CSL Limited was founded in 1916 and is headquartered in Parkville, Australia.",
    "website": "http://www.csl.com.au",
    "zipcode": "3052"
  },
  "CSL.AX": {
    "city": "Parkville",
    "country": "Australia",
    "currency": "AUD",
    "exchange": "ASX",
    "industry": "Biotechnology",
    "long_name": "CSL Limited",
    "market": "au_market",
    "market_cap": "Large Cap",
    "sector": "Healthcare",
    "short_name": "CSL FPO",
    "state": "VIC",
    "summary": "CSL Limited researches, develops, manufactures, markets, and distributes biopharmaceutical and allied products in Australia, the United States, Germany, the United Kingdom, Switzerland, China, and internationally. The company operates through two segments, CSL Behring and Seqirus. The CSL Behring segment offers plasma therapies for the treatment of immunodeficiency, bleeding disorders, hereditary angioedema, Alpha-1 antitrypsin deficiency, and neurological disorders. This segment also conducts research on plasma and non-plasma therapies; and receives license and royalty from the commercialization of intellectual property. The Seqirus segment manufactures and distributes non-plasma biotherapeutic products; and develops influenza vaccines. CSL Limited was founded in 1916 and is headquartered in Parkville, Australia.",
    "website": "http://www.csl.com.au",
    "zipcode": "3052"
  },
  "CSLLY": {
    "city": "Parkville",
    "country": "Australia",
    "currency": "USD",
    "exchange": "PNK",
    "industry": "Biotechnology",
    "long_name": "CSL Limited",
    "market": "us_market",
    "market_cap": "Large Cap",
    "sector": "Healthcare",
    "short_name": "CSL LTD",
    "state": "VIC",
    "summary": "CSL Limited researches, develops, manufactures, markets, and distributes biopharmaceutical and allied products in Australia, the United States, Germany, the United Kingdom, Switzerland, China, and internationally. The company operates through two segments, CSL Behring and Seqirus. The CSL Behring segment offers plasma therapies for the treatment of immunodeficiency, bleeding disorders, hereditary angioedema, Alpha-1 antitrypsin deficiency, and neurological disorders. This segment also conducts research on plasma and non-plasma therapies; and receives license and royalty from the commercialization of intellectual property. The Seqirus segment manufactures and distributes non-plasma biotherapeutic products; and develops influenza vaccines. CSL Limited was founded in 1916 and is headquartered in Parkville, Australia.",
    "website": "http://www.csl.com.au",
    "zipcode": "3052"
  },
  "CSLN.MX": {
    "city": "Parkville",
    "country": "Australia",
    "currency": "MXN",
    "exchange": "MEX",
    "industry": "Biotechnology",
    "long_name": "CSL Limited",
    "market": "mx_market",
    "market_cap": "Large Cap",
    "sector": "Healthcare",
    "short_name": "CSL LTD",
    "state": "VIC",
    "summary": "CSL Limited researches, develops, manufactures, markets, and distributes biopharmaceutical and allied products in Australia, the United States, Germany, the United Kingdom, Switzerland, China, and internationally. The company operates through two segments, CSL Behring and Seqirus. The CSL Behring segment offers plasma therapies for the treatment of immunodeficiency, bleeding disorders, hereditary angioedema, Alpha-1 antitrypsin deficiency, and neurological disorders. This segment also conducts research on plasma and non-plasma therapies; and receives license and royalty from the commercialization of intellectual property. The Seqirus segment manufactures and distributes non-plasma biotherapeutic products; and develops influenza vaccines. CSL Limited was founded in 1916 and is headquartered in Parkville, Australia.",
    "website": "http://www.csl.com.au",
    "zipcode": "3052"
  },
  "CSX.AX": {
    "city": "Artarmon",
    "country": "Australia",
    "currency": "AUD",
    "exchange": "ASX",
    "industry": "Medical Devices",
    "long_name": "CleanSpace Holdings Limited",
    "market": "au_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "CLEANSPACE FPO",
    "state": "NSW",
    "summary": "CleanSpace Holdings Limited engages in the design and manufacture of respiratory protection equipment for healthcare and industrial employers worldwide. It offers CleanSpace HALO, a personal respiratory protection for healthcare; CleanSpace ULTRA, a respirator for eye protection and water tolerance; CleanSpace2, a respirator for various working environments; and CleanSpace EX, an air purifying respirator. The company also provides accessories comprising respirators, masks, filters, cleaning and storage products, biohood system parts, and spares. It serves mining, infrastructure, energy, transport, metal, chemical, healthcare, and defense and government organizations. CleanSpace Holdings Limited was founded in 2009 and is based in Artarmon, Australia.",
    "website": "http://cleanspacetechnology.com",
    "zipcode": "2064"
  },
  "CTE.AX": {
    "city": "South Granville",
    "country": "Australia",
    "currency": "AUD",
    "exchange": "ASX",
    "industry": "Diagnostics & Research",
    "long_name": "Cryosite Limited",
    "market": "au_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "CRYOSITE FPO",
    "state": "NSW",
    "summary": "Cryosite Limited engages in the supply chain logistics and management of pharmaceutical products used in clinical trials, and biological materials in Australia. It operates in two segments, Clinical Trials & Biological Services Logistics, and Cord Blood and Tissues Storage. The Clinical Trials & Biological Services Logistics segment provides specialist temperature-controlled storage, sourcing, labelling, status management, secondary packaging, schedule drug distribution, destruction, returns, and biological storage services to the clinical trial and research industry. The Cord Blood and Tissues Storage segment offers long term storage for cord blood and tissue samples. It serves research, medical, pharmaceutical, veterinary, and biotechnology industries. Cryosite Limited was founded in 1999 and is based in South Granville, Australia.",
    "website": "http://www.cryosite.com",
    "zipcode": "2142"
  },
  "CUV.AX": {
    "city": "Melbourne",
    "country": "Australia",
    "currency": "AUD",
    "exchange": "ASX",
    "industry": "Biotechnology",
    "long_name": "Clinuvel Pharmaceuticals Limited",
    "market": "au_market",
    "market_cap": "Small Cap",
    "sector": "Healthcare",
    "short_name": "CLINUVEL FPO",
    "state": "VIC",
    "summary": "Clinuvel Pharmaceuticals Limited, a biopharmaceutical company, focuses on developing and delivering drugs for the treatment of patients with severe genetic and skin disorders worldwide. Its lead drug candidate is SCENESSE, a photoprotective drug for the prevention of phototoxicity in adult patients with erythropoietic protoporphyria (EPP). The company's pipeline products include CUV9900, an alpha-melanocyte stimulating hormone analogue; Parvysmelanotide (VLRX001), an addition to the family of melanocortin analogues, which provoke increased and prolonged cellular activity; and PRNUMBRA, a liquid injectable formulation of afamelanotide. Clinuvel Pharmaceuticals Limited has a collaboration agreement with HK Winhealth Pharma Group Co. Limited for launching SCENESSE under a named patient program for the treatment of patients with EPP in the People's Republic of China. The company was founded in 1987 and is headquartered in Melbourne, Australia.",
    "website": "http://www.clinuvel.com",
    "zipcode": "3000"
  },
  "CVJ.F": {
    "city": "Bundoora",
    "country": "Australia",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Drug Manufacturers - Specialty & Generic",
    "long_name": "Cann Group Limited",
    "market": "dr_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "CANN GROUP LTD",
    "state": "VIC",
    "summary": "Cann Group Limited engages in research and development, cultivation and production, manufacturing, clinical evaluation, processing, packaging, and distribution and supply of medicinal cannabis for various diseases and medical conditions in Australia. The company was founded in 2014 and is based in Bundoora, Australia.",
    "website": "http://www.canngrouplimited.com",
    "zipcode": "3083"
  },
  "CYC.AX": {
    "city": "Kingsgrove",
    "country": "Australia",
    "currency": "AUD",
    "exchange": "ASX",
    "industry": "Medical Devices",
    "long_name": "Cyclopharm Limited",
    "market": "au_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "CYCLOPHARM FPO",
    "state": "NSW",
    "summary": "Cyclopharm Limited engages in the research and development, manufacture, and sale of medical equipment and radiopharmaceuticals in the Asia Pacific, Europe, Canada, and internationally. The company operates through Technegas and Molecular Imaging segments. It offers diagnostic equipment and consumables used by physicians in the detection of pulmonary embolism. The company also provides radiopharmaceuticals that are used by physicians in the detection of cancer, neurological disorders, and cardiac diseases. It serves nuclear medicine departments. Cyclopharm Limited was founded in 1986 and is headquartered in Kingsgrove, Australia.",
    "website": "http://www.cyclopharm.com.au",
    "zipcode": "2208"
  },
  "CYP.AX": {
    "city": "Carlton",
    "country": "Australia",
    "currency": "AUD",
    "exchange": "ASX",
    "industry": "Biotechnology",
    "long_name": "Cynata Therapeutics Limited",
    "market": "au_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "CYNATA THR FPO",
    "state": "VIC",
    "summary": "Cynata Therapeutics Limited, together with its subsidiaries, develops and commercializes a proprietary mesenchymal stem cell technology under the Cymerus brand for human therapeutic use in Australia. The company's lead therapeutic product candidate is CYP-001, which has completed Phase I clinical trial for the treatment of graft versus host disease. It also develops products for the treatment of asthma, heart attack, diabetic wounds, coronary artery disease, acute respiratory distress syndrome, brain cancer, melanoma, sepsis, osteoarthritis, and critical limb ischemia, which are in a preclinical model. The company has a partnership with Monash University, University of Sydney, the Cooperative Research Centre for Cell Therapy Manufacturing, University of New South Wales, Critical Care Research Group, Massachusetts General Hospital, and the Royal College of Surgeons in Ireland to develop stem cell therapies. It also has a strategic partnership with Fujifilm Corporation of Japan for the development and research of Cymerus technology. The company was formerly known as Eco Quest Limited and changed its name to Cynata Therapeutics Limited in October 2013. Cynata Therapeutics Limited was founded in 2011 and is based in Carlton, Australia.",
    "website": "http://www.cynata.com",
    "zipcode": "3053"
  },
  "D4I.F": {
    "city": "East Melbourne",
    "country": "Australia",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Medical Care Facilities",
    "long_name": "Capitol Health Limited",
    "market": "dr_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "CAPITOL HEALTH LTD",
    "state": "VIC",
    "summary": "Capitol Health Limited provides diagnostic imaging and related services to the healthcare market in Australia. The company owns and operates clinics in Victoria, Tasmania, and Western Australia. It offers a range of diagnostic imaging services, including general x-ray, magnetic resonance imaging, ultrasound, mammography, Doppler, orthopantomogram, echocardiography, computed tomography, CT angiography, cone beam CT, nuclear medicine, bone densitometry, and fluoroscopy. The company was founded in 2005 and is headquartered in East Melbourne, Australia.",
    "website": "http://www.capitolhealth.com.au",
    "zipcode": "3002"
  },
  "DU8.F": {
    "city": "Fitzroy",
    "country": "Australia",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Diagnostics & Research",
    "long_name": "Genetic Technologies Limited",
    "market": "dr_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "GENETIC TEC.",
    "state": "VIC",
    "summary": "Genetic Technologies Limited, a molecular diagnostics company, provides predictive testing and assessment tools to help physicians manage women's health in Australia and the United States. The company's lead product is the BREVAGenplus, a clinically validated risk assessment test for non-hereditary breast cancer. It also markets BREVAGenplus to healthcare professionals in breast health care and imaging centers, as well as to obstetricians/gynecologists and breast cancer risk assessment specialists, such as breast surgeons. In addition, the company engages in the development of various cancer risk assessment tests under the GeneType for Colorectal Cancer and GeneType for Breast Cancer name. Further, it offers genetic testing services, including medical, animal, forensic, and plant testing. The company has research and collaboration agreements with the University of Melbourne, Translational Genomics Research Institute, Memorial Sloan Kettering New York Cambridge University, the Ohio State University, and Shivom. Genetic Technologies Limited was founded in 1989 and is headquartered in Fitzroy, Australia.",
    "website": "http://www.gtglabs.com",
    "zipcode": "3065"
  },
  "DU8S.F": {
    "city": "Fitzroy",
    "country": "Australia",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Diagnostics & Research",
    "long_name": "Genetic Technologies Limited",
    "market": "dr_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "GENETIC TECHS ADR/600",
    "state": "VIC",
    "summary": "Genetic Technologies Limited, a molecular diagnostics company, provides predictive testing and assessment tools to help physicians manage women's health in Australia and the United States. The company's lead product is the BREVAGenplus, a clinically validated risk assessment test for non-hereditary breast cancer. It also markets BREVAGenplus to healthcare professionals in breast health care and imaging centers, as well as to obstetricians/gynecologists and breast cancer risk assessment specialists, such as breast surgeons. In addition, the company engages in the development of various cancer risk assessment tests under the GeneType for Colorectal Cancer and GeneType for Breast Cancer name. Further, it offers genetic testing services, including medical, animal, forensic, and plant testing. The company has research and collaboration agreements with the University of Melbourne, Translational Genomics Research Institute, Memorial Sloan Kettering New York Cambridge University, the Ohio State University, and Shivom. Genetic Technologies Limited was founded in 1989 and is headquartered in Fitzroy, Australia.",
    "website": "http://www.gtglabs.com",
    "zipcode": "3065"
  },
  "DXB.AX": {
    "city": "Fitzroy",
    "country": "Australia",
    "currency": "AUD",
    "exchange": "ASX",
    "industry": "Biotechnology",
    "long_name": "Dimerix Limited",
    "market": "au_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "DIMERIX FPO",
    "state": "VIC",
    "summary": "Dimerix Limited, a biotechnology company, develops and commercializes new therapies in the area of unmet medical needs. It offers DMX-200, which is in Phase II clinical trial for the treatment of diabetic kidney diseases and focal segmental glomerulosclerosis; and DMX-700, which is in pre-clinical stage for the treatment of chronic obstructive pulmonary disease, as well as proprietary ReceptorHIT assay technology. The company was incorporated in 1975 and is headquartered in Fitzroy, Australia.",
    "website": "http://dimerix.com",
    "zipcode": "3065"
  },
  "E4N.F": {
    "city": "Osborne Park",
    "country": "Australia",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Biotechnology",
    "long_name": "Suda Pharmaceuticals Ltd",
    "market": "dr_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "SUDA PHARMACEUTICALS LTD.",
    "state": "WA",
    "summary": "Suda Pharmaceuticals Ltd engages in the development of drug delivery technology in Australia, India, Europe and Korea. It offers ZolpiMist, an oro-mucosal spray formulation of zolpidem tartrate marketed under the brand name of Ambien or Stilnox, a non-benzodiazepine prescribed for the short-term treatment of insomnia. The company's product pipeline includes Sumatriptan, an oral spray formulation for the treatment of acute migraine; and anagrelide, a platelet lowering agent for use in thrombosis, which is used for the treatment of cancer. Suda Pharmaceuticals Ltd has license and supply agreement with Teva Pharmaceuticals International GmbH and Mitsubishi Tanabe Pharma Singapore for ZolpiMist oral spray; product development, licence, and supply agreement with Cann Pharmaceutical Australia Ltd for the development of novel oral spray of pharmaceutical-grade cannabinoid derivatives for the treatment of drug resistant epilepsy, melanoma, and motion sickness; and feasibility and option agreement with Zelira Therapeutics for the use of cannabinoids for a range of uses, including insomnia, autism, opioid reduction, anxiety, pain, and cancer. The company also has a feasibility study and option agreement with Laboratorios Ordesa, S.L. The company was formerly known as Suda Limited and changed its name to Suda Pharmaceuticals Ltd in November 2017. Suda Pharmaceuticals Ltd was incorporated in 1999 and is headquartered in Osborne Park, Australia.",
    "website": "http://sudapharma.com",
    "zipcode": "6017"
  },
  "E8M.F": {
    "city": "Sydney",
    "country": "Australia",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Drug Manufacturers - Specialty & Generic",
    "long_name": "Elixinol Wellness Limited",
    "market": "dr_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "ELIXINOL WELLNESS LTD.",
    "state": "NSW",
    "summary": "Elixinol Global Limited, through its subsidiaries, manufactures and distributes industrial hemp-based nutraceutical, dietary supplements, and skincare products in the Americas, Europe, and Australia. It distributes hemp-derived cannabidiol products under the Elixinol brand. The company was incorporated in 2017 and is headquartered in Sydney, Australia.",
    "website": "http://www.elixinolglobal.com",
    "zipcode": "2000"
  },
  "EBO.AX": {
    "city": "Docklands",
    "country": "Australia",
    "currency": "AUD",
    "exchange": "ASX",
    "industry": "Medical Distribution",
    "long_name": "EBOS Group Limited",
    "market": "au_market",
    "market_cap": "Mid Cap",
    "sector": "Healthcare",
    "short_name": "EBOS FPO NZ",
    "state": "VIC",
    "summary": "EBOS Group Limited engages in the marketing, wholesale, and distribution of healthcare, medical, pharmaceutical, consumer, and animal care products in Australia and New Zealand. It operates in two segments, Healthcare and Animal Care. The company provides healthcare logistics; medication management solutions; pharmacy management software; loyalty, generics, compliance, business intelligence, and store software services; and multi-brand retail pharmacy services. It also offers vitamins, minerals and supplements, herbal and fruit teas, and natural toothpastes, as well as functional foods, including molasses and manuka honey; community based health care services and programs; Pharmacy Choice, a five step integrated retail program for independent pharmacies; and healthSAVE, a community pharmacy banner that allows members drive their retail businesses. In addition, the company supplies health and wellness products public and private hospitals, day surgeries, general practice, aged care facilities, specialist clinics, government, and non-profit health agencies, as well as clinically essential products; and pharmacy services to private and public hospitals, cancer centers, correctional facilities, and veterinary clinics. Further, it offers contract logistics services, such as healthcare distribution, warehousing, clinical trial management, and product registration services; and clinical trial logistics. Additionally, the company provides pet nutrition products, treats, clean-up products, grooming, and accessories; and wholesales veterinary products for companion animals, production animals, and equine athletes. The company was formerly known as Early Bros Dental & Surgical Supplies Ltd. and changed its name to EBOS Group Limited in 1986. EBOS Group Limited was founded in 1922 and is headquartered in Docklands, Australia.",
    "website": "http://www.ebosgroup.com",
    "zipcode": "3008"
  },
  "EBO.NZ": {
    "city": "Docklands",
    "country": "Australia",
    "currency": "NZD",
    "exchange": "NZE",
    "industry": "Medical Distribution",
    "long_name": "EBOS Group Limited",
    "market": "nz_market",
    "market_cap": "Mid Cap",
    "sector": "Healthcare",
    "short_name": "Ebos Group Limited Ordinary Sha",
    "state": "VIC",
    "summary": "EBOS Group Limited engages in the marketing, wholesale, and distribution of healthcare, medical, pharmaceutical, consumer, and animal care products in Australia and New Zealand. It operates in two segments, Healthcare and Animal Care. The company provides healthcare logistics; medication management solutions; pharmacy management software; loyalty, generics, compliance, business intelligence, and store software services; and multi-brand retail pharmacy services. It also offers vitamins, minerals and supplements, herbal and fruit teas, and natural toothpastes, as well as functional foods, including molasses and manuka honey; community based health care services and programs; Pharmacy Choice, a five step integrated retail program for independent pharmacies; and healthSAVE, a community pharmacy banner that allows members drive their retail businesses. In addition, the company supplies health and wellness products public and private hospitals, day surgeries, general practice, aged care facilities, specialist clinics, government, and non-profit health agencies, as well as clinically essential products; and pharmacy services to private and public hospitals, cancer centers, correctional facilities, and veterinary clinics. Further, it offers contract logistics services, such as healthcare distribution, warehousing, clinical trial management, and product registration services; and clinical trial logistics. Additionally, the company provides pet nutrition products, treats, clean-up products, grooming, and accessories; and wholesales veterinary products for companion animals, production animals, and equine athletes. The company was formerly known as Early Bros Dental & Surgical Supplies Ltd. and changed its name to EBOS Group Limited in 1986. EBOS Group Limited was founded in 1922 and is headquartered in Docklands, Australia.",
    "website": "http://www.ebosgroup.com",
    "zipcode": "3008"
  },
  "ECQ.F": {
    "city": "Bentley",
    "country": "Australia",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Biotechnology",
    "long_name": "PharmAust Limited",
    "market": "dr_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "PHARMAUST LTD.",
    "state": "WA",
    "summary": "PharmAust Limited, a clinical-stage company, develops targeted cancer therapeutics for human and animal healthcare. The company develops drug discovery intellectual property for the treatment of various cancers in humans and animals. Its lead candidate is Monepantel, which are in Phase II clinical trials for the treatment of cancer. The company also provides highly specialized medicinal and synthetic chemistry services on a contract basis to clients to the drug discovery and pharmaceutical industries. PharmAust Limited was incorporated in 2000 and is based in Bentley, Australia.",
    "website": "http://www.pharmaust.com",
    "zipcode": "6102"
  },
  "ECS.AX": {
    "city": "Launceston",
    "country": "Australia",
    "currency": "AUD",
    "exchange": "ASX",
    "industry": "Drug Manufacturers - Specialty & Generic",
    "long_name": "ECS Botanics Holdings Ltd",
    "market": "au_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "ECSBOTANIC FPO",
    "state": "TAS",
    "summary": "ECS Botanics Holdings Ltd, an agribusiness and hemp food company, cultivates and processes industrial hemp in Australia. It also supplies bulk hemp foods for cafes, whole food suppliers, food brands, or food manufacturers, as well as hemp seed to licensed operators for processing and sowing. The company is based in Launceston, Australia.",
    "website": "http://ecsbotanics.com.au",
    "zipcode": "7302"
  },
  "EGQ.F": {
    "city": "South Perth",
    "country": "Australia",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Diagnostics & Research",
    "long_name": "BARD1 Life Sciences Limited",
    "market": "dr_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "BARD1 LIFE SCIENCES",
    "state": "WA",
    "summary": "BARD1 Life Sciences Limited engages in the research and development of non-invasive diagnostic tests for early detection of cancer in Australia. The company offers hTERT test for diagnosis of bladder cancer, with the development-stage BARD1 autoantibody test for early detection of ovarian, breast and lung cancers; hTERT ICC test, an antibody-based immunocytochemistry stain that detects a component of telomerase; EXO-NET, a technology to capture and isolation of exosomes from any liquid biopsy sample; and BARD1 autoantibodies test to evaluate autoantibody panels and algorithms for detection of ovarian, breast and lung cancers. BARD1 Life Sciences Limited was incorporated in 1983 and is headquartered in South Perth, Australia.",
    "website": "http://www.bard1.com",
    "zipcode": "3168"
  },
  "EHE.AX": {
    "city": "Sydney",
    "country": "Australia",
    "currency": "AUD",
    "exchange": "ASX",
    "industry": "Medical Care Facilities",
    "long_name": "Estia Health Limited",
    "market": "au_market",
    "market_cap": "Small Cap",
    "sector": "Healthcare",
    "short_name": "ESTIA HLTH FPO",
    "state": "NSW",
    "summary": "Estia Health Limited operates residential aged care homes in Australia. As of June 30, 2020, it had 69 homes, which include 6,182 resident places in New South Wales, Queensland, South Australia, and Victoria. The company was founded in 2005 and is based in Sydney, Australia.",
    "website": "http://www.estiahealth.com.au",
    "zipcode": "2000"
  },
  "ELLXF": {
    "city": "Sydney",
    "country": "Australia",
    "currency": "USD",
    "exchange": "PNK",
    "industry": "Drug Manufacturers - Specialty & Generic",
    "long_name": "Elixinol Wellness Limited",
    "market": "us_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "ELIXINOL WELLNESS LTD",
    "state": "NSW",
    "summary": "Elixinol Global Limited, through its subsidiaries, manufactures and distributes industrial hemp-based nutraceutical, dietary supplements, and skincare products in the Americas, Europe, and Australia. It distributes hemp-derived cannabidiol products under the Elixinol brand. The company was incorporated in 2017 and is headquartered in Sydney, Australia.",
    "website": "http://www.elixinolglobal.com",
    "zipcode": "2000"
  },
  "EMD.AX": {
    "city": "West Leederville",
    "country": "Australia",
    "currency": "AUD",
    "exchange": "ASX",
    "industry": "Health Information Services",
    "long_name": "Emyria Limited",
    "market": "au_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "EMYRIAL FPO",
    "state": "WA",
    "summary": "Emyria Limited, a healthcare technology and services company, operates a network of specialist medical clinics. Its medical clinics offer treatments, such as cannabinoid-based medicines. As of July 31, 2020, the company operated four patient-focused medical clinics. It has a partnership agreement with Mind Medicine Australia to co-develop a gold-standard and data-driven clinical model for the safe provision of psychedelic-assisted therapies in Australia; and a collaboration agreement with Cann Group Limited to register CBD product as a schedule 3 medicine that would result in an over-the-counter, pharmacist-only CBD medicine. The company was formerly known as Emerald Clinics Limited and changed its name to Emyria Limited in September 2020. Emyria Limited was founded in 2018 and is based in West Leederville, Australia.",
    "website": "http://www.emyria.com",
    "zipcode": "6901"
  },
  "EMV.AX": {
    "city": "Macquarie Park",
    "country": "Australia",
    "currency": "AUD",
    "exchange": "ASX",
    "industry": "Medical Devices",
    "long_name": "EMvision Medical Devices Limited",
    "market": "au_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "EMVISION FPO",
    "state": "NSW",
    "summary": "EMvision Medical Devices Limited engages in the research, development, and commercialization of imaging and diagnostic technology for the purpose of commercializing portable medical device for stroke diagnosis and monitoring, and other medical imaging needs. The company has a strategic collaboration with Keysight Technologies Malaysia Sdn Bhd to develop a personalized vector network analysis solution for medical imaging in the healthcare sector. EMvision Medical Devices Limited was founded in 2017 and is based in Macquarie Park, Australia.",
    "website": "http://www.emvision.com.au",
    "zipcode": "2113"
  },
  "EOF.AX": {
    "city": "Sydney",
    "country": "Australia",
    "currency": "AUD",
    "exchange": "ASX",
    "industry": "Drug Manufacturers - Specialty & Generic",
    "long_name": "Ecofibre Limited",
    "market": "au_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "ECOFIBRE FPO",
    "state": "NSW",
    "summary": "Ecofibre Limited, together with its subsidiaries, engages in breeding, growing, processing, and distributing hemp products in the United States and Australia. It offers protein powders, dehulled hemp seeds, and hemp seed oil products. The company also produces hemp nutraceutical products for human and pet consumption, as well as topical creams and salves; and develops hemp related fiber products. It sells its products through wholesalers and distributors, as well as pharmacy stores under the Ananda Food and Woolworths Macro brand names. The company was founded in 2009 and is based in Sydney, Australia.",
    "website": "http://www.ecofibre.com",
    "zipcode": "2000"
  },
  "EOFBF": {
    "city": "Sydney",
    "country": "Australia",
    "currency": "USD",
    "exchange": "PNK",
    "industry": "Drug Manufacturers - Specialty & Generic",
    "long_name": "Ecofibre Limited",
    "market": "us_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "ECOFIBRE LTD",
    "state": "NSW",
    "summary": "Ecofibre Limited, together with its subsidiaries, engages in breeding, growing, processing, and distributing hemp products in the United States and Australia. It offers protein powders, dehulled hemp seeds, and hemp seed oil products. The company also produces hemp nutraceutical products for human and pet consumption, as well as topical creams and salves; and develops hemp related fiber products. It sells its products through wholesalers and distributors, as well as pharmacy stores under the Ananda Food and Woolworths Macro brand names. The company was founded in 2009 and is based in Sydney, Australia.",
    "website": "http://www.ecofibre.com",
    "zipcode": "2000"
  },
  "EPN.AX": {
    "city": "Sydney",
    "country": "Australia",
    "currency": "AUD",
    "exchange": "ASX",
    "industry": "Drug Manufacturers - Specialty & Generic",
    "long_name": "Epsilon Healthcare Limited",
    "market": "au_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "EPSILON FPO",
    "state": "NSW",
    "summary": "Epsilon Healthcare Limited operates as a healthcare and pharmaceuticals company primarily in Australia and Canada. It engages in the manufacture and distribution of hydroponics equipment, materials, and nutrients; and development and delivery of medicinal cannabis, as well as provides turnkey cultivation solutions. The company was formerly known as THC Global Group Limited and changed its name to Epsilon Healthcare Limited in February 2021. Epsilon Healthcare Limited was incorporated in 2016 and is based in Sydney, Australia.",
    "website": "http://www.epsilonhealthcare.com.au",
    "zipcode": "2000"
  },
  "EX1.AX": {
    "city": "Melbourne",
    "country": "Australia",
    "currency": "AUD",
    "exchange": "ASX",
    "industry": "Biotechnology",
    "long_name": "Exopharm Limited",
    "market": "au_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "EXOPHARM FPO",
    "state": "VIC",
    "summary": "Exopharm Limited, a biopharmaceutical company, focuses on developing and commercializing human therapeutics using extracellular vesicles (EVs) as medicines in Australia. The company is developing Nave EVs as regenerative medicines, including Plexaris for wound healing; and Cevaris used in inflammatory, immunomodulatory, and tissue remodeling activities. Its Engineered EVs products comprise Fortrexo CoV, an engineered EV product that reduce the duration and severity of SARS-CoV-2 infection in the early phase of a patient's exposure to COVID-19; and Plexodox, a platelet derived EV loaded with the approved anti-cancer drug doxorubicin as a novel and improved anticancer drug. The company was founded in 2013 and is headquartered in Melbourne, Australia.",
    "website": "http://www.exopharm.com",
    "zipcode": "3000"
  },
  "EXL.AX": {
    "city": "Sydney",
    "country": "Australia",
    "currency": "AUD",
    "exchange": "ASX",
    "industry": "Drug Manufacturers - Specialty & Generic",
    "long_name": "Elixinol Wellness Limited",
    "market": "au_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "ELIXINOL FPO",
    "state": "NSW",
    "summary": "Elixinol Global Limited, through its subsidiaries, manufactures and distributes industrial hemp-based nutraceutical, dietary supplements, and skincare products in the Americas, Europe, and Australia. It distributes hemp-derived cannabidiol products under the Elixinol brand. The company was incorporated in 2017 and is headquartered in Sydney, Australia.",
    "website": "http://www.elixinolglobal.com",
    "zipcode": "2000"
  },
  "EYE.AX": {
    "city": "Kent Town",
    "country": "Australia",
    "currency": "AUD",
    "exchange": "ASX",
    "industry": "Medical Devices",
    "long_name": "Nova Eye Medical Limited",
    "market": "au_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "NOVA EYE FPO",
    "state": "SA",
    "summary": "Nova Eye Medical Limited designs, manufactures, distributes, and services medical equipment and devices to diagnose and treat eye diseases. The company offers iTrack, a surgical system for the reduction of intraocular pressure (IOP) in adult patients with openangle glaucoma; and 2RT, a proprietary laser technology to treat patients in early/intermediate age-related macular degeneration. It operates in Australia, the United States, Europe, the Middle East, Japan, rest of Asia, South America, and internationally. Nova Eye Medical Limited was incorporated in 1970 and is headquartered in Kent Town, Australia.",
    "website": "http://www.nova-eye.com",
    "zipcode": "5067"
  },
  "FDMDF": {
    "city": "Melbourne",
    "country": "Australia",
    "currency": "USD",
    "exchange": "PNK",
    "industry": "Medical Devices",
    "long_name": "4DMedical Limited",
    "market": "us_market",
    "market_cap": "Small Cap",
    "sector": "Healthcare",
    "short_name": "4D MEDICAL LTD",
    "state": "VIC",
    "summary": "4DMedical Limited operates as a software technology company in Australia and the United States. It commercializes XV Technology, a four-dimensional lung imaging platform that utilizes proven and patented mathematic models and algorithms to convert X-ray scans into quantitative data to enhance the capacity of physicians to manage patients with respiratory diseases and diseases of the lung. The company is also developing VQ (Perfusion), a diagnostic to scan and measure ventilation and perfusion; and Contrast Free Pulmonary Angiography (CFPA) products, as well as small animal ventilators and preclinical scanners. 4Dmedical Limited partners with University of Miami Health System to establish the functional lung imaging research program. The company was founded in 2012 and is based in Melbourne, Australia.",
    "website": "http://www.4dmedical.com",
    "zipcode": "3004"
  },
  "FFC.AX": {
    "city": "Sydney",
    "country": "Australia",
    "currency": "AUD",
    "exchange": "ASX",
    "industry": "Medical Care Facilities",
    "long_name": "FarmaForce Limited",
    "market": "au_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "FARMAFORCE FPO",
    "state": "NSW",
    "summary": "FarmaForce Limited provides services as a contract sales organization to pharmaceutical industry in Australia. The company operates in two segments, Contract Sales and Marketing Services to External Customers; and Services to Related Parties. It also offers sales, data, and medical affairs solutions. The company was founded in 2014 and is based in Sydney, Australia. FarmaForce Limited is a subsidiary of The iQ Group Global Ltd.",
    "website": "http://farmaforce.com.au",
    "zipcode": "2000"
  },
  "FJY.F": {
    "city": "West Melbourne",
    "country": "Australia",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Biotechnology",
    "long_name": "Acrux Limited",
    "market": "dr_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "ACRUX LTD.",
    "state": "VIC",
    "summary": "Acrux Limited, together with its subsidiaries, develops and commercializes generic and specialty topical pharmaceuticals in Australia, Germany, the United States, and internationally. The company offers testosterone solutions, such as oral tablets, buccal tablets, subcutaneous pellets, transdermal patches, injections, and topical gels for treatment of adult males who have low or no testosterone. It also provides estradiol sprays for women under the Evamist and Lenzetto brand names for the treatment of flushes associated with menopause. Acrux Limited was founded in 1998 and is based in West Melbourne, Australia.",
    "website": "http://www.acrux.com.au",
    "zipcode": "3003"
  },
  "G1G.F": {
    "city": "Perth",
    "country": "Australia",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Biotechnology",
    "long_name": "Zelira Therapeutics Limited",
    "market": "dr_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "ZELIRA THERAPEUTICS LTD.",
    "state": "WA",
    "summary": "Zelira Therapeutics Limited, a bio-pharmaceutical company, engages in the development of cannabinoid-based formulations for the treatment of various medical conditions in Australia. It offers formulations under the HOPE brand in Pennsylvania and licenses in Louisiana, as well as develops Zenivol, a cannabinoid-based medicine for treatment of chronic insomnia. The company is also involved in a human clinical trial program focused on insomnia, autism, and opioid reduction; and a pre-clinical research program to examine the effect of cannabinoids in breast, brain, and pancreatic cancer, as well as the potential for cannabinoid formulations to treat diabetes-associated cognitive decline. It has a strategic partnership with CannPal Pty Ltd; and St Vincent's Hospital on opioid reduction study. The company was formerly known as Zelda Therapeutics Limited and changed its name to Zelira Therapeutics Limited in December 2019. Zelira Therapeutics Limited is based in Perth, Australia.",
    "website": "http://www.zeliratx.com",
    "zipcode": "6000"
  },
  "GENE": {
    "city": "Fitzroy",
    "country": "Australia",
    "currency": "USD",
    "exchange": "NMS",
    "industry": "Diagnostics & Research",
    "long_name": "Genetic Technologies Limited",
    "market": "us_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "Genetic Technologies Ltd",
    "state": "VIC",
    "summary": "Genetic Technologies Limited, a molecular diagnostics company, provides predictive testing and assessment tools to help physicians manage women's health in Australia and the United States. The company's lead product is the BREVAGenplus, a clinically validated risk assessment test for non-hereditary breast cancer. It also markets BREVAGenplus to healthcare professionals in breast health care and imaging centers, as well as to obstetricians/gynecologists and breast cancer risk assessment specialists, such as breast surgeons. In addition, the company engages in the development of various cancer risk assessment tests under the GeneType for Colorectal Cancer and GeneType for Breast Cancer name. Further, it offers genetic testing services, including medical, animal, forensic, and plant testing. The company has research and collaboration agreements with the University of Melbourne, Translational Genomics Research Institute, Memorial Sloan Kettering New York Cambridge University, the Ohio State University, and Shivom. Genetic Technologies Limited was founded in 1989 and is headquartered in Fitzroy, Australia.",
    "website": "http://www.gtglabs.com",
    "zipcode": "3065"
  },
  "GLH.AX": {
    "city": "Melbourne",
    "country": "Australia",
    "currency": "AUD",
    "exchange": "ASX",
    "industry": "Health Information Services",
    "long_name": "Global Health Limited",
    "market": "au_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "GLOBALHE FPO",
    "state": "VIC",
    "summary": "Global Health Limited develops, sells, and supports application software for the healthcare sector primarily in Australia. It provides mental health software for psychologists and psychiatrists; and integrated software solutions for various areas of community health and human services, including drug and alcohol, disability, dental, post-acute care, home and community care, mental health services, and community rehabilitation. The company's products include MasterCare PAS, a patient administration system for appointment scheduling, theatre bookings, and bed management; MasterCare + for practice management, client record, patient engagement, referral management, secure messaging, and scanned medical records; PrimaryClinic, a medical and practice software for general practitioners, specialists, and allied health practitioners; ReferralNet, a message delivery system for information exchange; LifeCard to hold records and track progress. It also provides MasterCare MHAGIC that supports the workflow of mental health service providers; MasterCare Data Warehouse, which enables reporting, analysis, and decision support for managers and clinicians; HotHealth, a patient engagement platform; Patient Portal that directs information required from patients straight into electronic medical record system or PAS; and Altitude, a cloud hosting service. Global Health Limited was founded in 1985 and is headquartered in Melbourne, Australia.",
    "website": "http://www.global-health.com",
    "zipcode": "3000"
  },
  "GSS.AX": {
    "city": "Sydney",
    "country": "Australia",
    "currency": "AUD",
    "exchange": "ASX",
    "industry": "Diagnostics & Research",
    "long_name": "Genetic Signatures Limited",
    "market": "au_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "GENETICSIG FPO",
    "state": "NSW",
    "summary": "Genetic Signatures Limited operates as a molecular diagnostic (MDx) company in North America and Australia. The company designs and manufactures a suite of real-time polymerase chain reaction based products for detection of infectious diseases under EasyScreen brand name. It also provides MDx 3Base platform technology that enables hospital and pathology laboratories to screen for a range of infectious pathogens. Genetic Signatures Limited was founded in 2001 and is headquartered in Sydney, Australia.",
    "website": "http://www.geneticsignatures.com",
    "zipcode": "2042"
  },
  "GTG.AX": {
    "city": "Fitzroy",
    "country": "Australia",
    "currency": "AUD",
    "exchange": "ASX",
    "industry": "Diagnostics & Research",
    "long_name": "Genetic Technologies Limited",
    "market": "au_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "GENE TECH FPO",
    "state": "VIC",
    "summary": "Genetic Technologies Limited, a molecular diagnostics company, provides predictive testing and assessment tools to help physicians manage women's health in Australia and the United States. The company's lead product is the BREVAGenplus, a clinically validated risk assessment test for non-hereditary breast cancer. It also markets BREVAGenplus to healthcare professionals in breast health care and imaging centers, as well as to obstetricians/gynecologists and breast cancer risk assessment specialists, such as breast surgeons. In addition, the company engages in the development of various cancer risk assessment tests under the GeneType for Colorectal Cancer and GeneType for Breast Cancer name. Further, it offers genetic testing services, including medical, animal, forensic, and plant testing. The company has research and collaboration agreements with the University of Melbourne, Translational Genomics Research Institute, Memorial Sloan Kettering New York Cambridge University, the Ohio State University, and Shivom. Genetic Technologies Limited was founded in 1989 and is headquartered in Fitzroy, Australia.",
    "website": "http://www.gtglabs.com",
    "zipcode": "3065"
  },
  "H5O.F": {
    "city": "West Perth",
    "country": "Australia",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Drug Manufacturers - Specialty & Generic",
    "long_name": "MGC Pharmaceuticals Limited",
    "market": "dr_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "MGC PHARMACEUTICALS LTD",
    "state": "WA",
    "summary": "MGC Pharmaceuticals Limited, together with its subsidiaries, produces and supplies phytocannabinoid derived medicines in Australia and Slovenia. It provides pharmaceutical products, such as Tetrinol for the treatment of cachexia; MXOT01GB01 to treat glioblastoma; MXOT02ME01 for the treatment of melanoma cancer; MXOT03PC01 to treat prostate cancer; TopiCann for the topical treatment of eczema and inflamed skin; and InCann, a biactive capsule to treat Chron's and IBS. The company's products under development include CannEpil, which is in Phase IIb clinical trial for the treatment in children and adolescents with refectory epilepsy; CogniCann that is in Phase II clinical trial to treat dementia and Alzheimer's diseases; and ArtemiC, which is in Phase II clinical trial for the treatment COVID-19. It has strategic collaborative partnership agreements Epilepsy Action Australia, Royal Melbourne Institute of Technology, the University of Notre Dame in Western Australia, as well as the National Institute of Biology & University Medical Centre, Ljubljana Slovenia. The company was formerly known as Erin Resources Limited and changed its name to MGC Pharmaceuticals Limited in December 2015. MGC Pharmaceuticals Limited was founded in 2014 and is headquartered in West Perth, Australia.",
    "website": "http://www.mgcpharma.com.au",
    "zipcode": "6005"
  },
  "HG6.F": {
    "city": "Salisbury South",
    "country": "Australia",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Drug Manufacturers - General",
    "long_name": "Mayne Pharma Group Limited",
    "market": "dr_market",
    "market_cap": "Small Cap",
    "sector": "Healthcare",
    "short_name": "MAYNE PHARMA GROUP LTD.",
    "state": "SA",
    "summary": "Mayne Pharma Group Limited, a specialty pharmaceutical company, manufactures and sells branded and generic pharmaceutical products in Australia, the United States, Korea, and internationally. The company operates through four segments: Generic Products, Specialty Brands, Metrics Contract Services, and Mayne Pharma International. It also offers oral drug delivery systems; and contract development and manufacturing services to third-party customers. The company was formerly known as Halcygen Pharmaceuticals Limited and changed its name to Mayne Pharma Group Limited in November 2010. Mayne Pharma Group Limited was incorporated in 2005 and is based in Salisbury South, Australia.",
    "website": "http://www.maynepharma.com",
    "zipcode": "5106"
  },
  "HLA.AX": {
    "city": "Bowen Hills",
    "country": "Australia",
    "currency": "AUD",
    "exchange": "ASX",
    "industry": "Medical Care Facilities",
    "long_name": "Healthia Limited",
    "market": "au_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "HEALTHIA FPO",
    "state": "QLD",
    "summary": "Healthia Limited provides health services in Australia. The company operates 72 podiatry clinics under the My FootDr brand; 23 physiotherapy clinics under the Allsports Physiotherapy brand; and 7 hand therapy clinics under the Extend Rehabilitation brand, as well as manufactures and sells 3D printed orthotic devices for podiatry clinics. It also sells podiatry and foot and nail care products, podiatry equipment, surgical instruments, orthotic materials, clinical consumables to podiatrists, hospitals, medical centres, nursing homes, and allied health professionals. The company was incorporated in 2018 and is based in Bowen Hills, Australia.",
    "website": "http://www.healthia.com.au",
    "zipcode": "4006"
  },
  "HLS.AX": {
    "city": "St Leonards",
    "country": "Australia",
    "currency": "AUD",
    "exchange": "ASX",
    "industry": "Medical Care Facilities",
    "long_name": "Healius Limited",
    "market": "au_market",
    "market_cap": "Small Cap",
    "sector": "Healthcare",
    "short_name": "HEALIUS FPO",
    "state": "NSW",
    "summary": "Healius Limited provides facilities and support services to independent general practitioners, radiologists, and other healthcare professionals in Australia. The company operates through three segments: Pathology, Imaging, and Day Hospitals. It offers diagnostic imaging services, including X-ray, ultrasound, computerized tomography, mammography, magnetic resonance imaging, nuclear medicine, positron emission tomography, and interventional radiology; and private medical laboratory and pathology services. The company also provides cataract surgery, colonoscopy, gastroscopy, plastic and cosmetic surgery, skin, cancer removal, IVF egg collection, and gynaecological surgery services. It operates 2,234 pathology sites; 15 day hospital sites; and 146 imaging sites. The company was formerly known as Primary Health Care Limited and changed its name to Healius Limited in December 2018. Healius Limited was incorporated in 1994 and is based in St Leonards, Australia.",
    "website": "http://www.healius.com.au",
    "zipcode": "2065"
  },
  "HMD.AX": {
    "city": "Sydney",
    "country": "Australia",
    "currency": "AUD",
    "exchange": "ASX",
    "industry": "Medical Devices",
    "long_name": "HeraMED Limited",
    "market": "au_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "HERAMED FPO",
    "state": "NSW",
    "summary": "HeraMED Limited, together with its subsidiaries, develops, manufactures, and sells foetal heart beat monitors and other pregnancy monitoring solutions for home use in Australia, Europe, and Israel. The company provides HeraBEAT, a fetal heart rate monitor principally for use by an expectant mother to monitor their fetus' heartbeat. It is also involved in developing EchoBEAT, the next generation of its home-oriented pregnancy monitoring devices; and Orion, an artificial intelligence powered pregnancy monitoring system for pregnancy monitoring analysis. The company has a collaboration agreement with Mayo Clinic for the development of its HeraCARE pregnancy management platform. HeraMED Limited was incorporated in 2011 and is based in Sydney, Australia.",
    "website": "http://www.hera-med.com",
    "zipcode": "2000"
  },
  "HXL.AX": {
    "city": "Melbourne",
    "country": "Australia",
    "currency": "AUD",
    "exchange": "ASX",
    "industry": "Biotechnology",
    "long_name": "Hexima Limited",
    "market": "au_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "HEXIMA FPO",
    "state": "VIC",
    "summary": "Hexima Limited, a biotechnology company, engages in the research and development of plant-derived proteins and peptides for applications as human therapeutics. The company's lead drug candidate is HXP124, which is in a phase IIb clinical trial for the treatment of fungal toenail infections. It operates in the topical antifungal sector of the pharmaceutical product development industry worldwide. The company was founded in 1997 and is headquartered in Melbourne, Australia.",
    "website": "http://www.hexima.com.au",
    "zipcode": "3086"
  },
  "ICR.AX": {
    "city": "Leederville",
    "country": "Australia",
    "currency": "AUD",
    "exchange": "ASX",
    "industry": "Health Information Services",
    "long_name": "Intelicare Holdings Limited",
    "market": "au_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "INTELICARE FPO",
    "state": "WA",
    "summary": "Intelicare Holdings Limited engages in the sale of a predictive analytics hardware and software package for use in the aged care and health industries in Australia. The company offers InteliCare Pro, a monitoring system; and InteliLiving that is designed for seniors and people with disability. Intelicare Holdings Limited was founded in 2016 and is based in Leederville, Australia.",
    "website": "http://intelicare.com.au",
    "zipcode": "6007"
  },
  "ICS.AX": {
    "city": "Sydney",
    "country": "Australia",
    "currency": "AUD",
    "exchange": "ASX",
    "industry": "Health Information Services",
    "long_name": "ICS Global Limited",
    "market": "au_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "ICSGLOBAL FPO",
    "state": "NSW",
    "summary": "ICS Global Limited, an investment holding company, provides medical billing services primarily in the United Kingdom. The company offers medical billing and collection services to medical consultants and specialists. The company was founded in 1999 and is based in Sydney, Australia.",
    "website": "http://icsglobal.com.au",
    "zipcode": "1225"
  },
  "IDT.AX": {
    "city": "Boronia",
    "country": "Australia",
    "currency": "AUD",
    "exchange": "ASX",
    "industry": "Drug Manufacturers - Specialty & Generic",
    "long_name": "IDT Australia Limited",
    "market": "au_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "IDT AUST FPO",
    "state": "VIC",
    "summary": "IDT Australia Limited engages in the research, development, manufacture, and sale of active pharmaceutical ingredients (APIs) and finished dose form products in Australia and internationally. The company offers analytical method development, stability chambers, and chemistry and microbiology quality control laboratory services, as well as pharmaceutical development services in all dosage forms. Its services also include project management, chemical, analytical chemistry, pharmacy, clinical packaging, and regulatory affairs. In addition, the company offers medical cannabis products; and various contract manufacturing services. IDT Australia Limited was founded in 1975 and is headquartered in Boronia, Australia.",
    "website": "http://www.idtaus.com.au",
    "zipcode": "3155"
  },
  "IDX.AX": {
    "city": "Melbourne",
    "country": "Australia",
    "currency": "AUD",
    "exchange": "ASX",
    "industry": "Diagnostics & Research",
    "long_name": "Integral Diagnostics Limited",
    "market": "au_market",
    "market_cap": "Small Cap",
    "sector": "Healthcare",
    "short_name": "INTEG DIAG FPO",
    "state": "VIC",
    "summary": "Integral Diagnostics Limited, a healthcare services company, provides diagnostic imaging services to general practitioners, medical specialists, and allied health professionals and their patients in Australia and New Zealand. The company provides its services through 64 radiology clinics, including 20 hospital sites. Integral Diagnostics Limited was incorporated in 2008 and is headquartered in Melbourne, Australia.",
    "website": "http://www.integraldiagnostics.com.au",
    "zipcode": "3000"
  },
  "IG7.F": {
    "city": "Homebush",
    "country": "Australia",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Biotechnology",
    "long_name": "Memphasys Limited",
    "market": "dr_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "MEMPHASYS LTD",
    "state": "NSW",
    "summary": "Memphasys Limited, a bio-separations company, develops, manufactures, and sells cell and protein separation devices, and related consumables for the healthcare, veterinary, and biotechnology market sectors in Australia. It primarily develops Felix that uses high quality sperm cells from semen samples for human assisted reproductive technologies for treating male factor infertility; hydrogels; and other polymer membranes to separate cells from fluids. The company was formerly known as NuSep Holdings Limited and changed its name to Memphasys Limited in July 2016. Memphasys Limited was incorporated in 2006 and is headquartered in Homebush, Australia.",
    "website": "http://www.memphasys.com",
    "zipcode": "2140"
  },
  "IHL.AX": {
    "city": "Melbourne",
    "country": "Australia",
    "currency": "AUD",
    "exchange": "ASX",
    "industry": "Drug Manufacturers - Specialty & Generic",
    "long_name": "Incannex Healthcare Limited",
    "market": "au_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "INHEALTH FPO",
    "state": "VIC",
    "summary": "Incannex Healthcare Limited engages in the research, development, and sale of medicinal cannabinoid products in Australia. It offers pharmaceutical grade cannabinoid products under the Incannex brand name. The company's therapeutic products in clinical trials include IHL-42X for obstructive sleep apnea; IHL-216A for traumatic brain injury; IHL-675A for sepsis associated acute respiratory distress syndrome; and IHL-493C for temporomandibular joint dysfunction. It has partnership with The Alfred Hospital and Novotech on IHL-42X clinical program for obstructive sleep apnea. Incannex Healthcare Limited has a partnership with Monash Trauma Group at the Department of Neuroscience, Monash University to conduct an in vivo study on the protective effect of IHL-216A in sports concussion. The company was formerly known as Impression Healthcare Limited and changed its name to Incannex Healthcare Limited in June 2020. Incannex Healthcare Limited is based in Melbourne, Australia.",
    "website": "http://www.incannex.com.au",
    "zipcode": "3000"
  },
  "ILA.AX": {
    "city": "Camberwell",
    "country": "Australia",
    "currency": "AUD",
    "exchange": "ASX",
    "industry": "Biotechnology",
    "long_name": "Island Pharmaceuticals Limited",
    "market": "au_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "ISLAND PHA FPO",
    "state": "VIC",
    "summary": "Island Pharmaceuticals Limited, a drug research and repurposing company, focuses on the development of preventative or therapeutic drugs for viral infections. Its lead product candidate is ISLA-101, a drug with safety profile for the prevention and treatment of dengue fever and other mosquito borne diseases. The company was founded in 2017 and is based in Camberwell, Australia.",
    "website": "http://www.islandpharmaceuticals.com",
    "zipcode": "3124"
  },
  "IMC.AX": {
    "city": "Carlton",
    "country": "Australia",
    "currency": "AUD",
    "exchange": "ASX",
    "industry": "Biotechnology",
    "long_name": "Immuron Limited",
    "market": "au_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "IMMURON FPO",
    "state": "VIC",
    "summary": "Immuron Limited, a biopharmaceutical company, researches and develops oral immunotherapy polyclonal antibodies for the treatment and prevention of infectious and immune modulated diseases in Australia, the United States, and internationally. The company operates through two segments, Research and Development, and Hyperimmune Products. The company markets Travelan and Protectyn for the prevention of travellers' diarrhea. Its lead product candidates include IMM-124E that is in Phase II clinical trials for non-alcoholic steatohepatitis, severe alcoholic hepatitis, and non-alcoholic fatty liver disease, as well as used in antiviral activity against the COVID-19 virus in laboratory studies; and IMM-529, a clinical stage product for clostridium difficile infections. Immuron Limited was founded in 1994 and is based in Carlton, Australia.",
    "website": "http://www.immuron.com.au",
    "zipcode": "3053"
  },
  "IME.AX": {
    "city": "Mascot",
    "country": "Australia",
    "currency": "AUD",
    "exchange": "ASX",
    "industry": "Health Information Services",
    "long_name": "ImExHS Limited",
    "market": "au_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "IMEXHS FPO",
    "state": "NSW",
    "summary": "ImExHS Limited operates as an imaging software as a service and ancillary service provider in Australia and internationally. It is involved in developing and selling Hiruko software platform that comprises radiology information system, which manages the workflow management system with a patient data and image distribution system, as well as picture archiving and communication system that allows healthcare organization to capture, store, view, and share radiology images. The company was founded in 2012 and is headquartered in Mascot, Australia.",
    "website": "http://www.imexhs.com",
    "zipcode": "2020"
  },
  "IMM.AX": {
    "city": "Sydney",
    "country": "Australia",
    "currency": "AUD",
    "exchange": "ASX",
    "industry": "Biotechnology",
    "long_name": "Immutep Limited",
    "market": "au_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "IMMUTEP FPO",
    "state": "NSW",
    "summary": "Immutep Limited, a biotech company, engages in the research and development of pharmaceutical product candidates. The company develops immunotherapeutic products for the treatment of cancer and autoimmune diseases. Its principal product candidate is IMP321, also known as eftilagimod alpha' or efti', which is a recombinant protein that is in Phase IIb clinical trial as a chemoimmunotherapy combination for metastatic breast cancer termed AIPAC and in a Phase I combination therapy trial in metastatic melanoma termed TACTI-mel; and is being evaluated as a combination therapy in head and neck squamous cell carcinoma and non-small cell lung carcinoma in a Phase II clinical trial called TACTI-002 and an investigator initiated Phase I trial called INSIGHT in advanced solid tumors. Its other products include IMP761, IMP701 and IMP731, all of which are related to lymphocyte activation gene 3, a gene linked to the regulation of T cells in immune responses. Immutep Limited has partnerships with GlaxoSmithKline, Novartis, CYTLIMIC Inc., INSIGHT, and EOC Pharma. The company was formerly known as Prima BioMed Ltd and changed its name to Immutep Limited in November 2017. Immutep Limited was incorporated in 1987 and is based in Sydney, Australia.",
    "website": "http://www.immutep.com",
    "zipcode": "2000"
  },
  "IMMP": {
    "city": "Sydney",
    "country": "Australia",
    "currency": "USD",
    "exchange": "NMS",
    "industry": "Biotechnology",
    "long_name": "Immutep Limited",
    "market": "us_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "Immutep Limited",
    "state": "NSW",
    "summary": "Immutep Limited, a biotech company, engages in the research and development of pharmaceutical product candidates. The company develops immunotherapeutic products for the treatment of cancer and autoimmune diseases. Its principal product candidate is IMP321, also known as eftilagimod alpha' or efti', which is a recombinant protein that is in Phase IIb clinical trial as a chemoimmunotherapy combination for metastatic breast cancer termed AIPAC and in a Phase I combination therapy trial in metastatic melanoma termed TACTI-mel; and is being evaluated as a combination therapy in head and neck squamous cell carcinoma and non-small cell lung carcinoma in a Phase II clinical trial called TACTI-002 and an investigator initiated Phase I trial called INSIGHT in advanced solid tumors. Its other products include IMP761, IMP701 and IMP731, all of which are related to lymphocyte activation gene 3, a gene linked to the regulation of T cells in immune responses. Immutep Limited has partnerships with GlaxoSmithKline, Novartis, CYTLIMIC Inc., INSIGHT, and EOC Pharma. The company was formerly known as Prima BioMed Ltd and changed its name to Immutep Limited in November 2017. Immutep Limited was incorporated in 1987 and is based in Sydney, Australia.",
    "website": "http://www.immutep.com",
    "zipcode": "2000"
  },
  "IMRN": {
    "city": "Carlton",
    "country": "Australia",
    "currency": "USD",
    "exchange": "NMS",
    "industry": "Biotechnology",
    "long_name": "Immuron Limited",
    "market": "us_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "Immuron Limited",
    "state": "VIC",
    "summary": "Immuron Limited, a biopharmaceutical company, researches and develops oral immunotherapy polyclonal antibodies for the treatment and prevention of infectious and immune modulated diseases in Australia, the United States, and internationally. The company operates through two segments, Research and Development, and Hyperimmune Products. The company markets Travelan and Protectyn for the prevention of travellers' diarrhea. Its lead product candidates include IMM-124E that is in Phase II clinical trials for non-alcoholic steatohepatitis, severe alcoholic hepatitis, and non-alcoholic fatty liver disease, as well as used in antiviral activity against the COVID-19 virus in laboratory studies; and IMM-529, a clinical stage product for clostridium difficile infections. Immuron Limited was founded in 1994 and is based in Carlton, Australia.",
    "website": "http://www.immuron.com.au",
    "zipcode": "3053"
  },
  "IMU.AX": {
    "city": "Sydney",
    "country": "Australia",
    "currency": "AUD",
    "exchange": "ASX",
    "industry": "Biotechnology",
    "long_name": "Imugene Limited",
    "market": "au_market",
    "market_cap": "Small Cap",
    "sector": "Healthcare",
    "short_name": "IMUGENE FPO",
    "state": "NSW",
    "summary": "Imugene Limited, a clinical stage immuno-oncology company, develops a range of immunotherapies to activate the immune system of cancer patients to treat and eradicate tumors in Australia. Its lead product is HER-Vaxx, a HER2-positive cancer vaccine that stimulates a polyclonal antibody response against HER2/neu receptors in gastric and breast cancer. The company's HER-Vaxx is in Phase 1b/2 study for gastric cancer. It also engages in developing PD1-Vaxx, a cancer vaccine that aims to induce the body to produce polyclonal antibodies that block PD-1 signalling; B-Vaxx, a cancer vaccine to treat tumors that over-express the HER2/neu receptor; and CF-33, a combination of genomic sequences from various vaccinia virus strains to generate potent virus. Imugene Limited was incorporated in 1986 and is headquartered in Sydney, Australia.",
    "website": "http://www.imugene.com",
    "zipcode": "2000"
  },
  "INNMF": {
    "city": "Melbourne",
    "country": "Australia",
    "currency": "USD",
    "exchange": "PNK",
    "industry": "Biotechnology",
    "long_name": "Amplia Therapeutics Limited",
    "market": "us_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "AMPLIA THERAPEUTICS LTD",
    "state": "VIC",
    "summary": "Amplia Therapeutics Limited, a pharmaceutical company, focuses on advancing a pipeline of focal adhesion kinase (FAK) inhibitors for cancer and fibrosis in Australia. The company's clinical development pipeline comprises two lead molecules, AMP945 and AMP886 that inhibits (FAK). It has a collaboration agreement with the Garvan Institute of Media Research in Sydney. The company was formerly known as Innate Immunotherapeutics Limited and changed its name to Amplia Therapeutics Limited in September 2018. Amplia Therapeutics Limited was incorporated in 2000 and is based in Melbourne, Australia.",
    "website": "http://www.ampliatx.com",
    "zipcode": "3000"
  },
  "IPD.AX": {
    "city": "Pinkenba",
    "country": "Australia",
    "currency": "AUD",
    "exchange": "ASX",
    "industry": "Medical Devices",
    "long_name": "ImpediMed Limited",
    "market": "au_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "IMPEDIMED FPO",
    "state": "QLD",
    "summary": "ImpediMed Limited, a medical software technology company, together with its subsidiaries, develops, manufactures, and sells bioimpedance spectroscopy (BIS) devices and software services in Australia, North America, and internationally. It offers SOZO, a noninvasive bioimpedance spectroscopy device for the detection of lymphedema and fluid status monitoring of heart failure patients; SFB7, a single-channel, tetrapolar BIS device to analyze body composition in healthy individuals; and ImpediVET, a single-channel, tetrapolar (BIS) device that measures fluid status and tissue composition for veterinary applications. The company sells its devices to hospitals and clinics. ImpediMed Limited was founded in 1999 and is headquartered in Pinkenba, Australia.",
    "website": "http://www.impedimed.com",
    "zipcode": "4008"
  },
  "IPDQF": {
    "city": "Pinkenba",
    "country": "Australia",
    "currency": "USD",
    "exchange": "PNK",
    "industry": "Medical Devices",
    "long_name": "ImpediMed Limited",
    "market": "us_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "IMPEDIMED LIMITED",
    "state": "QLD",
    "summary": "ImpediMed Limited, a medical software technology company, together with its subsidiaries, develops, manufactures, and sells bioimpedance spectroscopy (BIS) devices and software services in Australia, North America, and internationally. It offers SOZO, a noninvasive bioimpedance spectroscopy device for the detection of lymphedema and fluid status monitoring of heart failure patients; SFB7, a single-channel, tetrapolar BIS device to analyze body composition in healthy individuals; and ImpediVET, a single-channel, tetrapolar (BIS) device that measures fluid status and tissue composition for veterinary applications. The company sells its devices to hospitals and clinics. ImpediMed Limited was founded in 1999 and is headquartered in Pinkenba, Australia.",
    "website": "http://www.impedimed.com",
    "zipcode": "4008"
  },
  "IQI.F": {
    "city": "Melbourne",
    "country": "Australia",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Drug Manufacturers - Specialty & Generic",
    "long_name": "Incannex Healthcare Limited",
    "market": "dr_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "INCANNEX HEALTHCARE LTD.",
    "state": "VIC",
    "summary": "Incannex Healthcare Limited engages in the research, development, and sale of medicinal cannabinoid products in Australia. It offers pharmaceutical grade cannabinoid products under the Incannex brand name. The company's therapeutic products in clinical trials include IHL-42X for obstructive sleep apnea; IHL-216A for traumatic brain injury; IHL-675A for sepsis associated acute respiratory distress syndrome; and IHL-493C for temporomandibular joint dysfunction. It has partnership with The Alfred Hospital and Novotech on IHL-42X clinical program for obstructive sleep apnea. Incannex Healthcare Limited has a partnership with Monash Trauma Group at the Department of Neuroscience, Monash University to conduct an in vivo study on the protective effect of IHL-216A in sports concussion. The company was formerly known as Impression Healthcare Limited and changed its name to Incannex Healthcare Limited in June 2020. Incannex Healthcare Limited is based in Melbourne, Australia.",
    "website": "http://www.incannex.com.au",
    "zipcode": "3000"
  },
  "IUGNF": {
    "city": "Sydney",
    "country": "Australia",
    "currency": "USD",
    "exchange": "PNK",
    "industry": "Biotechnology",
    "long_name": "Imugene Limited",
    "market": "us_market",
    "market_cap": "Small Cap",
    "sector": "Healthcare",
    "short_name": "IMUGENE LIMITED",
    "state": "NSW",
    "summary": "Imugene Limited, a clinical stage immuno-oncology company, develops a range of immunotherapies to activate the immune system of cancer patients to treat and eradicate tumors in Australia. Its lead product is HER-Vaxx, a HER2-positive cancer vaccine that stimulates a polyclonal antibody response against HER2/neu receptors in gastric and breast cancer. The company's HER-Vaxx is in Phase 1b/2 study for gastric cancer. It also engages in developing PD1-Vaxx, a cancer vaccine that aims to induce the body to produce polyclonal antibodies that block PD-1 signalling; B-Vaxx, a cancer vaccine to treat tumors that over-express the HER2/neu receptor; and CF-33, a combination of genomic sequences from various vaccinia virus strains to generate potent virus. Imugene Limited was incorporated in 1986 and is headquartered in Sydney, Australia.",
    "website": "http://www.imugene.com",
    "zipcode": "2000"
  },
  "IVIXF": {
    "city": "Melbourne",
    "country": "Australia",
    "currency": "USD",
    "exchange": "PNK",
    "industry": "Drug Manufacturers - Specialty & Generic",
    "long_name": "Invion Limited",
    "market": "us_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "INVION LTD",
    "state": "VIC",
    "summary": "Invion Limited, a clinical-stage life-sciences company, researches and develops photodynamic therapy for the treatment of various cancers in Australia. The company is developing IVX-PDT, a chlorophyll-based photosensitizer to treat skin cancers, as well as solid cancers, including lung, prostrate, ovarian, and mesothelioma cancers. It has a research and development agreement with Hudson Institute of Medical Research to collaborate on a range of research and development projects for the Photosoft technology for the treatment of a range of cancers; and research agreement with Peter MacCallum Cancer Centre to undertake pre-clinical and in-vitro studies on Invion's IVX-PDT Photodynamic therapy for ano-genital cancers, including penile and anal cancer. The company was incorporated in 2000 and is headquartered in Melbourne, Australia.",
    "website": "http://www.inviongroup.com",
    "zipcode": "3102"
  },
  "IVX.AX": {
    "city": "Melbourne",
    "country": "Australia",
    "currency": "AUD",
    "exchange": "ASX",
    "industry": "Drug Manufacturers - Specialty & Generic",
    "long_name": "Invion Limited",
    "market": "au_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "INVION FPO",
    "state": "VIC",
    "summary": "Invion Limited, a clinical-stage life-sciences company, researches and develops photodynamic therapy for the treatment of various cancers in Australia. The company is developing IVX-PDT, a chlorophyll-based photosensitizer to treat skin cancers, as well as solid cancers, including lung, prostrate, ovarian, and mesothelioma cancers. It has a research and development agreement with Hudson Institute of Medical Research to collaborate on a range of research and development projects for the Photosoft technology for the treatment of a range of cancers; and research agreement with Peter MacCallum Cancer Centre to undertake pre-clinical and in-vitro studies on Invion's IVX-PDT Photodynamic therapy for ano-genital cancers, including penile and anal cancer. The company was incorporated in 2000 and is headquartered in Melbourne, Australia.",
    "website": "http://www.inviongroup.com",
    "zipcode": "3102"
  },
  "IXC.AX": {
    "city": "Subiaco",
    "country": "Australia",
    "currency": "AUD",
    "exchange": "ASX",
    "industry": "Biotechnology",
    "long_name": "Invex Therapeutics Ltd",
    "market": "au_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "INVEX THER FPO",
    "state": "WA",
    "summary": "Invex Therapeutics Ltd, a biopharmaceutical company, engages in the research and development of treatments for neurological conditions in Australia. It is involved in developing Exenatide, a treatment for neurological conditions derived from or involving raised intracranial pressure, such as idiopathic intracranial hypertension, acute stroke, and traumatic brain injury that has completed Phase II clinical trial. The company was incorporated in 2019 and is based in Subiaco, Australia.",
    "website": "http://www.invextherapeutics.com",
    "zipcode": "6008"
  },
  "JHC.AX": {
    "city": "Southbank",
    "country": "Australia",
    "currency": "AUD",
    "exchange": "ASX",
    "industry": "Medical Care Facilities",
    "long_name": "Japara Healthcare Limited",
    "market": "au_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "JAPARA FPO",
    "state": "VIC",
    "summary": "Japara Healthcare Limited, together with its subsidiaries, owns, develops, and operates residential aged care homes in Australia. It operates approximately 4,400 resident places across 51 homes located in Victoria, New South Wales, Queensland, South Australia, and Tasmania; and 180 independent living units across 5 retirement villages. The company was founded in 2005 and is based in Southbank, Australia.",
    "website": "http://japara.com.au",
    "zipcode": "3006"
  },
  "JHL.AX": {
    "city": "Milton",
    "country": "Australia",
    "currency": "AUD",
    "exchange": "ASX",
    "industry": "Health Information Services",
    "long_name": "Jayex Healthcare Limited",
    "market": "au_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "JAYEX FPO",
    "state": "QLD",
    "summary": "Jayex Healthcare Limited develops healthcare industry service technologies and integrated dispensing automation systems for the pharmaceutical and healthcare sectors in Australia and the United Kingdom. The company offers Jayex Connect platform, a cloud-based patient engagement platform, which allow users for appointment booking, patient calling, patient check-in, health messaging, and script management. Jayex Healthcare Limited was founded in 2006 and is based in Milton, Australia.",
    "website": "http://www.jayex.com/en-au/",
    "zipcode": "4064"
  },
  "KMLXF": {
    "city": "Melbourne",
    "country": "Australia",
    "currency": "USD",
    "exchange": "PNK",
    "industry": "Medical Devices",
    "long_name": "Respiri Limited",
    "market": "us_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "RESPIRI LTD",
    "state": "VIC",
    "summary": "Respiri Limited, an e-health SaaS company, researches, develops, and commercializes, medical devices in Australia and Israel. The company produces and sells mobile health applications. Its products include Wheezo, a mobile app, which has asthma management diary, medication usage and reminders, and symptoms and triggers to help asthma sufferers; and Wholter, a device for home ambulatory recording of nocturnal wheeze and cough. The company also offers PulmoTrack, a computerized wheeze detection product designed for hospital/clinical based real-time monitoring of wheeze and cough in the management of acute asthma in the ER and ICU, and for pediatric pulmonary function testing and sleep labs. The company was formerly known as iSonea Limited and changed its name to Respiri Limited in December 2015. Respiri Limited is based in Melbourne, Australia.",
    "website": "http://www.respiri.co",
    "zipcode": "3004"
  },
  "KZA.AX": {
    "city": "Sydney",
    "country": "Australia",
    "currency": "AUD",
    "exchange": "ASX",
    "industry": "Biotechnology",
    "long_name": "Kazia Therapeutics Limited",
    "market": "au_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "KAZIA FPO",
    "state": "NSW",
    "summary": "Kazia Therapeutics Limited, an oncology-focused biotechnology company, develops anti-cancer drugs. Its lead development candidate is GDC-0084, a small molecule, brain-penetrant inhibitor of the PI3K/Akt/mTor pathway, which is developed as a potential therapy for glioblastoma. The company is also developing Cantrixil, which is being developed for the treatment of ovarian cancer and is in hospitals across Australia and the United States under an Investigational New Drug application. Kazia Therapeutics Limited has collaboration agreements with St Jude Childrens Hospital; Dana-Farber Cancer Institute; Alliance for Clinical Trials in Oncology; Memorial Sloan Kettering Cancer Centre; and University of Newcastle. Kazia Therapeutics Limited has collaboration with Dana-Farber Cancer Institute to investigate the use of Kazia's investigational new drug, paxalisib, in primary central nervous system lymphoma; and Kintara Therapeutics, Inc. for the activation of paxalisib and VAL-083. The company was formerly known as Novogen Limited and changed its name to Kazia Therapeutics Limited in November 2017. Kazia Therapeutics Limited was founded in 1994 and is based in Sydney, Australia.",
    "website": "http://www.kaziatherapeutics.com",
    "zipcode": "2000"
  },
  "KZIA": {
    "city": "Sydney",
    "country": "Australia",
    "currency": "USD",
    "exchange": "NCM",
    "industry": "Biotechnology",
    "long_name": "Kazia Therapeutics Limited",
    "market": "us_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "Kazia Therapeutics Limited",
    "state": "NSW",
    "summary": "Kazia Therapeutics Limited, an oncology-focused biotechnology company, develops anti-cancer drugs. Its lead development candidate is GDC-0084, a small molecule, brain-penetrant inhibitor of the PI3K/Akt/mTor pathway, which is developed as a potential therapy for glioblastoma. The company is also developing Cantrixil, which is being developed for the treatment of ovarian cancer and is in hospitals across Australia and the United States under an Investigational New Drug application. Kazia Therapeutics Limited has collaboration agreements with St Jude Childrens Hospital; Dana-Farber Cancer Institute; Alliance for Clinical Trials in Oncology; Memorial Sloan Kettering Cancer Centre; and University of Newcastle. Kazia Therapeutics Limited has collaboration with Dana-Farber Cancer Institute to investigate the use of Kazia's investigational new drug, paxalisib, in primary central nervous system lymphoma; and Kintara Therapeutics, Inc. for the activation of paxalisib and VAL-083. The company was formerly known as Novogen Limited and changed its name to Kazia Therapeutics Limited in November 2017. Kazia Therapeutics Limited was founded in 1994 and is based in Sydney, Australia.",
    "website": "http://www.kaziatherapeutics.com",
    "zipcode": "2000"
  },
  "L2H.F": {
    "city": "Melbourne",
    "country": "Australia",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Diagnostics & Research",
    "long_name": "Lifespot Health Ltd",
    "market": "dr_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "LIFESPOT HEALTH LTD.",
    "state": "VIC",
    "summary": "Lifespot Health Ltd provides diagnostic systems and delivery platforms to healthcare enterprises in Australia. The company is developing the BodyTel System that integrates multiple sensors for capturing diagnostic information for additional diseases; Seng-Vital, a Bluetooth enabled vaporizer and health platform designed for the use of medical cannabis; and FeverTel, a dual mode digital thermometer to record and track family's symptoms. Lifespot Health Ltd was incorporated in 2016 and is based in Melbourne, Australia.",
    "website": "http://www.lifespot-health.com",
    "zipcode": "3000"
  },
  "LBT.AX": {
    "city": "Adelaide",
    "country": "Australia",
    "currency": "AUD",
    "exchange": "ASX",
    "industry": "Medical Devices",
    "long_name": "LBT Innovations Limited",
    "market": "au_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "LABTECH FPO",
    "state": "SA",
    "summary": "LBT Innovations Limited engages in the research, development, and commercialization of technologies for the healthcare and laboratory supply markets in Australia and Switzerland. It offers MicroStreak, an automated culture-plate streaking and inoculation system; Automated Plate Assessment System, an intelligent imaging and machine learning software; and WoundVue, a technology that uses artificial intelligence to assist clinicians in the assessment and care of chronic wounds. The company was founded in 2004 and is headquartered in Adelaide, Australia.",
    "website": "http://www.lbtinnovations.com",
    "zipcode": "5000"
  },
  "LCT.AX": {
    "city": "Melbourne",
    "country": "Australia",
    "currency": "AUD",
    "exchange": "ASX",
    "industry": "Biotechnology",
    "long_name": "Living Cell Technologies Limited",
    "market": "au_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "LIV CELL FPO",
    "state": "VIC",
    "summary": "Living Cell Technologies Limited, a biotechnology company, discovers, develops, and commercializes regenerative treatments that use naturally occurring cells to restore functions in New Zealand. The company's lead product is NTCELL, an alginate coated capsule, which is in clinical trials for the treatment of Parkinson's disease. It also develops LP-003, a peptide drug that reduces caloric intake targeting obesity; and LC-002, a novel calcitonin gene-related peptide antagonist targeting migraine. Living Cell Technologies Limited has a research collaboration agreement with the University of Auckland to identify products that utilize patented novel peptide synthetic chemistry technology for the treatments for obesity and migraine. The company was founded in 1987 and is based in Melbourne, Australia.",
    "website": "http://www.lctglobal.com",
    "zipcode": "3000"
  },
  "LGP.AX": {
    "city": "West Perth",
    "country": "Australia",
    "currency": "AUD",
    "exchange": "ASX",
    "industry": "Drug Manufacturers - Specialty & Generic",
    "long_name": "Little Green Pharma Ltd",
    "market": "au_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "LITTLEGRN FPO",
    "state": "WA",
    "summary": "Little Green Pharma Ltd engages in the research and development, cultivation, production, manufacturing, and distribution of medicinal cannabis products in Australia and internationally. It offers a range of medical cannabis preparations in oil formulation under the LGP Natural and LGP Advanced names. The company was founded in 2016 and is headquartered in West Perth, Australia.",
    "website": "http://www.littlegreenpharma.com",
    "zipcode": "6005"
  },
  "LHI.F": {
    "city": "Melbourne",
    "country": "Australia",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Biotechnology",
    "long_name": "Living Cell Technologies Limited",
    "market": "dr_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "LIVING CELL TECHS",
    "state": "VIC",
    "summary": "Living Cell Technologies Limited, a biotechnology company, discovers, develops, and commercializes regenerative treatments that use naturally occurring cells to restore functions in New Zealand. The company's lead product is NTCELL, an alginate coated capsule, which is in clinical trials for the treatment of Parkinson's disease. It also develops LP-003, a peptide drug that reduces caloric intake targeting obesity; and LC-002, a novel calcitonin gene-related peptide antagonist targeting migraine. Living Cell Technologies Limited has a research collaboration agreement with the University of Auckland to identify products that utilize patented novel peptide synthetic chemistry technology for the treatments for obesity and migraine. The company was founded in 1987 and is based in Melbourne, Australia.",
    "website": "http://www.lctglobal.com",
    "zipcode": "3000"
  },
  "LSH.AX": {
    "city": "Melbourne",
    "country": "Australia",
    "currency": "AUD",
    "exchange": "ASX",
    "industry": "Diagnostics & Research",
    "long_name": "Lifespot Health Ltd",
    "market": "au_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "LIFESPOT FPO",
    "state": "VIC",
    "summary": "Lifespot Health Ltd provides diagnostic systems and delivery platforms to healthcare enterprises in Australia. The company is developing the BodyTel System that integrates multiple sensors for capturing diagnostic information for additional diseases; Seng-Vital, a Bluetooth enabled vaporizer and health platform designed for the use of medical cannabis; and FeverTel, a dual mode digital thermometer to record and track family's symptoms. Lifespot Health Ltd was incorporated in 2016 and is based in Melbourne, Australia.",
    "website": "http://www.lifespot-health.com",
    "zipcode": "3000"
  },
  "LSM.F": {
    "city": "Adelaide",
    "country": "Australia",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Medical Devices",
    "long_name": "LBT Innovations Limited",
    "market": "dr_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "LBT INNOVATIONS LTD.",
    "state": "SA",
    "summary": "LBT Innovations Limited engages in the research, development, and commercialization of technologies for the healthcare and laboratory supply markets in Australia and Switzerland. It offers MicroStreak, an automated culture-plate streaking and inoculation system; Automated Plate Assessment System, an intelligent imaging and machine learning software; and WoundVue, a technology that uses artificial intelligence to assist clinicians in the assessment and care of chronic wounds. The company was founded in 2004 and is based in Adelaide, Australia.",
    "website": "http://www.lbtinnovations.com",
    "zipcode": "5000"
  },
  "LV1.AX": {
    "city": "Melbourne",
    "country": "Australia",
    "currency": "AUD",
    "exchange": "ASX",
    "industry": "Drug Manufacturers - Specialty & Generic",
    "long_name": "Live Verdure Ltd",
    "market": "au_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "LIVEVLIM FPO",
    "state": "VIC",
    "summary": "Live Verdure Ltd develops hemp plant-based solutions in Australia. The company offers hemp seed oil, seed oil capsules, infused manuka honey, honey, drinking chocolate, seed, greens, chai powder, porridge with dried fruit, falafel, health booster, falafel spicy, porridge, flour, food, muesli, protein powder, and falafel lemon and pepper. It distributes its products under the 13 Seeds brand name. The company was formerly known as 13 Seeds Pty Ltd and changed its name to Live Verdure Ltd in October 2020. Live Verdure Ltd was incorporated in 2016 and is based in Melbourne, Australia.",
    "website": "http://www.liveverdure.com.au",
    "zipcode": "3000"
  },
  "LVCLF": {
    "city": "Melbourne",
    "country": "Australia",
    "currency": "USD",
    "exchange": "PNK",
    "industry": "Biotechnology",
    "long_name": "Living Cell Technologies Limited",
    "market": "us_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "LIVING CELL TECHNOLOGIES",
    "state": "VIC",
    "summary": "Living Cell Technologies Limited, a biotechnology company, discovers, develops, and commercializes regenerative treatments that use naturally occurring cells to restore functions in New Zealand. The company's lead product is NTCELL, an alginate coated capsule, which is in clinical trials for the treatment of Parkinson's disease. It also develops LP-003, a peptide drug that reduces caloric intake targeting obesity; and LC-002, a novel calcitonin gene-related peptide antagonist targeting migraine. Living Cell Technologies Limited has a research collaboration agreement with the University of Auckland to identify products that utilize patented novel peptide synthetic chemistry technology for the treatments for obesity and migraine. The company was founded in 1987 and is based in Melbourne, Australia.",
    "website": "http://www.lctglobal.com",
    "zipcode": "3000"
  },
  "LVCLY": {
    "city": "Melbourne",
    "country": "Australia",
    "currency": "USD",
    "exchange": "PNK",
    "industry": "Biotechnology",
    "long_name": "Living Cell Technologies Limited",
    "market": "us_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "LIVING CELL TECHNOLOGIES",
    "state": "VIC",
    "summary": "Living Cell Technologies Limited, a biotechnology company, discovers, develops, and commercializes regenerative treatments that use naturally occurring cells to restore functions in New Zealand. The company's lead product is NTCELL, an alginate coated capsule, which is in clinical trials for the treatment of Parkinson's disease. It also develops LP-003, a peptide drug that reduces caloric intake targeting obesity; and LC-002, a novel calcitonin gene-related peptide antagonist targeting migraine. Living Cell Technologies Limited has a research collaboration agreement with the University of Auckland to identify products that utilize patented novel peptide synthetic chemistry technology for the treatments for obesity and migraine. The company was founded in 1987 and is based in Melbourne, Australia.",
    "website": "http://www.lctglobal.com",
    "zipcode": "3000"
  },
  "LWB.F": {
    "city": "Melbourne",
    "country": "Australia",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Biotechnology",
    "long_name": "Mesoblast Limited",
    "market": "dr_market",
    "market_cap": "Small Cap",
    "sector": "Healthcare",
    "short_name": "MESOBLAST LTD.",
    "state": "VIC",
    "summary": "Mesoblast Limited, a biopharmaceutical company, develops and commercializes allogeneic cellular medicines. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage adult stem cells. The company's products under the Phase III clinical trials include MSC-100-IV for steroid refractory acute graft versus host disease; MPC-150-IM for advanced heart failure; and MPC-06-ID for chronic low back pain due to degenerative disc disease. It is also developing MPC-300-IV that is in Phase II clinical trials for the treatment of biologic refractory rheumatoid arthritis, diabetic kidney diseases, and type 2 diabetic nephropathy. It operates in the United States, Australia, Singapore, the United Kingdom, and Switzerland. Mesoblast Limited has strategic partnerships with Tasly Pharmaceutical Group to offer MPC-150-IM for heart failure and MPC-25-IC for heart attacks in China; JCR Pharmaceuticals Co. Ltd. for the treatment of wound healing in patients with epidermolysis bullosa; and Grnenthal to develop and commercialize cell therapy for the treatment of chronic low back pain. The company was founded in 2004 and is headquartered in Melbourne, Australia.",
    "website": "http://www.mesoblast.com",
    "zipcode": "3000"
  },
  "LWBA.F": {
    "city": "Melbourne",
    "country": "Australia",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Biotechnology",
    "long_name": "Mesoblast Limited",
    "market": "dr_market",
    "market_cap": "Small Cap",
    "sector": "Healthcare",
    "short_name": "MESOBLAST SP.ADRS 144A/5",
    "state": "VIC",
    "summary": "Mesoblast Limited, a biopharmaceutical company, develops and commercializes allogeneic cellular medicines. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage adult stem cells. The company's products under the Phase III clinical trials include MSC-100-IV for steroid refractory acute graft versus host disease; MPC-150-IM for advanced heart failure; and MPC-06-ID for chronic low back pain due to degenerative disc disease. It is also developing MPC-300-IV that is in Phase II clinical trials for the treatment of biologic refractory rheumatoid arthritis, diabetic kidney diseases, and type 2 diabetic nephropathy. It operates in the United States, Australia, Singapore, the United Kingdom, and Switzerland. Mesoblast Limited has strategic partnerships with Tasly Pharmaceutical Group to offer MPC-150-IM for heart failure and MPC-25-IC for heart attacks in China; JCR Pharmaceuticals Co. Ltd. for the treatment of wound healing in patients with epidermolysis bullosa; and Grnenthal to develop and commercialize cell therapy for the treatment of chronic low back pain. The company was founded in 2004 and is headquartered in Melbourne, Australia.",
    "website": "http://www.mesoblast.com",
    "zipcode": "3000"
  },
  "MAYNF": {
    "city": "Salisbury South",
    "country": "Australia",
    "currency": "USD",
    "exchange": "PNK",
    "industry": "Drug Manufacturers - General",
    "long_name": "Mayne Pharma Group Limited",
    "market": "us_market",
    "market_cap": "Small Cap",
    "sector": "Healthcare",
    "short_name": "MAYNE PHARMA GROUP LIMITED",
    "state": "SA",
    "summary": "Mayne Pharma Group Limited, a specialty pharmaceutical company, manufactures and sells branded and generic pharmaceutical products in Australia, the United States, Korea, and internationally. The company operates through four segments: Generic Products, Specialty Brands, Metrics Contract Services, and Mayne Pharma International. It also offers oral drug delivery systems; and contract development and manufacturing services to third-party customers. The company was formerly known as Halcygen Pharmaceuticals Limited and changed its name to Mayne Pharma Group Limited in November 2010. Mayne Pharma Group Limited was incorporated in 2005 and is based in Salisbury South, Australia.",
    "website": "http://www.maynepharma.com",
    "zipcode": "5106"
  },
  "MDBIF": {
    "city": "Melbourne",
    "country": "Australia",
    "currency": "USD",
    "exchange": "PNK",
    "industry": "Health Information Services",
    "long_name": "Medibio Limited",
    "market": "us_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "MEDIBIO LIMITED",
    "state": "VIC",
    "summary": "Medibio Limited, a health technology company, researches, develops, and commercializes mental health technology to assist in the screening, diagnosing, monitoring, and management of depression and other mental health conditions in Australia and the United States. It offers mental well-being solutions for businesses through corporate health product; and develops products for healthcare provider market. Medibio Limited has a clinical trial agreement with MedBridge Healthcare LLC to support Medibio's sleep analysis of depressive burden (SADB) trial. The company was formerly known as BioProspect Limited and changed its name to Medibio Limited in November 2014. Medibio Limited was incorporated in 1987 and is based in Melbourne, Australia.",
    "website": "http://medibio.com.au",
    "zipcode": "3205"
  },
  "MDC.AX": {
    "city": "Alexandria",
    "country": "Australia",
    "currency": "AUD",
    "exchange": "ASX",
    "industry": "Biotechnology",
    "long_name": "Medlab Clinical Limited",
    "market": "au_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "MEDLAB FPO",
    "state": "NSW",
    "summary": "Medlab Clinical Limited, a medical research and development facility, engages in the nutraceutical products and pharmaceutical research businesses in Australia. The company develops bio-therapeutics for chronic kidney diseases, pre-diabetes/obesity, depression, musculoskeletal muscle loss associated with ageing, and non-opioid pain management. It also provides nutraceuticals for anti-inflammatory, cardiovascular support, endocrine support, gastrointestinal support, immunological support, infants and toddlers, metabolic support, musculoskeletal support, neurological support, sports performance, urogenital support, and weight management, as well as for men, pregnancy, seniors, teenagers, and women support. Medlab Clinical Limited was founded in 2012 and is headquartered in Botany, Australia.",
    "website": "http://www.medlab.co",
    "zipcode": "2015"
  },
  "MDR.AX": {
    "city": "Camberwell",
    "country": "Australia",
    "currency": "AUD",
    "exchange": "ASX",
    "industry": "Health Information Services",
    "long_name": "MedAdvisor Limited",
    "market": "au_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "MEDADVISOR FPO",
    "state": "VIC",
    "summary": "MedAdvisor Limited, together with its subsidiaries, develops and delivers software for personal medication management in Australia. It develops and deploys the MedAdvisor, a medication and adherence platform that connects health professionals with patients using mobile and web technologies. MedAdvisor Limited was incorporated in 2010 and is headquartered in Camberwell, Australia.",
    "website": "http://www.medadvisor.com.au",
    "zipcode": "3124"
  },
  "MEB.AX": {
    "city": "Melbourne",
    "country": "Australia",
    "currency": "AUD",
    "exchange": "ASX",
    "industry": "Health Information Services",
    "long_name": "Medibio Limited",
    "market": "au_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "MEDIBIOLTD FPO",
    "state": "VIC",
    "summary": "Medibio Limited, a health technology company, researches, develops, and commercializes mental health technology to assist in the screening, diagnosing, monitoring, and management of depression and other mental health conditions in Australia and the United States. It offers mental well-being solutions for businesses through corporate health product; and develops products for healthcare provider market. Medibio Limited has a clinical trial agreement with MedBridge Healthcare LLC to support Medibio's sleep analysis of depressive burden (SADB) trial. The company was formerly known as BioProspect Limited and changed its name to Medibio Limited in November 2014. Medibio Limited was incorporated in 1987 and is based in Melbourne, Australia.",
    "website": "http://medibio.com.au",
    "zipcode": "3205"
  },
  "MEM.AX": {
    "city": "Homebush",
    "country": "Australia",
    "currency": "AUD",
    "exchange": "ASX",
    "industry": "Biotechnology",
    "long_name": "Memphasys Limited",
    "market": "au_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "MEMPHASYS FPO",
    "state": "NSW",
    "summary": "Memphasys Limited, a bio-separations company, develops, manufactures, and sells cell and protein separation devices, and related consumables for the healthcare, veterinary, and biotechnology market sectors in Australia. It primarily develops Felix that uses high quality sperm cells from semen samples for human assisted reproductive technologies for treating male factor infertility; hydrogels; and other polymer membranes to separate cells from fluids. The company was formerly known as NuSep Holdings Limited and changed its name to Memphasys Limited in July 2016. Memphasys Limited was incorporated in 2006 and is headquartered in Homebush, Australia.",
    "website": "http://www.memphasys.com",
    "zipcode": "2140"
  },
  "MEOBF": {
    "city": "Melbourne",
    "country": "Australia",
    "currency": "USD",
    "exchange": "PNK",
    "industry": "Biotechnology",
    "long_name": "Mesoblast Limited",
    "market": "us_market",
    "market_cap": "Small Cap",
    "sector": "Healthcare",
    "short_name": "MESOBLAST LTD",
    "state": "VIC",
    "summary": "Mesoblast Limited, a biopharmaceutical company, develops and commercializes allogeneic cellular medicines. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage adult stem cells. The company's products under the Phase III clinical trials include MSC-100-IV for steroid refractory acute graft versus host disease; MPC-150-IM for advanced heart failure; and MPC-06-ID for chronic low back pain due to degenerative disc disease. It is also developing MPC-300-IV that is in Phase II clinical trials for the treatment of biologic refractory rheumatoid arthritis, diabetic kidney diseases, and type 2 diabetic nephropathy. It operates in the United States, Australia, Singapore, the United Kingdom, and Switzerland. Mesoblast Limited has strategic partnerships with Tasly Pharmaceutical Group to offer MPC-150-IM for heart failure and MPC-25-IC for heart attacks in China; JCR Pharmaceuticals Co. Ltd. for the treatment of wound healing in patients with epidermolysis bullosa; and Grnenthal to develop and commercialize cell therapy for the treatment of chronic low back pain. The company was founded in 2004 and is headquartered in Melbourne, Australia.",
    "website": "http://www.mesoblast.com",
    "zipcode": "3000"
  },
  "MESO": {
    "city": "Melbourne",
    "country": "Australia",
    "currency": "USD",
    "exchange": "NMS",
    "industry": "Biotechnology",
    "long_name": "Mesoblast Limited",
    "market": "us_market",
    "market_cap": "Small Cap",
    "sector": "Healthcare",
    "short_name": "Mesoblast Limited",
    "state": "VIC",
    "summary": "Mesoblast Limited, a biopharmaceutical company, develops and commercializes allogeneic cellular medicines. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage adult stem cells. The company's products under the Phase III clinical trials include MSC-100-IV for steroid refractory acute graft versus host disease; MPC-150-IM for advanced heart failure; and MPC-06-ID for chronic low back pain due to degenerative disc disease. It is also developing MPC-300-IV that is in Phase II clinical trials for the treatment of biologic refractory rheumatoid arthritis, diabetic kidney diseases, and type 2 diabetic nephropathy. It operates in the United States, Australia, Singapore, the United Kingdom, and Switzerland. Mesoblast Limited has strategic partnerships with Tasly Pharmaceutical Group to offer MPC-150-IM for heart failure and MPC-25-IC for heart attacks in China; JCR Pharmaceuticals Co. Ltd. for the treatment of wound healing in patients with epidermolysis bullosa; and Grnenthal to develop and commercialize cell therapy for the treatment of chronic low back pain. The company was founded in 2004 and is headquartered in Melbourne, Australia.",
    "website": "http://www.mesoblast.com",
    "zipcode": "3000"
  },
  "MFJ.F": {
    "city": "Port Melbourne",
    "country": "Australia",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Biotechnology",
    "long_name": "PolyNovo Limited",
    "market": "dr_market",
    "market_cap": "Small Cap",
    "sector": "Healthcare",
    "short_name": "POLYNOVO LTD",
    "state": "VIC",
    "summary": "Polynovo Limited develops medical devices in the United States, Australia, New Zealand, and internationally. The company offers NovoSorb Biodegradable Temporising Matrix, which is used in a fully debrided clean surgical wound to physiologically close the wound. It is also developing Syntrel hernia devices for hernia repair; breast devices in partnership with Establishment Labs; NovoSorb dermal beta cell implant in collaboration with BetaCell Technologies Pty Ltd; and NovoSorb drug elution depots. The company was formerly known as Calzada Limited and changed its name to Polynovo Limited in November 2014. Polynovo Limited was incorporated in 1998 and is based in Port Melbourne, Australia.",
    "website": "http://www.polynovo.com.au",
    "zipcode": "3207"
  },
  "MGCLF": {
    "city": "West Perth",
    "country": "Australia",
    "currency": "USD",
    "exchange": "PNK",
    "industry": "Drug Manufacturers - Specialty & Generic",
    "long_name": "MGC Pharmaceuticals Limited",
    "market": "us_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "MGC PHARMACEUTICALS LTD",
    "state": "WA",
    "summary": "MGC Pharmaceuticals Limited, together with its subsidiaries, produces and supplies phytocannabinoid derived medicines in Australia and Slovenia. It provides pharmaceutical products, such as Tetrinol for the treatment of cachexia; MXOT01GB01 to treat glioblastoma; MXOT02ME01 for the treatment of melanoma cancer; MXOT03PC01 to treat prostate cancer; TopiCann for the topical treatment of eczema and inflamed skin; and InCann, a biactive capsule to treat Chron's and IBS. The company's products under development include CannEpil, which is in Phase IIb clinical trial for the treatment in children and adolescents with refectory epilepsy; CogniCann that is in Phase II clinical trial to treat dementia and Alzheimer's diseases; and ArtemiC, which is in Phase II clinical trial for the treatment COVID-19. It has strategic collaborative partnership agreements Epilepsy Action Australia, Royal Melbourne Institute of Technology, the University of Notre Dame in Western Australia, as well as the National Institute of Biology & University Medical Centre, Ljubljana Slovenia. The company was formerly known as Erin Resources Limited and changed its name to MGC Pharmaceuticals Limited in December 2015. MGC Pharmaceuticals Limited was founded in 2014 and is headquartered in West Perth, Australia.",
    "website": "http://www.mgcpharma.com.au",
    "zipcode": "6005"
  },
  "MIGI": {
    "city": "North Sydney",
    "country": "Australia",
    "currency": "USD",
    "exchange": "PNK",
    "industry": "Biotechnology",
    "long_name": "Mawson Infrastructure Group Inc.",
    "market": "us_market",
    "market_cap": "Small Cap",
    "sector": "Healthcare",
    "short_name": "MAWSON INFRASTRUCTURE GROUP INC",
    "state": "NSW",
    "summary": "Cosmos Capital Limited, a digital asset infrastructure company, develops and deploys solutions to provide the space and capacity required for businesses, governments, organizations, and individuals to process transactions on distributed networks. The company was incorporated in 2019 and is based in North Sydney, Australia.",
    "website": "http://cosmoscapital.io",
    "zipcode": "2060"
  },
  "MIS.F": {
    "city": "Richmond",
    "country": "Australia",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Diagnostics & Research",
    "long_name": "Monash IVF Group Limited",
    "market": "dr_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "MONASH IVF GROUP LTD",
    "state": "VIC",
    "summary": "Monash IVF Group Limited provides assisted reproductive and specialist women imaging services in Australia and Malaysia. The company offers diagnosis and treatment of infertility, fertility research and treatment services, tertiary level prenatal diagnostic services, low intervention IVF services, and diagnostic ultrasound services. Monash IVF Group Limited was incorporated in 2014 and is based in Richmond, Australia.",
    "website": "http://www.monashivfgroup.com.au",
    "zipcode": "3121"
  },
  "MLPH": {
    "city": "Perth",
    "country": "Australia",
    "currency": "USD",
    "exchange": "PNK",
    "industry": "Biotechnology",
    "long_name": "Molecular Pharmacology (USA), Ltd.",
    "market": "us_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "MOLECULAR PHARMACOLOGY LIMITED",
    "state": "WA",
    "summary": "Molecular Pharmacology (USA) Limited, a development stage company, develops and commercializes pain and inflammation management products primarily in Australia and the United States. The company, through its subsidiary, Molecular Pharmacology Pty. Ltd., develops analgesic and anti-inflammatory molecule, known as Tripeptofen for the treatment of common every-day pain. Its products are available in various dosage forms, formulations, line extensions, and package configurations. The company focuses on marketing its products through pharmaceutical distributors, and through collaborative dealings with companies in the United States and Europe. It also has an agreement with Dermatology Development Corporation to develop and market a range of therapeutic, cosmetic, and cosmecutical products based on the ThermaLIFE product range and its active ingredient. The company is based in Perth, Australia. Molecular Pharmacology (USA) Limited is a subsidiary of PharmaNet Group Limited.",
    "website": null,
    "zipcode": "6007"
  },
  "MMJ.AX": {
    "city": "Sydney",
    "country": "Australia",
    "currency": "AUD",
    "exchange": "ASX",
    "industry": "Drug Manufacturers - Specialty & Generic",
    "long_name": "MMJ Group Holdings Limited",
    "market": "au_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "MMJGROUP FPO",
    "state": "NSW",
    "summary": "MMJ Group Holdings Limited operates as a cannabis investment company worldwide. It owns a portfolio of cannabis sector investments. The company was formerly known as MMJ PhytoTech Limited. MMJ Group Holdings Limited was incorporated in 2014 and is based in Sydney, Australia.",
    "website": "http://www.mmjgh.com.au",
    "zipcode": "2000"
  },
  "MMJJF": {
    "city": "Sydney",
    "country": "Australia",
    "currency": "USD",
    "exchange": "PNK",
    "industry": "Drug Manufacturers - Specialty & Generic",
    "long_name": "MMJ Group Holdings Limited",
    "market": "us_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "MMJ GROUP HOLDINGS LTD",
    "state": "NSW",
    "summary": "MMJ Group Holdings Limited operates as a cannabis investment company worldwide. It owns a portfolio of cannabis sector investments. The company was formerly known as MMJ PhytoTech Limited. MMJ Group Holdings Limited was incorporated in 2014 and is based in Sydney, Australia.",
    "website": "http://www.mmjgh.com.au",
    "zipcode": "2000"
  },
  "MSB.AX": {
    "city": "Melbourne",
    "country": "Australia",
    "currency": "AUD",
    "exchange": "ASX",
    "industry": "Biotechnology",
    "long_name": "Mesoblast Limited",
    "market": "au_market",
    "market_cap": "Small Cap",
    "sector": "Healthcare",
    "short_name": "MESOBLAST FPO",
    "state": "VIC",
    "summary": "Mesoblast Limited, a biopharmaceutical company, develops and commercializes allogeneic cellular medicines. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage adult stem cells. The company's products under the Phase III clinical trials include MSC-100-IV for steroid refractory acute graft versus host disease; MPC-150-IM for advanced heart failure; and MPC-06-ID for chronic low back pain due to degenerative disc disease. It is also developing MPC-300-IV that is in Phase II clinical trials for the treatment of biologic refractory rheumatoid arthritis, diabetic kidney diseases, and type 2 diabetic nephropathy. It operates in the United States, Australia, Singapore, the United Kingdom, and Switzerland. Mesoblast Limited has strategic partnerships with Tasly Pharmaceutical Group to offer MPC-150-IM for heart failure and MPC-25-IC for heart attacks in China; JCR Pharmaceuticals Co. Ltd. for the treatment of wound healing in patients with epidermolysis bullosa; and Grnenthal to develop and commercialize cell therapy for the treatment of chronic low back pain. The company was founded in 2004 and is headquartered in Melbourne, Australia.",
    "website": "http://www.mesoblast.com",
    "zipcode": "3000"
  },
  "MVF.AX": {
    "city": "Richmond",
    "country": "Australia",
    "currency": "AUD",
    "exchange": "ASX",
    "industry": "Diagnostics & Research",
    "long_name": "Monash IVF Group Limited",
    "market": "au_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "MONASH IVF FPO",
    "state": "VIC",
    "summary": "Monash IVF Group Limited provides assisted reproductive and specialist women imaging services in Australia and Malaysia. The company offers diagnosis and treatment of infertility, fertility research and treatment services, tertiary level prenatal diagnostic services, low intervention IVF services, and diagnostic ultrasound services. Monash IVF Group Limited was incorporated in 2014 and is based in Richmond, Australia.",
    "website": "http://www.monashivfgroup.com.au",
    "zipcode": "3121"
  },
  "MVP.AX": {
    "city": "Scoresby",
    "country": "Australia",
    "currency": "AUD",
    "exchange": "ASX",
    "industry": "Drug Manufacturers - Specialty & Generic",
    "long_name": "Medical Developments International Limited",
    "market": "au_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "MEDICALDEV FPO",
    "state": "VIC",
    "summary": "Medical Developments International Limited manufactures and distributes pharmaceutical and veterinary products, and medical devices. The company operates through three segments: Pharmaceuticals, Medical Devices, and Veterinary Products. It offers asthma and COPD pressurized metered dose inhalers, as well as masks and peak flow meters for asthma management for use in home or in hospitals; Penthrox, a prescription only medicine for pain relief; medical devices; and various veterinary anesthetic machines to veterinarians. The company operates in Australia, New Zealand, the United Kingdom, rest of Europe, Canada, the Middle East, Asia, South Africa, North America, and internationally. Medical Developments International Limited was incorporated in 2003 and is headquartered in Scoresby, Australia.",
    "website": "http://medicaldev.com",
    "zipcode": "3179"
  },
  "MX1.AX": {
    "city": "Tonsley",
    "country": "Australia",
    "currency": "AUD",
    "exchange": "ASX",
    "industry": "Medical Devices",
    "long_name": "Micro-X Limited",
    "market": "au_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "MICRO-X FPO",
    "state": "SA",
    "summary": "Micro-X Limited designs, develops, and manufactures ultra-lightweight carbon nano tube based X-ray products for the healthcare and improvised explosive device imaging security markets in Australia. The company offers Carestream DRX Revolution Nano, an ultra-lightweight digital mobile X-ray system for bedside imaging for use in hospital wards and intensive care units; and Rover, a digital mobile X-Ray unit for deployed military hospitals. It is also developing Mobile Backscatter Imager for stand-off imaging of improvised explosive devices. The company was founded in 2011 and is based in Tonsley, Australia.",
    "website": "http://www.micro-x.com",
    "zipcode": "5042"
  },
  "MXC.AX": {
    "city": "West Perth",
    "country": "Australia",
    "currency": "AUD",
    "exchange": "ASX",
    "industry": "Drug Manufacturers - Specialty & Generic",
    "long_name": "MGC Pharmaceuticals Limited",
    "market": "au_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "MGC PHARMA FPO",
    "state": "WA",
    "summary": "MGC Pharmaceuticals Limited, together with its subsidiaries, produces and supplies phytocannabinoid derived medicines in Australia and Slovenia. It provides pharmaceutical products, such as Tetrinol for the treatment of cachexia; MXOT01GB01 to treat glioblastoma; MXOT02ME01 for the treatment of melanoma cancer; MXOT03PC01 to treat prostate cancer; TopiCann for the topical treatment of eczema and inflamed skin; and InCann, a biactive capsule to treat Chron's and IBS. The company's products under development include CannEpil, which is in Phase IIb clinical trial for the treatment in children and adolescents with refectory epilepsy; CogniCann that is in Phase II clinical trial to treat dementia and Alzheimer's diseases; and ArtemiC, which is in Phase II clinical trial for the treatment COVID-19. It has strategic collaborative partnership agreements Epilepsy Action Australia, Royal Melbourne Institute of Technology, the University of Notre Dame in Western Australia, as well as the National Institute of Biology & University Medical Centre, Ljubljana Slovenia. The company was formerly known as Erin Resources Limited and changed its name to MGC Pharmaceuticals Limited in December 2015. MGC Pharmaceuticals Limited was founded in 2014 and is headquartered in West Perth, Australia.",
    "website": "http://www.mgcpharma.com.au",
    "zipcode": "6005"
  },
  "MXC.L": {
    "city": "West Perth",
    "country": "Australia",
    "currency": "GBp",
    "exchange": "LSE",
    "industry": "Drug Manufacturers - Specialty & Generic",
    "long_name": "MGC Pharmaceuticals Limited",
    "market": "gb_market",
    "market_cap": null,
    "sector": "Healthcare",
    "short_name": "MGC PHARMACEUTICALS LIMITED ORD",
    "state": "WA",
    "summary": "MGC Pharmaceuticals Limited, together with its subsidiaries, produces and supplies phytocannabinoid derived medicines in Australia and Slovenia. It provides pharmaceutical products, such as Tetrinol for the treatment of cachexia; MXOT01GB01 to treat glioblastoma; MXOT02ME01 for the treatment of melanoma cancer; MXOT03PC01 to treat prostate cancer; TopiCann for the topical treatment of eczema and inflamed skin; and InCann, a biactive capsule to treat Chron's and IBS. The company's products under development include CannEpil, which is in Phase IIb clinical trial for the treatment in children and adolescents with refectory epilepsy; CogniCann that is in Phase II clinical trial to treat dementia and Alzheimer's diseases; and ArtemiC, which is in Phase II clinical trial for the treatment COVID-19. It has strategic collaborative partnership agreements Epilepsy Action Australia, Royal Melbourne Institute of Technology, the University of Notre Dame in Western Australia, as well as the National Institute of Biology & University Medical Centre, Ljubljana Slovenia. The company was formerly known as Erin Resources Limited and changed its name to MGC Pharmaceuticals Limited in December 2015. MGC Pharmaceuticals Limited was founded in 2014 and is headquartered in West Perth, Australia.",
    "website": "http://www.mgcpharma.com.au",
    "zipcode": "6005"
  },
  "MYX.AX": {
    "city": "Salisbury South",
    "country": "Australia",
    "currency": "AUD",
    "exchange": "ASX",
    "industry": "Drug Manufacturers - General",
    "long_name": "Mayne Pharma Group Limited",
    "market": "au_market",
    "market_cap": "Small Cap",
    "sector": "Healthcare",
    "short_name": "M PHARMA FPO",
    "state": "SA",
    "summary": "Mayne Pharma Group Limited, a specialty pharmaceutical company, manufactures and sells branded and generic pharmaceutical products in Australia, the United States, Korea, and internationally. The company operates through four segments: Generic Products, Specialty Brands, Metrics Contract Services, and Mayne Pharma International. It also offers oral drug delivery systems; and contract development and manufacturing services to third-party customers. The company was formerly known as Halcygen Pharmaceuticals Limited and changed its name to Mayne Pharma Group Limited in November 2010. Mayne Pharma Group Limited was incorporated in 2005 and is based in Salisbury South, Australia.",
    "website": "http://www.maynepharma.com",
    "zipcode": "5106"
  },
  "N6A.F": {
    "city": "North Sydney",
    "country": "Australia",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Medical Devices",
    "long_name": "OncoSil Medical Limited",
    "market": "dr_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "ONCOSIL MEDICAL LTD",
    "state": "NSW",
    "summary": "OncoSil Medical Limited, a medical device company, focuses on the development of localized treatments for pancreatic and liver cancer in Australia. Its lead product is OncoSil, a brachytherapy device that implants a pre-determined dose of beta radiation directly into cancerous tissue for the treatment of cancer. The company was formerly known as NeuroDiscovery Limited and changed its name to OncoSil Medical Limited in June 2013. OncoSil Medical Limited is headquartered in North Sydney, Australia.",
    "website": "http://www.oncosil.com.au",
    "zipcode": "2060"
  },
  "NAN.AX": {
    "city": "Lane Cove",
    "country": "Australia",
    "currency": "AUD",
    "exchange": "ASX",
    "industry": "Medical Instruments & Supplies",
    "long_name": "Nanosonics Limited",
    "market": "au_market",
    "market_cap": "Small Cap",
    "sector": "Healthcare",
    "short_name": "NANOSONICS FPO",
    "state": "NSW",
    "summary": "Nanosonics Limited, together with its subsidiaries, engages in the research, development, and commercialization of infection control and decontamination products and related technologies. The company manufactures and distributes the trophon ultrasound probe disinfector, and its associated consumables and accessories for reducing cross-contamination between patients and the spread of healthcare acquired infections. It also provides trophon2, an ultrasound probe high level disinfection device; and trophon EPR, a device designed to disinfect intracavity and surface ultrasound probes. In addition, the company offers trophon EPR and trophon2 consumables and accessories, including NanoNebulant, a proprietary disinfectant liquid; trophon chemical indicators; trophon AcuTrace operator cards, medical instrument tags, printers, printer USB cables, printer label rolls, and logbooks; trophon wall mounts, printer wall mounts, carts, and printer cart mounts; trophon companion drying wipes and companion wipes wall mounts; clean ultrasound probe covers; and trophon AcuTrace PLUS activation cards. It operates in North America, Europe, the Middle East, and the Asia Pacific. The company was incorporated in 2000 and is headquartered in Lane Cove, Australia.",
    "website": "http://www.nanosonics.com.au",
    "zipcode": "2066"
  },
  "NC6.AX": {
    "city": "Nedlands",
    "country": "Australia",
    "currency": "AUD",
    "exchange": "ASX",
    "industry": "Biotechnology",
    "long_name": "Nanollose Limited",
    "market": "au_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "NANOLLOSE FPO",
    "state": "WA",
    "summary": "Nanollose Limited, a biotechnology company, engages in the research and development, and promotion of the microbial nanocellulose technology in Australia. It focuses on the development of Nullarbor, a plant-free viscose-rayon fibre. The company's products are used in textiles, nonwoven fabric, and other industries. Nanollose Limited was founded in 2014 and is based in Nedlands, Australia.",
    "website": "http://www.nanollose.com",
    "zipcode": "6009"
  },
  "NEU.AX": {
    "city": "Camberwell",
    "country": "Australia",
    "currency": "AUD",
    "exchange": "ASX",
    "industry": "Biotechnology",
    "long_name": "Neuren Pharmaceuticals Limited",
    "market": "au_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "NEUREN FPO NZ",
    "state": "VIC",
    "summary": "Neuren Pharmaceuticals Limited, a biopharmaceutical company, develops drugs for the treatment of neurological disorders. Its lead product is trofinetide, which is in Phase III clinical trial for the treatment of Rett syndrome, as well as has completed Phase II clinical trial to treat Fragile X syndrome. The company also develops NNZ-2591, which has completed Phase I clinical trial for the treatment of Phelan-McDermid, Angelman, and Pitt Hopkins syndromes. In addition, it provides development services; and holds loan funded shares. Neuren Pharmaceuticals Limited was incorporated in 2001 and is based in Camberwell, Australia.",
    "website": "http://www.neurenpharma.com",
    "zipcode": "3124"
  },
  "NNCSF": {
    "city": "Lane Cove",
    "country": "Australia",
    "currency": "USD",
    "exchange": "PNK",
    "industry": "Medical Instruments & Supplies",
    "long_name": "Nanosonics Limited",
    "market": "us_market",
    "market_cap": "Small Cap",
    "sector": "Healthcare",
    "short_name": "NANOSONICS LIMITED",
    "state": "NSW",
    "summary": "Nanosonics Limited, together with its subsidiaries, engages in the research, development, and commercialization of infection control and decontamination products and related technologies. The company manufactures and distributes the trophon ultrasound probe disinfector, and its associated consumables and accessories for reducing cross-contamination between patients and the spread of healthcare acquired infections. It also provides trophon2, an ultrasound probe high level disinfection device; and trophon EPR, a device designed to disinfect intracavity and surface ultrasound probes. In addition, the company offers trophon EPR and trophon2 consumables and accessories, including NanoNebulant, a proprietary disinfectant liquid; trophon chemical indicators; trophon AcuTrace operator cards, medical instrument tags, printers, printer USB cables, printer label rolls, and logbooks; trophon wall mounts, printer wall mounts, carts, and printer cart mounts; trophon companion drying wipes and companion wipes wall mounts; clean ultrasound probe covers; and trophon AcuTrace PLUS activation cards. It operates in North America, Europe, the Middle East, and the Asia Pacific. The company was incorporated in 2000 and is headquartered in Lane Cove, Australia.",
    "website": "http://www.nanosonics.com.au",
    "zipcode": "2066"
  },
  "NOX.AX": {
    "city": "Gordon",
    "country": "Australia",
    "currency": "AUD",
    "exchange": "ASX",
    "industry": "Biotechnology",
    "long_name": "Noxopharm Limited",
    "market": "au_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "NOXOPHARM FPO",
    "state": "NSW",
    "summary": "Noxopharm Limited, a drug development company, focuses on the research and development of drugs to enhance radiotherapy in Australia and internationally. It primarily develops Veyonda, an adjuvant therapy in chemotherapy and radiotherapy for the treatment of late-stage cancers. The company also focuses on developing NYX-330, a PCSK9-inhibitor and LDL-cholesterol-lowering drug; NYX-104, a neuroprotectant that protects the brain from further damage after stroke and traumatic brain injury; and NYX-205, an anti-inflammatory drug for the treatment of nerve tissue inflammation. In addition, it develops anti-autoimmune drugs, such as IRAK4 and TPL2 inhibitors; and LuPIN for the combined therapy of Veyonda and 177Lu-PSMA-617. Noxopharm Limited has a partnership with Hudson Institute of Medical Research and a collaboration with The Australian National University to develop a better treatment for septic shock. The company was incorporated in 2015 and is based in Gordon, Australia.",
    "website": "http://www.noxopharm.com",
    "zipcode": "2072"
  },
  "NOXOF": {
    "city": "Gordon",
    "country": "Australia",
    "currency": "USD",
    "exchange": "PNK",
    "industry": "Biotechnology",
    "long_name": "Noxopharm Limited",
    "market": "us_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "NOXOPHARM LTD",
    "state": "NSW",
    "summary": "Noxopharm Limited, a drug development company, focuses on the research and development of drugs to enhance radiotherapy in Australia and internationally. It primarily develops Veyonda, an adjuvant therapy in chemotherapy and radiotherapy for the treatment of late-stage cancers. The company also focuses on developing NYX-330, a PCSK9-inhibitor and LDL-cholesterol-lowering drug; NYX-104, a neuroprotectant that protects the brain from further damage after stroke and traumatic brain injury; and NYX-205, an anti-inflammatory drug for the treatment of nerve tissue inflammation. In addition, it develops anti-autoimmune drugs, such as IRAK4 and TPL2 inhibitors; and LuPIN for the combined therapy of Veyonda and 177Lu-PSMA-617. Noxopharm Limited has a partnership with Hudson Institute of Medical Research and a collaboration with The Australian National University to develop a better treatment for septic shock. The company was incorporated in 2015 and is based in Gordon, Australia.",
    "website": "http://www.noxopharm.com",
    "zipcode": "2072"
  },
  "NSB.AX": {
    "city": "Nedlands",
    "country": "Australia",
    "currency": "AUD",
    "exchange": "ASX",
    "industry": "Biotechnology",
    "long_name": "NeuroScientific Biopharmaceuticals Limited",
    "market": "au_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "NEUROSCIEN FPO",
    "state": "WA",
    "summary": "NeuroScientific Biopharmaceuticals Limited develops diagnostic and therapeutic treatments for neurodegenerative diseases through preclinical studies of patented technologies. The company's lead drug candidates include EmtinB for treatment of neurodegenerative dementia and Alzheimer's disease, and degenerative conditions of the optic nerve. NeuroScientific Biopharmaceuticals Limited was incorporated in 2002 and is based in Cottesloe, Australia.",
    "website": "http://www.neuroscientific.com",
    "zipcode": "6009"
  },
  "NTI.AX": {
    "city": "Nedlands",
    "country": "Australia",
    "currency": "AUD",
    "exchange": "ASX",
    "industry": "Medical Devices",
    "long_name": "Neurotech International Limited",
    "market": "au_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "NEUROTECH FPO",
    "state": "WA",
    "summary": "Neurotech International Limited, together with its subsidiaries, engages in the research, design, development, and manufacture of medical devices and solutions in Australia. Its product includes Mente Autism, a portable electroencephalographic medical device that uses neuro feedback to relax the minds of children with autism spectrum disorder. The company focuses on developing neuro-stimulation and neuro-diagnostic solutions that enable medical practitioners to monitor and play an active role in home-based therapies. It also engages in executing of medical research projects; and developing of technological devices and other solutions for the screening and treatment of neurological disorders. The company was incorporated in 2016 and is based in Nedlands, Australia.",
    "website": "http://www.neurotechinternational.com",
    "zipcode": "6009"
  },
  "NUG.F": {
    "city": "Brisbane",
    "country": "Australia",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Health Information Services",
    "long_name": "ResApp Health Limited",
    "market": "dr_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "RESAPP HEALTH",
    "state": "QLD",
    "summary": "ResApp Health Limited develops digital healthcare solutions to assist doctors and allow patients to diagnose and manage respiratory disease. The company offers ResAppDx, a smartphone-based acute respiratory disease diagnostic test for use in telehealth, emergency department, and primary care markets; and SleepCheck, a direct-to-consumer smartphone application for the self-assessment of sleep apnoea in 36 countries. Its technology uses sound to diagnose respiratory diseases, including pneumonia, bronchiolitis, bronchitis, chronic obstructive pulmonary disease, and asthma. ResApp Health Limited has a joint development and pilot agreement with Medgate AG to integrate and test smartphone-based acute respiratory diagnostic test. The company was formerly known as Narhex Life Sciences Limited. ResApp Health Limited was founded in 2014 and is headquartered in Brisbane, Australia.",
    "website": "http://www.resapphealth.com.au",
    "zipcode": "4000"
  },
  "NURPF": {
    "city": "Camberwell",
    "country": "Australia",
    "currency": "USD",
    "exchange": "PNK",
    "industry": "Biotechnology",
    "long_name": "Neuren Pharmaceuticals Limited",
    "market": "us_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "NEUREN PHARMACEUTICALS LTD",
    "state": "VIC",
    "summary": "Neuren Pharmaceuticals Limited, a biopharmaceutical company, develops drugs for the treatment of neurological disorders. Its lead product is trofinetide, which is in Phase III clinical trial for the treatment of Rett syndrome, as well as has completed Phase II clinical trial to treat Fragile X syndrome. The company also develops NNZ-2591, which has completed Phase I clinical trial for the treatment of Phelan-McDermid, Angelman, and Pitt Hopkins syndromes. In addition, it provides development services; and holds loan funded shares. Neuren Pharmaceuticals Limited was incorporated in 2001 and is based in Camberwell, Australia.",
    "website": "http://www.neurenpharma.com",
    "zipcode": "3124"
  },
  "NV9.F": {
    "city": "Sydney",
    "country": "Australia",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Biotechnology",
    "long_name": "Kazia Therapeutics Limited",
    "market": "dr_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "KAZIA THERAPEUTICS",
    "state": "NSW",
    "summary": "Kazia Therapeutics Limited, an oncology-focused biotechnology company, develops anti-cancer drugs. Its lead development candidate is GDC-0084, a small molecule, brain-penetrant inhibitor of the PI3K/Akt/mTor pathway, which is developed as a potential therapy for glioblastoma. The company is also developing Cantrixil, which is being developed for the treatment of ovarian cancer and is in hospitals across Australia and the United States under an Investigational New Drug application. Kazia Therapeutics Limited has collaboration agreements with St Jude Childrens Hospital; Dana-Farber Cancer Institute; Alliance for Clinical Trials in Oncology; Memorial Sloan Kettering Cancer Centre; and University of Newcastle. Kazia Therapeutics Limited has collaboration with Dana-Farber Cancer Institute to investigate the use of Kazia's investigational new drug, paxalisib, in primary central nervous system lymphoma; and Kintara Therapeutics, Inc. for the activation of paxalisib and VAL-083. The company was formerly known as Novogen Limited and changed its name to Kazia Therapeutics Limited in November 2017. Kazia Therapeutics Limited was founded in 1994 and is based in Sydney, Australia.",
    "website": "http://www.kaziatherapeutics.com",
    "zipcode": "2000"
  },
  "NV9M.F": {
    "city": "Sydney",
    "country": "Australia",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Biotechnology",
    "long_name": "Kazia Therapeutics Limited",
    "market": "dr_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "KAZIA THER.LTD.ADR 10 NEW",
    "state": "NSW",
    "summary": "Kazia Therapeutics Limited, an oncology-focused biotechnology company, develops anti-cancer drugs. Its lead development candidate is GDC-0084, a small molecule, brain-penetrant inhibitor of the PI3K/Akt/mTor pathway, which is developed as a potential therapy for glioblastoma. The company is also developing Cantrixil, which is being developed for the treatment of ovarian cancer and is in hospitals across Australia and the United States under an Investigational New Drug application. Kazia Therapeutics Limited has collaboration agreements with St Jude Childrens Hospital; Dana-Farber Cancer Institute; Alliance for Clinical Trials in Oncology; Memorial Sloan Kettering Cancer Centre; and University of Newcastle. Kazia Therapeutics Limited has collaboration with Dana-Farber Cancer Institute to investigate the use of Kazia's investigational new drug, paxalisib, in primary central nervous system lymphoma; and Kintara Therapeutics, Inc. for the activation of paxalisib and VAL-083. The company was formerly known as Novogen Limited and changed its name to Kazia Therapeutics Limited in November 2017. Kazia Therapeutics Limited was founded in 1994 and is based in Sydney, Australia.",
    "website": "http://www.kaziatherapeutics.com",
    "zipcode": "2000"
  },
  "NXS.AX": {
    "city": "Chatswood",
    "country": "Australia",
    "currency": "AUD",
    "exchange": "ASX",
    "industry": "Drug Manufacturers - Specialty & Generic",
    "long_name": "Next Science Limited",
    "market": "au_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "NEXTSCIENC FPO",
    "state": "NSW",
    "summary": "Next Science Limited, a medical technology company, researches, develops, and commercializes technologies to eradicate issues in human health caused by biofilms. The company develops its products using its Xbio Technology platform. It offers SURGX, an antimicrobial gel designed to reduce surgical site and post-surgical infections; and BACTISURE, a surgical lavage that is used to wash out the surgery site and Intramedullary canal. The company also provides BlastX, an antimicrobial wound gel that destroys bacteria within the gel and defends from recolonization while maintaining a moist wound environment; and XPERIENCE, an no rinse antimicrobial solution that helps prevent surgical site and post-operative infections. It has strategic partnerships with Montana State University Center for Biofilm Engineering, Mayo Clinic, Texas Tech University Clinical Research Institute, Southwest Regional Wound Care Center, University of Florida Department of Otolaryngology, and Jacksonville Center for Clinical Research. Next Science Limited has operations in the United States and Australia. The company was founded in 2012 and is headquartered in Chatswood, Australia.",
    "website": "http://www.nextscience.com",
    "zipcode": "2067"
  },
  "NXSCF": {
    "city": "Chatswood",
    "country": "Australia",
    "currency": "USD",
    "exchange": "PNK",
    "industry": "Drug Manufacturers - Specialty & Generic",
    "long_name": "Next Science Limited",
    "market": "us_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "NEXT SCIENCE LTD",
    "state": "NSW",
    "summary": "Next Science Limited, a medical technology company, researches, develops, and commercializes technologies to eradicate issues in human health caused by biofilms. The company develops its products using its Xbio Technology platform. It offers SURGX, an antimicrobial gel designed to reduce surgical site and post-surgical infections; and BACTISURE, a surgical lavage that is used to wash out the surgery site and Intramedullary canal. The company also provides BlastX, an antimicrobial wound gel that destroys bacteria within the gel and defends from recolonization while maintaining a moist wound environment; and XPERIENCE, an no rinse antimicrobial solution that helps prevent surgical site and post-operative infections. It has strategic partnerships with Montana State University Center for Biofilm Engineering, Mayo Clinic, Texas Tech University Clinical Research Institute, Southwest Regional Wound Care Center, University of Florida Department of Otolaryngology, and Jacksonville Center for Clinical Research. Next Science Limited has operations in the United States and Australia. The company was founded in 2012 and is headquartered in Chatswood, Australia.",
    "website": "http://www.nextscience.com",
    "zipcode": "2067"
  },
  "NYR.AX": {
    "city": "Gordon",
    "country": "Australia",
    "currency": "AUD",
    "exchange": "ASX",
    "industry": "Biotechnology",
    "long_name": "Nyrada Inc.",
    "market": "au_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "NYRADA CDI FORUS",
    "state": "NSW",
    "summary": "Nyrada Inc., a pre-clinical stage drug development company, engages in the development of small molecule drugs for cardiovascular, neurodegenerative, and chronic inflammatory diseases. Its products in drug development stage include PCSK9 inhibitor for the treatment of high blood LDL-cholesterol levels in patients poorly responsive to or unable to take statin drugs; a neuroprotectant drug to reduce the impact of long-term disability in patients with ischaemic stroke and traumatic brain injury; a drug to treat pain associated with peripheral nerve damage; and a drug to treat autoimmune diseases, such as psoriasis. Nyrada Inc. has collaboration with Walter Reed Army Institute of Research and UNSW. The company was founded in 2017 and is based in Gordon, Australia.",
    "website": "http://www.nyrada.com",
    "zipcode": "2072"
  },
  "OAK.AX": {
    "city": "Mile End South",
    "country": "Australia",
    "currency": "AUD",
    "exchange": "ASX",
    "industry": "Health Information Services",
    "long_name": "Oakridge International Limited",
    "market": "au_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "OAKRIDGE FPO",
    "state": "SA",
    "summary": "Oakridge International Limited develops Internet of Things technology solutions for consumer, commercial, industrial, and healthcare markets. It operates through Healthcare Technology, Technology Development, and Geothermal Projects segments. The company offers DiscoverBus wireless sensor network designed to create secure indoor wireless networks for smart office, smart building, industrial, and commercial applications; and DiscoverBus wired hub and node network primarily designed for wired networks for smart office, smart building, industrial, and commercial applications. It also provides Smart Home Gateway to automate, monitor, and control home; communication technology solutions, including the development and distribution of range of nurse call hardware and software solutions for use in hospitals, aged care, disability care, and supported independent living; and operates various geothermal projects. The company was formerly known as Xped Limited and changed its name to Oakridge International Limited in April 2021. Oakridge International Limited is based in Payneham, Australia.",
    "website": "http://www.xped.com",
    "zipcode": "5031"
  },
  "OC5.F": {
    "city": "Sydney",
    "country": "Australia",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Medical Devices",
    "long_name": "Cochlear Limited",
    "market": "dr_market",
    "market_cap": "Large Cap",
    "sector": "Healthcare",
    "short_name": "COCHLEAR LTD",
    "state": "NSW",
    "summary": "Cochlear Limited provides implantable hearing solutions in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers cochlear implants, including Nucleus 7, Nucleus 6, Nucleus CP802, and Kanso sound processors; and Baha bone conduction implants, such as Baha attract system, Baha connect system, Baha softband, Baha soundarc, Baha 5 sound processor, and Baha sound processor. It also provides Cochlear true wireless accessories comprising mini microphones, phone clips, and TV streamers; Nucleus water-safe accessories; and training and development services. Cochlear Limited was founded in 1981 and is headquartered in Sydney, Australia.",
    "website": "http://www.cochlear.com",
    "zipcode": "2109"
  },
  "OC50.F": {
    "city": "Sydney",
    "country": "Australia",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Medical Devices",
    "long_name": "Cochlear Limited",
    "market": "dr_market",
    "market_cap": "Large Cap",
    "sector": "Healthcare",
    "short_name": "COCHLEAR LTD ADR 1/2/O.N.",
    "state": "NSW",
    "summary": "Cochlear Limited provides implantable hearing solutions in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers cochlear implants, including Nucleus 7, Nucleus 6, Nucleus CP802, and Kanso sound processors; and Baha bone conduction implants, such as Baha attract system, Baha connect system, Baha softband, Baha soundarc, Baha 5 sound processor, and Baha sound processor. It also provides Cochlear true wireless accessories comprising mini microphones, phone clips, and TV streamers; Nucleus water-safe accessories; and training and development services. Cochlear Limited was founded in 1981 and is headquartered in Sydney, Australia.",
    "website": "http://www.cochlear.com",
    "zipcode": "2109"
  },
  "OCC.AX": {
    "city": "Murdoch",
    "country": "Australia",
    "currency": "AUD",
    "exchange": "ASX",
    "industry": "Biotechnology",
    "long_name": "Orthocell Limited",
    "market": "au_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "ORTHOCELL FPO",
    "state": "WA",
    "summary": "Orthocell Limited, a regenerative medicine company, develops and commercializes cell therapies and biological medical devices for the repair and regeneration of human tendon, bone, nerve, and cartilage defects in Australia. The company's principal products include CelGro, a naturally derived collagen medical device for soft tissue repair that is under clinical trials for use as an augment to the surgical repair of tendons, peripheral nerves, bones, and articular cartilage; and Ortho-ATI, a cell therapy for treatment of chronic tendon injuries. It also provides Ortho-ACI, an autologous chondrocyte implantation for the treatment of symptomatic defects of the articulating cartilage of the joints, primarily in the knee and ankle. Orthocell Limited was founded in 2006 and is based in Murdoch, Australia.",
    "website": "http://www.orthocell.com.au",
    "zipcode": "6150"
  },
  "OEZ.F": {
    "city": "Clayton",
    "country": "Australia",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Biotechnology",
    "long_name": "Avecho Biotechnology Limited",
    "market": "dr_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "AVECHO BIOTECHN. LTD",
    "state": "VIC",
    "summary": "Avecho Biotechnology Limited, a biotechnology company, develops, produces, sells, and licenses products using its patented platform technology, Targeted Penetration Matrix (TPM) drug delivery system for the pharmaceutical, animal health, and nutrition industries in Australia and internationally. The company operates through Production, Human Health, and Other segments. It offers TPM and Vital ET products for use in drug delivery and cosmetic formulations; and develops TPM/Oxymorphone and TPM/Oxycodone. The company's human health portfolio covers delivery of pharmaceutical products through gels, injectables, and patches. It provides non-antibiotic feed additive products to enhance feed efficiency and the health of livestock animals. The company was formerly known as Phosphagenics Limited and changed its name to Avecho Biotechnology Limited in May 2019. Avecho Biotechnology Limited was incorporated in 1992 is based in Clayton, Australia.",
    "website": "http://avecho.com.au",
    "zipcode": "3168"
  },
  "ONT.AX": {
    "city": "Townsville",
    "country": "Australia",
    "currency": "AUD",
    "exchange": "ASX",
    "industry": "Medical Care Facilities",
    "long_name": "1300SMILES Limited",
    "market": "au_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "SMILES LTD FPO",
    "state": "QLD",
    "summary": "1300SMILES Limited provides dental and management services in Australia. It enables the delivery of services to patients by offering the use of dental surgeries, practice management, and other services to self-employed dentists who carry on their own dental practices. The company also provides services in the areas of marketing, administration, billing and collections, and facilities certification and licensing to participating dentists; and support staff, equipment, and facilities, as well as sources various consumable goods. In addition, it offers general, restorative, cosmetic, preventive, and children's dentistry services, as well as orthodontics services. The company serves dentists ranging from new graduates to experienced dental professionals. It owns and operates approximately 30 full-service dental facilities in Queensland, Sydney, and Adelaide. The company was founded in 2000 and is based in Townsville, Australia.",
    "website": "http://www.1300smiles.com.au",
    "zipcode": "4810"
  },
  "OPL.AX": {
    "city": "St Kilda",
    "country": "Australia",
    "currency": "AUD",
    "exchange": "ASX",
    "industry": "Health Information Services",
    "long_name": "Opyl Limited",
    "market": "au_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "OPYLLIMITD FPO",
    "state": "VIC",
    "summary": "Opyl Limited operates a SaaS platform that allows to search and source user generated content (UGC). Its UGC Discovery platform protects against unauthorized use of people's social and digital content. The company also offers social media marketing agency services, including client and account management services; a MediaConsent Clinical platform that aggregates structured and unstructured data from various sources giving consumers or patients control over their health data and to contribute their data to medical research; and consumer data and privacy compliance services. It operates in Australia and the United States. The company was formerly known as ShareRoot Limited and changed its name to Opyl Limited in December 2019. Opyl Limited was incorporated in 1994 and is based in St Kilda, Australia.",
    "website": "http://www.opyl.ai",
    "zipcode": "3182"
  },
  "OPT": {
    "city": "South Yarra",
    "country": "Australia",
    "currency": "USD",
    "exchange": "NMS",
    "industry": "Biotechnology",
    "long_name": "Opthea Limited",
    "market": "us_market",
    "market_cap": "Small Cap",
    "sector": "Healthcare",
    "short_name": "Opthea Limited",
    "state": "VIC",
    "summary": "Opthea Limited, a biotechnology company, develops and commercializes therapies primarily for eye disease in Australia. The company's development activities are based on the intellectual property portfolio covering Vascular Endothelial Growth Factors (VEGF) VEGF-C, VEGF-D, and VEGF Receptor-3 for the treatment of diseases associated with blood and lymphatic vessel growth, as well as vascular leakage. Its lead molecule is OPT-302, a soluble form of VEGFR-3 for the treatment of wet age-related macular degeneration and diabetic macular edema. The company was formerly known as Circadian Technologies Limited and changed its name to Opthea Limited in December 2015. Opthea Limited was incorporated in 1984 and is based in South Yarra, Australia.",
    "website": "http://www.opthea.com",
    "zipcode": "3141"
  },
  "OPT.AX": {
    "city": "South Yarra",
    "country": "Australia",
    "currency": "AUD",
    "exchange": "ASX",
    "industry": "Biotechnology",
    "long_name": "Opthea Limited",
    "market": "au_market",
    "market_cap": "Small Cap",
    "sector": "Healthcare",
    "short_name": "OPTHEA FPO",
    "state": "VIC",
    "summary": "Opthea Limited, a biotechnology company, develops and commercializes therapies primarily for eye disease in Australia. The company's development activities are based on the intellectual property portfolio covering Vascular Endothelial Growth Factors (VEGF) VEGF-C, VEGF-D, and VEGF Receptor-3 for the treatment of diseases associated with blood and lymphatic vessel growth, as well as vascular leakage. Its lead molecule is OPT-302, a soluble form of VEGFR-3 for the treatment of wet age-related macular degeneration and diabetic macular edema. The company was formerly known as Circadian Technologies Limited and changed its name to Opthea Limited in December 2015. Opthea Limited was incorporated in 1984 and is based in South Yarra, Australia.",
    "website": "http://www.opthea.com",
    "zipcode": "3141"
  },
  "OQS.F": {
    "city": "Lane Cove",
    "country": "Australia",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Medical Instruments & Supplies",
    "long_name": "Nanosonics Limited",
    "market": "dr_market",
    "market_cap": "Small Cap",
    "sector": "Healthcare",
    "short_name": "NANOSONICS LTD",
    "state": "NSW",
    "summary": "Nanosonics Limited, together with its subsidiaries, engages in the research, development, and commercialization of infection control and decontamination products and related technologies. The company manufactures and distributes the trophon ultrasound probe disinfector, and its associated consumables and accessories for reducing cross-contamination between patients and the spread of healthcare acquired infections. It also provides trophon2, an ultrasound probe high level disinfection device; and trophon EPR, a device designed to disinfect intracavity and surface ultrasound probes. In addition, the company offers trophon EPR and trophon2 consumables and accessories, including NanoNebulant, a proprietary disinfectant liquid; trophon chemical indicators; trophon AcuTrace operator cards, medical instrument tags, printers, printer USB cables, printer label rolls, and logbooks; trophon wall mounts, printer wall mounts, carts, and printer cart mounts; trophon companion drying wipes and companion wipes wall mounts; clean ultrasound probe covers; and trophon AcuTrace PLUS activation cards. It operates in North America, Europe, the Middle East, and the Asia Pacific. The company was incorporated in 2000 and is headquartered in Lane Cove, Australia.",
    "website": "http://www.nanosonics.com.au",
    "zipcode": "2066"
  },
  "OSL.AX": {
    "city": "North Sydney",
    "country": "Australia",
    "currency": "AUD",
    "exchange": "ASX",
    "industry": "Medical Devices",
    "long_name": "OncoSil Medical Limited",
    "market": "au_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "ONCOSIL FPO",
    "state": "NSW",
    "summary": "OncoSil Medical Limited, a medical device company, focuses on the development of localized treatments for pancreatic and liver cancer in Australia. Its lead product is OncoSil, a brachytherapy device that implants a pre-determined dose of beta radiation directly into cancerous tissue for the treatment of cancer. The company was formerly known as NeuroDiscovery Limited and changed its name to OncoSil Medical Limited in June 2013. OncoSil Medical Limited is headquartered in North Sydney, Australia.",
    "website": "http://www.oncosil.com.au",
    "zipcode": "2060"
  },
  "OVN.AX": {
    "city": "Indooroopilly",
    "country": "Australia",
    "currency": "AUD",
    "exchange": "ASX",
    "industry": "Medical Devices",
    "long_name": "Oventus Medical Limited",
    "market": "au_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "OVENTUS FPO",
    "state": "QLD",
    "summary": "Oventus Medical Limited, a medical device company, develops and commercializes oral appliances for the treatment of obstructive sleep apnoea (OSA) and snoring in Australia, Canada, and the United States. The company offers O2Vent Optima, a customized 3D-printed nylon oral appliance for OSA patients; and ExVent, an alternative for CPAP-intolerant individuals. It also develops O2Vent. The company was incorporated in 2015 and is headquartered in Indooroopilly, Australia.",
    "website": "http://o2vent.com",
    "zipcode": "4068"
  },
  "PAA.AX": {
    "city": "Bentley",
    "country": "Australia",
    "currency": "AUD",
    "exchange": "ASX",
    "industry": "Biotechnology",
    "long_name": "PharmAust Limited",
    "market": "au_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "PHARMAUST FPO",
    "state": "WA",
    "summary": "PharmAust Limited, a clinical-stage company, develops targeted cancer therapeutics for human and animal healthcare. The company develops drug discovery intellectual property for the treatment of various cancers in humans and animals. Its lead candidate is Monepantel, which are in Phase II clinical trials for the treatment of cancer. The company also provides highly specialized medicinal and synthetic chemistry services on a contract basis to clients to the drug discovery and pharmaceutical industries. PharmAust Limited was incorporated in 2000 and is based in Bentley, Australia.",
    "website": "http://www.pharmaust.com",
    "zipcode": "6102"
  },
  "PAB.AX": {
    "city": "Melbourne",
    "country": "Australia",
    "currency": "AUD",
    "exchange": "ASX",
    "industry": "Biotechnology",
    "long_name": "Patrys Limited",
    "market": "au_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "PATRYS FPO",
    "state": "VIC",
    "summary": "Patrys Limited, together with its subsidiaries, develops and commercializes antibody technologies for the treatment of cancer in Australia. Its lead technology is Deoxymab 3E10, a DNA damage-repair antibody that penetrates live cell nuclei and inhibits mechanisms of DNA repair in target cancer cells. The company also focuses on developing PAT-DX1 as a treatment for metastatic triple negative breast cancer and glioblastoma. In addition, it engages in developing PAT-SC1's target/antigen CD55PAT-SC1, an isoform of the membrane-bound CD55 for the treatment of gastric cancer. Patrys Limited was founded in 2006 and is based in South Melbourne, Australia.",
    "website": "http://www.patrys.com",
    "zipcode": "3205"
  },
  "PAR.AX": {
    "city": "Melbourne",
    "country": "Australia",
    "currency": "AUD",
    "exchange": "ASX",
    "industry": "Biotechnology",
    "long_name": "Paradigm Biopharmaceuticals Limited",
    "market": "au_market",
    "market_cap": "Small Cap",
    "sector": "Healthcare",
    "short_name": "PARA BIO FPO",
    "state": "VIC",
    "summary": "Paradigm Biopharmaceuticals Limited, a biopharmaceutical company, engages in the research and development of therapeutic products for human use in Australia. It offers pentosan polysulphate sodium drugs in the injectable form for the treatment of bone marrow edema, respiratory, and alphaviral arthritis diseases. The company was incorporated in 2014 and is based in Melbourne, Australia.",
    "website": "http://www.paradigmbiopharma.com",
    "zipcode": "3000"
  },
  "PARNF": {
    "city": "Alexandria",
    "country": "Australia",
    "currency": "USD",
    "exchange": "PNK",
    "industry": "Drug Manufacturers - Specialty & Generic",
    "long_name": "Parnell Pharmaceuticals Holdings Ltd",
    "market": "us_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "PARNELL PHARMACEUTICALS HLDGS L",
    "state": "NSW",
    "summary": "Parnell Pharmaceuticals Holdings Ltd, a veterinary pharmaceutical company, focuses on developing, manufacturing, and commercializing various animal health solutions. The company operates through four segments: Companion Animal, Production Animal - U.S., Production Animal - Rest of World, and Manufacturing Operations. It markets various products, including estroPLAN and GONAbreed reproductive hormone products for improving cattle breeding performance; Zydax for the treatment of osteoarthritis (OA) in dogs and horses; and Glyde, a nutraceutical product aids in the treatment of OA, as well as Parnell PROcept, which adds an additional injection of estroPLAN after the first injection. The company also operates mySYNCH, a digital tool to help veterinarians and producers optimize reproduction and maximize economic gains. Parnell Pharmaceuticals Holdings Ltd was incorporated in 2009 and is headquartered in Alexandria, Australia.",
    "website": "http://www.parnell.com",
    "zipcode": "2015"
  },
  "PBIGF": {
    "city": "Melbourne",
    "country": "Australia",
    "currency": "USD",
    "exchange": "PNK",
    "industry": "Biotechnology",
    "long_name": "Paradigm Biopharmaceuticals Limited",
    "market": "us_market",
    "market_cap": "Small Cap",
    "sector": "Healthcare",
    "short_name": "PARADIGM BIOPHARMACEUTICALS LTD",
    "state": "VIC",
    "summary": "Paradigm Biopharmaceuticals Limited, a biopharmaceutical company, engages in the research and development of therapeutic products for human use in Australia. It offers pentosan polysulphate sodium drugs in the injectable form for the treatment of bone marrow edema, respiratory, and alphaviral arthritis diseases. The company was incorporated in 2014 and is based in Melbourne, Australia.",
    "website": "http://www.paradigmbiopharma.com",
    "zipcode": "3000"
  },
  "PBN.F": {
    "city": "Melbourne",
    "country": "Australia",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Biotechnology",
    "long_name": "Alterity Therapeutics Limited",
    "market": "dr_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "ALTERITY THERAPEUT. LTD",
    "state": "VIC",
    "summary": "Alterity Therapeutics Limited researches and develops therapeutic drugs for the treatment of Parkinsonian's disease and other neurodegenerative diseases in Australia. The company's lead drug candidates is ATH434 that has completed Phase I clinical trial for the treatment of Parkinson's disease. It is also developing PBT2 for used as an antimicrobial agent. The company was formerly known as Prana Biotechnology Limited and changed its name to Alterity Therapeutics Limited in April 2019. The company was founded in 1997 and is based in Melbourne, Australia.",
    "website": "http://www.alteritytherapeutics.com",
    "zipcode": "3000"
  },
  "PBNN.F": {
    "city": "Melbourne",
    "country": "Australia",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Biotechnology",
    "long_name": "Alterity Therapeutics Limited",
    "market": "dr_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "ALTERITY THERAPEUT.ADR/60",
    "state": "VIC",
    "summary": "Alterity Therapeutics Limited researches and develops therapeutic drugs for the treatment of Parkinsonian's disease and other neurodegenerative diseases in Australia. The company's lead drug candidates is ATH434 that has completed Phase I clinical trial for the treatment of Parkinson's disease. It is also developing PBT2 for used as an antimicrobial agent. The company was formerly known as Prana Biotechnology Limited and changed its name to Alterity Therapeutics Limited in April 2019. The company was founded in 1997 and is based in Melbourne, Australia.",
    "website": "http://www.alteritytherapeutics.com",
    "zipcode": "3000"
  },
  "PBP.AX": {
    "city": "Laverton North",
    "country": "Australia",
    "currency": "AUD",
    "exchange": "ASX",
    "industry": "Drug Manufacturers - Specialty & Generic",
    "long_name": "Probiotec Limited",
    "market": "au_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "PROBIOTEC FPO",
    "state": "VIC",
    "summary": "Probiotec Limited engages in the development, manufacture and sale of pharmaceuticals, consumer health, and nutraceutical products in Australia and internationally. The company provides contract manufacturing services for solid dose tablets, capsules, and caplets; tablets coating; blister packing; liquids, creams, gels, and ointments and suspensions; powders and powder blending; and sprays, as well as manufacturing and packaging of finished doses. It also offers analytical and stability testing services; new product formulation and production trials, and ongoing research and development services; and packaging options for human and animal nutrition products, as well as manufactures and exports a range of nutraceuticals and functional ingredient raw materials. In addition, the company provides packing services and formats, including foil, carded and clamshell blister packing, bottle filling, labelling, secondary packaging, and other services for the pharmaceutical, cosmetic, and food industries. Probiotec Limited was incorporated in 1996 and is headquartered in Laverton North, Australia.",
    "website": "http://www.probiotec.com.au",
    "zipcode": "3026"
  },
  "PCK.AX": {
    "city": "Sydney",
    "country": "Australia",
    "currency": "AUD",
    "exchange": "ASX",
    "industry": "Health Information Services",
    "long_name": "PainChek Limited",
    "market": "au_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "PAINCHEK FPO",
    "state": "NSW",
    "summary": "PainChek Limited develops and commercializes mobile medical device applications that provides pain assessment for individuals primarily in Australia and Europe. The company offers PainChek, which uses camera in smartphone and tablets to capture video that is analyzed in real time using facial recognition software to indicate the presence of the pain. It serves patients suffering with dementia. The company was formerly known as ePAT Technologies Ltd and changed its name to PainChek Limited. in January 2018. PainChek Limited is based in Sydney, Australia.",
    "website": "http://www.painchek.com",
    "zipcode": "2000"
  },
  "PD1A.F": {
    "city": "Richmond",
    "country": "Australia",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Medical Instruments & Supplies",
    "long_name": "Ansell Limited",
    "market": "dr_market",
    "market_cap": "Mid Cap",
    "sector": "Healthcare",
    "short_name": "ANSELL LTD.",
    "state": "VIC",
    "summary": "Ansell Limited designs, develops, and manufactures protection solutions in the Asia Pacific, Europe, the Middle East, Africa, Latin America, Caribbean, and North America. It operates in two segments, Healthcare and Industrial. The Healthcare segment manufactures and markets solutions comprising surgical gloves, single use and examination gloves, and clean and sterile gloves and garments, as well as consumables used by healthcare, life sciences, and industrial workers for a range of customers, including hospitals, surgical centers, dental surgeries, veterinary clinics, first responders, manufacturers, auto repair shops, chemical plants, laboratories, and pharmaceutical companies. The Industrial segment manufactures and markets high-performance hand and chemical protective clothing solutions for a range of industrial applications, including automotive, chemical, metal fabrication, machinery and equipment, food, construction, mining, oil and gas, and first responders. The company was formerly known as Pacific Dunlop Limited and changed its name to Ansell Limited in 2002. Ansell Limited was founded in 1893 and is based in Richmond, Australia.",
    "website": "http://www.ansell.com",
    "zipcode": "3121"
  },
  "PGC.AX": {
    "city": "Melbourne",
    "country": "Australia",
    "currency": "AUD",
    "exchange": "ASX",
    "industry": "Medical Distribution",
    "long_name": "Paragon Care Limited",
    "market": "au_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "PARAGON FPO",
    "state": "VIC",
    "summary": "Paragon Care Limited supplies durable medical equipment, medical devices, and consumable medical products to health and aged care markets in Australia, New Zealand, and internationally. The company offers clinical solutions for anaesthetists, intensivists, cardiac, vascular, and pain management; designs, manufactures, and distributes reagent red blood cells, monoclonal blood grouping reagents, and ancillary products for immunohaematology laboratories; and eye care products, such as ophthalmology and optometry, neonatal vision screening, and procedural kits. It also provides neonatal and paediatric assessment and treatment, including newborn hearing and vision screening, jaundice management, targeted temperature management, cerebral function monitoring, and seizure detection, as well as pain management and enteral feeding solutions; surgical products for hip and knee arthroplasty, infection prevention, pain management, specialty orthopaedics, biologics, and spine; and equipment repair and maintenance services. In addition, the company offers sterilisable transducers for surgical procedures such as neurology, hepatobiliary, renal, colorectal, vascular, laparoscopic, and robotic procedures; ultrasound systems, shockwave therapy, lasers, and accessories for infection control; and veterinary products, including point-of-care blood analyzers, centrifuges, laser technology, IV lines and fluid therapy, and closed system transfer devices for hazardous drugs. Further, it provides telephony, nurse call, access control, CCTV, cordless, and Wi-Fi products. The company was formerly known as Citrofresh International Limited and changed its name to Paragon Care Limited in June 2008. Paragon Care Limited was incorporated in 1994 and is based in Melbourne, Australia.",
    "website": "http://www.paragoncare.com.au",
    "zipcode": "3205"
  },
  "PGZ.F": {
    "city": "St Leonards",
    "country": "Australia",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Medical Care Facilities",
    "long_name": "Healius Limited",
    "market": "dr_market",
    "market_cap": "Small Cap",
    "sector": "Healthcare",
    "short_name": "HEALIUS LTD",
    "state": "NSW",
    "summary": "Healius Limited provides facilities and support services to independent general practitioners, radiologists, and other healthcare professionals in Australia. The company operates through three segments: Pathology, Imaging, and Day Hospitals. It offers diagnostic imaging services, including X-ray, ultrasound, computerized tomography, mammography, magnetic resonance imaging, nuclear medicine, positron emission tomography, and interventional radiology; and private medical laboratory and pathology services. The company also provides cataract surgery, colonoscopy, gastroscopy, plastic and cosmetic surgery, skin, cancer removal, IVF egg collection, and gynaecological surgery services. It operates 2,234 pathology sites; 15 day hospital sites; and 146 imaging sites. The company was formerly known as Primary Health Care Limited and changed its name to Healius Limited in December 2018. Healius Limited was incorporated in 1994 and is based in St Leonards, Australia.",
    "website": "http://www.healius.com.au",
    "zipcode": "2065"
  },
  "PH7.F": {
    "city": "Nedlands",
    "country": "Australia",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Biotechnology",
    "long_name": "PYC Therapeutics Limited",
    "market": "dr_market",
    "market_cap": "Small Cap",
    "sector": "Healthcare",
    "short_name": "PYC THERAPEUTICS LTD.",
    "state": "WA",
    "summary": "PYC Therapeutics Limited provides drug discovery services utilizing peptide libraries and proprietary screening capabilities in Australia. The company provides next generation delivery platform for cell-penetrating peptides (CPPs), a small biological molecule. The company's proprietary peptide libraries contain fragments from diverse and evolutionarily distinct microbial genomes - organisms which known as cell-penetrating properties. It develops CPP- Antisense Oligonucleotides (ASOs), a pipeline of drugs for the treatment of retinal disease. The company was formerly known as Phylogica Limited and changed its name to PYC Therapeutics Limited in November 2019. PYC Therapeutics Limited was incorporated in 2001 and is based in Nedlands, Australia.",
    "website": "http://pyctx.com",
    "zipcode": "6009"
  },
  "PH7.SG": {
    "city": "Nedlands",
    "country": "Australia",
    "currency": "EUR",
    "exchange": "STU",
    "industry": "Biotechnology",
    "long_name": "PYC Therapeutics Limited",
    "market": "dr_market",
    "market_cap": "Small Cap",
    "sector": "Healthcare",
    "short_name": "Phylogica Ltd. Registered Share",
    "state": "WA",
    "summary": "PYC Therapeutics Limited provides drug discovery services utilizing peptide libraries and proprietary screening capabilities in Australia. The company provides next generation delivery platform for cell-penetrating peptides (CPPs), a small biological molecule. The company's proprietary peptide libraries contain fragments from diverse and evolutionarily distinct microbial genomes - organisms which known as cell-penetrating properties. It develops CPP- Antisense Oligonucleotides (ASOs), a pipeline of drugs for the treatment of retinal disease. The company was formerly known as Phylogica Limited and changed its name to PYC Therapeutics Limited in November 2019. PYC Therapeutics Limited was incorporated in 2001 and is based in Nedlands, Australia.",
    "website": "http://pyctx.com",
    "zipcode": "6009"
  },
  "PIQ.AX": {
    "city": "Perth",
    "country": "Australia",
    "currency": "AUD",
    "exchange": "ASX",
    "industry": "Biotechnology",
    "long_name": "Proteomics International Laboratories Limited",
    "market": "au_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "PROTEOMICS FPO",
    "state": "WA",
    "summary": "Proteomics International Laboratories Limited operates as a medical technology company with a focus on the area of proteomics. It provides PromarkerD, a predictive test for diabetic kidney disease; and develops diagnostic tests for endometriosis and giardia. The company also offers analytical services, including specialist contract research, analytical, and consultancy. Proteomics International Laboratories Ltd has a research agreement with the Busselton Population Medical Research Institute to enhance diagnosis and treatment of lung conditions, such as asthma and chronic obstructive pulmonary disease; the Janssen Research & Development, LLC for the research of diabetic kidney and heart disease treatment; and partnership with QIMR Berghofer Medical Research Institute for the detection of oesophageal adenocarcinoma, the primary common form of oesophageal cancer in Australia. The company was founded in 2001 and is based in Perth, Australia.",
    "website": "http://www.proteomics.com.au",
    "zipcode": "6009"
  },
  "PKS.AX": {
    "city": "Redfern",
    "country": "Australia",
    "currency": "AUD",
    "exchange": "ASX",
    "industry": "Health Information Services",
    "long_name": "PKS Holdings Limited",
    "market": "au_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "PKSHOLDING FPO",
    "state": "NSW",
    "summary": "PKS Holdings Limited, a healthcare technology company, engages in the development and provision of software services for the healthcare industry in Australia, Europe, the Americas, and internationally. It operates in two segments: CDS and Pavilion. The company offers RippleDown Auditor, a knowledge-based system that allows various departments to audit data entered into healthcare information system in real-time; as well as error in submitting data; and RippleDown Expert, an clinical decision support system that provides interpretations, decision making to various healthcare organisations. It also provides LabQ, a data mining tool; PICQ, an auditing tool used in hospitals; RISQ, a tool for reviewing records in datasets to assess the quality of condition onset flags data and incidences of hospital-acquired complications; and Codexpert, a web-based eBook application that provides health-data classification reference for clinical coding of patient episodes. It serves customers through direct sales and channel partners. The company was formerly known as QPro Holdings Limited. PKS Holdings Limited was founded in 1996 and is headquartered in Redfern, Australia.",
    "website": "http://www.pks.com.au",
    "zipcode": "2016"
  },
  "PMC.F": {
    "city": "Richmond",
    "country": "Australia",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Health Information Services",
    "long_name": "Pro Medicus Limited",
    "market": "dr_market",
    "market_cap": "Mid Cap",
    "sector": "Healthcare",
    "short_name": "PRO MEDICUS LTD.",
    "state": "VIC",
    "summary": "Pro Medicus Limited provides radiology information systems (RIS), picture archiving and communication systems (PACS), and advanced visualization solutions in Australia, Europe, and North America. It offers medical software for practice management; integration products; Promedicus.net secure email; healthcare software that provides radiologist and clinicians with advanced visualization capability for viewing 2-D, 3-D, and 4-D medical images; and PACS/Digital imaging software. The company offers its products under the Visage RIS, Visage RIS/PACS, and Visage 7 names. It also provides Visage Ease Pro, a mobile applications, which allow users access to medical imaging results that are stored on a Visage 7 server; training, installation, and professional services; and after sale support and service products. The company offers its products and services to hospitals, diagnostic imaging groups, and other health related entities. Pro Medicus Limited was founded in 1983 and is headquartered in Richmond, Australia.",
    "website": "http://www.promed.com.au",
    "zipcode": "3121"
  },
  "PMCUF": {
    "city": "Richmond",
    "country": "Australia",
    "currency": "USD",
    "exchange": "PNK",
    "industry": "Health Information Services",
    "long_name": "Pro Medicus Limited",
    "market": "us_market",
    "market_cap": "Mid Cap",
    "sector": "Healthcare",
    "short_name": "PRO MEDICUS",
    "state": "VIC",
    "summary": "Pro Medicus Limited provides radiology information systems (RIS), picture archiving and communication systems (PACS), and advanced visualization solutions in Australia, Europe, and North America. It offers medical software for practice management; integration products; Promedicus.net secure email; healthcare software that provides radiologist and clinicians with advanced visualization capability for viewing 2-D, 3-D, and 4-D medical images; and PACS/Digital imaging software. The company offers its products under the Visage RIS, Visage RIS/PACS, and Visage 7 names. It also provides Visage Ease Pro, a mobile applications, which allow users access to medical imaging results that are stored on a Visage 7 server; training, installation, and professional services; and after sale support and service products. The company offers its products and services to hospitals, diagnostic imaging groups, and other health related entities. Pro Medicus Limited was founded in 1983 and is headquartered in Richmond, Australia.",
    "website": "http://www.promed.com.au",
    "zipcode": "3121"
  },
  "PME.AX": {
    "city": "Richmond",
    "country": "Australia",
    "currency": "AUD",
    "exchange": "ASX",
    "industry": "Health Information Services",
    "long_name": "Pro Medicus Limited",
    "market": "au_market",
    "market_cap": "Mid Cap",
    "sector": "Healthcare",
    "short_name": "PROMEDICUS FPO",
    "state": "VIC",
    "summary": "Pro Medicus Limited provides radiology information systems (RIS), picture archiving and communication systems (PACS), and advanced visualization solutions in Australia, Europe, and North America. It offers medical software for practice management; integration products; Promedicus.net secure email; healthcare software that provides radiologist and clinicians with advanced visualization capability for viewing 2-D, 3-D, and 4-D medical images; and PACS/Digital imaging software. The company offers its products under the Visage RIS, Visage RIS/PACS, and Visage 7 names. It also provides Visage Ease Pro, a mobile applications, which allow users access to medical imaging results that are stored on a Visage 7 server; training, installation, and professional services; and after sale support and service products. The company offers its products and services to hospitals, diagnostic imaging groups, and other health related entities. Pro Medicus Limited was founded in 1983 and is headquartered in Richmond, Australia.",
    "website": "http://www.promed.com.au",
    "zipcode": "3121"
  },
  "PNV.AX": {
    "city": "Port Melbourne",
    "country": "Australia",
    "currency": "AUD",
    "exchange": "ASX",
    "industry": "Biotechnology",
    "long_name": "PolyNovo Limited",
    "market": "au_market",
    "market_cap": "Small Cap",
    "sector": "Healthcare",
    "short_name": "POLYNOVO FPO",
    "state": "VIC",
    "summary": "Polynovo Limited develops medical devices in the United States, Australia, New Zealand, and internationally. The company offers NovoSorb Biodegradable Temporising Matrix, which is used in a fully debrided clean surgical wound to physiologically close the wound. It is also developing Syntrel hernia devices for hernia repair; breast devices in partnership with Establishment Labs; NovoSorb dermal beta cell implant in collaboration with BetaCell Technologies Pty Ltd; and NovoSorb drug elution depots. The company was formerly known as Calzada Limited and changed its name to Polynovo Limited in November 2014. Polynovo Limited was incorporated in 1998 and is based in Port Melbourne, Australia.",
    "website": "http://www.polynovo.com.au",
    "zipcode": "3207"
  },
  "PPCB": {
    "city": "Camberwell",
    "country": "Australia",
    "currency": "USD",
    "exchange": "PNK",
    "industry": "Biotechnology",
    "long_name": "Propanc Biopharma, Inc.",
    "market": "us_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "PROPANC BIOPHARMA INC",
    "state": "VIC",
    "summary": "Propanc Biopharma, Inc., a development-stage healthcare company, focuses on the development of cancer treatments for patients with pancreatic, ovarian, and colorectal cancer in Australia. Its lead product is PRP, a formulation that is in preclinical phase of development designed to enhance the anti-cancer effects of multiple enzymes acting synergistically. The company has a research collaboration with University of Jan to commence the POP1 joint drug discovery program. The company was formerly known as Propanc Health Group Corporation and changed its name to Propanc Biopharma, Inc. in April 2017. Propanc Biopharma, Inc. was founded in 2007 and is based in Camberwell, Australia.",
    "website": "http://www.propanc.com",
    "zipcode": "3124"
  },
  "PQ6.F": {
    "city": "Abbotsford",
    "country": "Australia",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Biotechnology",
    "long_name": "Starpharma Holdings Limited",
    "market": "dr_market",
    "market_cap": "Small Cap",
    "sector": "Healthcare",
    "short_name": "STARPHARMA HOLDINGS LTD.",
    "state": "VIC",
    "summary": "Starpharma Holdings Limited engages in the research, development, and commercialization of dendrimer products for pharmaceutical, life-science, and other applications worldwide. The company offers VivaGel, a non-antibiotic therapy for the management and prevention of bacterial vaginosis. It also develops VivaGel condom, an antiviral condom; and DEP, a dendrimer drug delivery technology, including DEP docetaxel that is in Phase II clinical trials, DEP cabazitaxel that is in Phase 1 clinical trial, and DEP irinotecan that is in phase 1/2 clinical trials for the treatment of solid tumors. The company was founded in 1996 and is headquartered in Abbotsford, Australia.",
    "website": "http://starpharma.com",
    "zipcode": "3067"
  },
  "PRNAF": {
    "city": "Melbourne",
    "country": "Australia",
    "currency": "USD",
    "exchange": "PNK",
    "industry": "Biotechnology",
    "long_name": "Alterity Therapeutics Limited",
    "market": "us_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "ALTERITY THERAPEUTICS LIMITED",
    "state": "VIC",
    "summary": "Alterity Therapeutics Limited researches and develops therapeutic drugs for the treatment of Parkinsonian's disease and other neurodegenerative diseases in Australia. The company's lead drug candidates is ATH434 that has completed Phase I clinical trial for the treatment of Parkinson's disease. It is also developing PBT2 for used as an antimicrobial agent. The company was formerly known as Prana Biotechnology Limited and changed its name to Alterity Therapeutics Limited in April 2019. The company was founded in 1997 and is based in Melbourne, Australia.",
    "website": "http://www.alteritytherapeutics.com",
    "zipcode": "3000"
  },
  "PRRUF": {
    "city": "Sydney",
    "country": "Australia",
    "currency": "USD",
    "exchange": "PNK",
    "industry": "Biotechnology",
    "long_name": "Immutep Limited",
    "market": "us_market",
    "market_cap": "Small Cap",
    "sector": "Healthcare",
    "short_name": "IMMUTEP LTD",
    "state": "NSW",
    "summary": "Immutep Limited, a biotech company, engages in the research and development of pharmaceutical product candidates. The company develops immunotherapeutic products for the treatment of cancer and autoimmune diseases. Its principal product candidate is IMP321, also known as eftilagimod alpha' or efti', which is a recombinant protein that is in Phase IIb clinical trial as a chemoimmunotherapy combination for metastatic breast cancer termed AIPAC and in a Phase I combination therapy trial in metastatic melanoma termed TACTI-mel; and is being evaluated as a combination therapy in head and neck squamous cell carcinoma and non-small cell lung carcinoma in a Phase II clinical trial called TACTI-002 and an investigator initiated Phase I trial called INSIGHT in advanced solid tumors. Its other products include IMP761, IMP701 and IMP731, all of which are related to lymphocyte activation gene 3, a gene linked to the regulation of T cells in immune responses. Immutep Limited has partnerships with GlaxoSmithKline, Novartis, CYTLIMIC Inc., INSIGHT, and EOC Pharma. The company was formerly known as Prima BioMed Ltd and changed its name to Immutep Limited in November 2017. Immutep Limited was incorporated in 1987 and is based in Sydney, Australia.",
    "website": "http://www.immutep.com",
    "zipcode": "2000"
  },
  "PSQ.AX": {
    "city": "East Maitland",
    "country": "Australia",
    "currency": "AUD",
    "exchange": "ASX",
    "industry": "Medical Care Facilities",
    "long_name": "Pacific Smiles Group Limited",
    "market": "au_market",
    "market_cap": "Small Cap",
    "sector": "Healthcare",
    "short_name": "PACSMILES FPO",
    "state": "NSW",
    "summary": "Pacific Smiles Group Limited, together with its subsidiaries, owns and operates dental centers under the Pacific Smiles Dental and nib Dental Care brand names in Eastern Australia. The company provides general dentistry services, including check-ups, teeth cleaning, fillings, and extractions; dental treatments, such as crowns, bridges, fillings, and extractions; advanced dentistry comprising dental implants; and specialist dentistry, such as orthodontics, prosthodontics, endodontics, and periodontics, as well as other treatments under general anaesthetic and intravenous sedation. As of June 30, 2020, it operated 94 centers. The company was incorporated in 2002 and is headquartered in East Maitland, Australia.",
    "website": "http://www.pacificsmilesgroup.com.au",
    "zipcode": "2323"
  },
  "PTX.AX": {
    "city": "Melbourne",
    "country": "Australia",
    "currency": "AUD",
    "exchange": "ASX",
    "industry": "Biotechnology",
    "long_name": "Prescient Therapeutics Limited",
    "market": "au_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "PRESCIENT FPO",
    "state": "VIC",
    "summary": "Prescient Therapeutics Limited, a clinical stage oncology company, develops novel drugs for the treatment of a range of cancers in Australia. The company's lead drug candidate is PTX-200, which is in Phase II clinical trial for HER2-negative breast cancer, Phase IB/2 clinical trial in relapsed and refractory AML, and Phase 1b in recurrent or persistent platinum-resistant ovarian cancer; and PTX-100, a RhoA inhibitor, for hematological and solid malignancies that focuses on cancers with Ras and RhoA mutations. Prescient Therapeutics Limited has a collaboration agreement with Carina Biotech to develop cell therapies. The company was formerly known as Virax Holdings Limited and changed its name to Prescient Therapeutics Limited in December 2014. Prescient Therapeutics Limited was incorporated in 1986 and is based in South Melbourne, Australia.",
    "website": "http://ptxtherapeutics.com",
    "zipcode": "3205"
  },
  "PXS.AX": {
    "city": "Frenchs Forest",
    "country": "Australia",
    "currency": "AUD",
    "exchange": "ASX",
    "industry": "Drug Manufacturers - General",
    "long_name": "Pharmaxis Ltd",
    "market": "au_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "PHARMAXIS FPO",
    "state": "NSW",
    "summary": "Pharmaxis Ltd engages in the research, development, and commercialization of healthcare products for the treatment of fibrotic and inflammatory diseases worldwide. The company operates through two segments, Mannitol business, and New Drug Development. It offers Bronchitol, an inhaled dry powder for the treatment of cystic fibrosis; and Aridol, an airways inflammation test that is used to identify twitchy or hyper-responsive airways, as well as to assist in diagnosing and managing asthma. The company's product pipeline consists of amine oxidase inhibitors comprising semicarbazide-sensitive amine oxidase for diabetic retinopathy; selective lysyl oxidase like inhibitors targeting chronic fibrotic diseases, such as NASH, pulmonary fibrosis, kidney fibrosis, and cardiac fibrosis; and pan-lysyl oxidase inhibitors targeting severe fibrotic indications, which includes cancers and scarring. It is also developing Orbital, a dry powder inhaler to deliver high drug doses to lungs. Pharmaxis Ltd was founded in 1998 and is headquartered in Frenchs Forest, Australia.",
    "website": "http://www.pharmaxis.com.au",
    "zipcode": "2086"
  },
  "PXS.F": {
    "city": "Melbourne",
    "country": "Australia",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Medical Distribution",
    "long_name": "Paragon Care Limited",
    "market": "dr_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "PARAGON CARE LTD",
    "state": "VIC",
    "summary": "Paragon Care Limited supplies durable medical equipment, medical devices, and consumable medical products to health and aged care markets in Australia, New Zealand, and internationally. The company offers clinical solutions for anaesthetists, intensivists, cardiac, vascular, and pain management; designs, manufactures, and distributes reagent red blood cells, monoclonal blood grouping reagents, and ancillary products for immunohaematology laboratories; and eye care products, such as ophthalmology and optometry, neonatal vision screening, and procedural kits. It also provides neonatal and paediatric assessment and treatment, including newborn hearing and vision screening, jaundice management, targeted temperature management, cerebral function monitoring, and seizure detection, as well as pain management and enteral feeding solutions; surgical products for hip and knee arthroplasty, infection prevention, pain management, specialty orthopaedics, biologics, and spine; and equipment repair and maintenance services. In addition, the company offers sterilisable transducers for surgical procedures such as neurology, hepatobiliary, renal, colorectal, vascular, laparoscopic, and robotic procedures; ultrasound systems, shockwave therapy, lasers, and accessories for infection control; and veterinary products, including point-of-care blood analyzers, centrifuges, laser technology, IV lines and fluid therapy, and closed system transfer devices for hazardous drugs. Further, it provides telephony, nurse call, access control, CCTV, cordless, and Wi-Fi products. The company was formerly known as Citrofresh International Limited and changed its name to Paragon Care Limited in June 2008. Paragon Care Limited was incorporated in 1994 and is based in Melbourne, Australia.",
    "website": "http://www.paragoncare.com.au",
    "zipcode": "3205"
  },
  "PXSLY": {
    "city": "Frenchs Forest",
    "country": "Australia",
    "currency": "USD",
    "exchange": "PNK",
    "industry": "Drug Manufacturers - General",
    "long_name": "Pharmaxis Ltd",
    "market": "us_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "PHARMAXIS",
    "state": "NSW",
    "summary": "Pharmaxis Ltd engages in the research, development, and commercialization of healthcare products for the treatment of fibrotic and inflammatory diseases worldwide. The company operates through two segments, Mannitol business, and New Drug Development. It offers Bronchitol, an inhaled dry powder for the treatment of cystic fibrosis; and Aridol, an airways inflammation test that is used to identify twitchy or hyper-responsive airways, as well as to assist in diagnosing and managing asthma. The company's product pipeline consists of amine oxidase inhibitors comprising semicarbazide-sensitive amine oxidase for diabetic retinopathy; selective lysyl oxidase like inhibitors targeting chronic fibrotic diseases, such as NASH, pulmonary fibrosis, kidney fibrosis, and cardiac fibrosis; and pan-lysyl oxidase inhibitors targeting severe fibrotic indications, which includes cancers and scarring. It is also developing Orbital, a dry powder inhaler to deliver high drug doses to lungs. Pharmaxis Ltd was founded in 1998 and is headquartered in Frenchs Forest, Australia.",
    "website": "http://www.pharmaxis.com.au",
    "zipcode": "2086"
  },
  "PYC.AX": {
    "city": "Nedlands",
    "country": "Australia",
    "currency": "AUD",
    "exchange": "ASX",
    "industry": "Biotechnology",
    "long_name": "PYC Therapeutics Limited",
    "market": "au_market",
    "market_cap": "Small Cap",
    "sector": "Healthcare",
    "short_name": "PYC THERAP FPO",
    "state": "WA",
    "summary": "PYC Therapeutics Limited provides drug discovery services utilizing peptide libraries and proprietary screening capabilities in Australia. The company provides next generation delivery platform for cell-penetrating peptides (CPPs), a small biological molecule. The company's proprietary peptide libraries contain fragments from diverse and evolutionarily distinct microbial genomes - organisms which known as cell-penetrating properties. It develops CPP- Antisense Oligonucleotides (ASOs), a pipeline of drugs for the treatment of retinal disease. The company was formerly known as Phylogica Limited and changed its name to PYC Therapeutics Limited in November 2019. PYC Therapeutics Limited was incorporated in 2001 and is based in Nedlands, Australia.",
    "website": "http://pyctx.com",
    "zipcode": "6009"
  },
  "QA9.F": {
    "city": "Geelong",
    "country": "Australia",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Drug Manufacturers - Specialty & Generic",
    "long_name": "Australian Primary Hemp Limited",
    "market": "dr_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "AUSTRAL.PRIMARY HEMP LTD",
    "state": "VIC",
    "summary": "Australian Primary Hemp Limited manufactures and distributes hemp products under the Australian Primary Hemp brand to retail, wholesale, and white label customers in Australia. The company offers hemp seeds, cold pressed hemp oil, hemp fiber powder, hemp flour, hemp protein powder, hemp and bush balm mint hand sanitizers, hemp boost, hemp balance, and hemp and honey nut bars. It is also involved in the cultivation and production of hemp; handling various areas of hemp seed selection, farming, processing, and distribution; hemp contract packaging; and bulk and retail sale of edible hemp products. The company was founded in 2016 and is headquartered in Geelong, Australia.",
    "website": "http://www.ausprimaryhemp.com.au",
    "zipcode": "3220"
  },
  "QD4.F": {
    "city": "Rosebery",
    "country": "Australia",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Medical Devices",
    "long_name": "Quantum Health Group Limited",
    "market": "dr_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "QUANTUM HEALTH GROUP LTD.",
    "state": "NSW",
    "summary": "Quantum Health Group Limited distributes medical imaging and patient treatment equipment and services in Australia, Thailand, South Korea, Vietnam, New Zealand, the Philippines, and China. It operates in two segments, Medical and Environmental Services. The company distributes medical products in the field of radiology, oncology, aesthetics, and environmental health. It also manufactures energy saving heat pump technology used for heating and cooling systems internationally. The company was formerly known as Quantum Energy Limited. Quantum Health Group Limited was founded in 1975 and is headquartered in Rosebery, Australia.",
    "website": "http://www.qhealthcare.com.au",
    "zipcode": "2018"
  },
  "QTM.AX": {
    "city": "Rosebery",
    "country": "Australia",
    "currency": "AUD",
    "exchange": "ASX",
    "industry": "Medical Devices",
    "long_name": "Quantum Health Group Limited",
    "market": "au_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "QUANTHEGRP FPO",
    "state": "NSW",
    "summary": "Quantum Health Group Limited distributes medical imaging and patient treatment equipment and services in Australia, Thailand, South Korea, Vietnam, New Zealand, the Philippines, and China. It operates in two segments, Medical and Environmental Services. The company distributes medical products in the field of radiology, oncology, aesthetics, and environmental health. It also manufactures energy saving heat pump technology used for heating and cooling systems internationally. The company was formerly known as Quantum Energy Limited. Quantum Health Group Limited was founded in 1975 and is headquartered in Rosebery, Australia.",
    "website": "http://www.qhealthcare.com.au",
    "zipcode": "2018"
  },
  "R9Q.F": {
    "city": "Sydney",
    "country": "Australia",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Biotechnology",
    "long_name": "Recce Pharmaceuticals Ltd",
    "market": "dr_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "RECCE PHARMACEUTICALS LTD",
    "state": "NSW",
    "summary": "Recce Pharmaceuticals Ltd, a biotechnology company, engages in the research, development, and commercialization of synthetic antibiotics in Australia, the United States, and the United Kingdom. The company's lead candidate is RECCE 327 to treat blood infections and sepsis derived from E. coli and S. aureus bacteria, including their superbug forms. It also develops RECCE 529, a synthetic anti-infective for viral infections; and RECCE 435, a synthetic polymer antibiotics. The company was formerly known as Recce Limited and changed its name to Recce Pharmaceuticals Ltd in November 2017. Recce Pharmaceuticals Ltd was incorporated in 2007 and is headquartered in Sydney, Australia.",
    "website": "http://www.recce.com.au",
    "zipcode": "2000"
  },
  "RAC.AX": {
    "city": "Sydney",
    "country": "Australia",
    "currency": "AUD",
    "exchange": "ASX",
    "industry": "Biotechnology",
    "long_name": "Race Oncology Limited",
    "market": "au_market",
    "market_cap": "Small Cap",
    "sector": "Healthcare",
    "short_name": "RACEONCO FPO",
    "state": "NSW",
    "summary": "Race Oncology Limited operates as a specialty pharmaceutical company in Australia. The company is developing Bisantrene, a small molecule cancer chemotherapy drug that is used for the treatment of acute myeloid leukaemia. It has a preclinical research program with the University of Newcastle to explore the use of Bisantrene to treat melanoma. The company was formerly known as Coronado Resources Limited and changed its name to Race Oncology Limited in July 2016. Race Oncology Limited was incorporated in 2011 and is based in Sydney, Australia.",
    "website": "http://www.raceoncology.com",
    "zipcode": "2000"
  },
  "RAONF": {
    "city": "Sydney",
    "country": "Australia",
    "currency": "USD",
    "exchange": "PNK",
    "industry": "Biotechnology",
    "long_name": "Race Oncology Limited",
    "market": "us_market",
    "market_cap": "Small Cap",
    "sector": "Healthcare",
    "short_name": "RACE ONCOLOGY LTD",
    "state": "NSW",
    "summary": "Race Oncology Limited operates as a specialty pharmaceutical company in Australia. The company is developing Bisantrene, a small molecule cancer chemotherapy drug that is used for the treatment of acute myeloid leukaemia. It has a preclinical research program with the University of Newcastle to explore the use of Bisantrene to treat melanoma. The company was formerly known as Coronado Resources Limited and changed its name to Race Oncology Limited in July 2016. Race Oncology Limited was incorporated in 2011 and is based in Sydney, Australia.",
    "website": "http://www.raceoncology.com",
    "zipcode": "2000"
  },
  "RAP.AX": {
    "city": "Brisbane",
    "country": "Australia",
    "currency": "AUD",
    "exchange": "ASX",
    "industry": "Health Information Services",
    "long_name": "ResApp Health Limited",
    "market": "au_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "RESAPP FPO",
    "state": "QLD",
    "summary": "ResApp Health Limited develops digital healthcare solutions to assist doctors and allow patients to diagnose and manage respiratory disease. The company offers ResAppDx, a smartphone-based acute respiratory disease diagnostic test for use in telehealth, emergency department, and primary care markets; and SleepCheck, a direct-to-consumer smartphone application for the self-assessment of sleep apnoea in 36 countries. Its technology uses sound to diagnose respiratory diseases, including pneumonia, bronchiolitis, bronchitis, chronic obstructive pulmonary disease, and asthma. ResApp Health Limited has a joint development and pilot agreement with Medgate AG to integrate and test smartphone-based acute respiratory diagnostic test. The company was formerly known as Narhex Life Sciences Limited. ResApp Health Limited was founded in 2014 and is headquartered in Brisbane, Australia.",
    "website": "http://www.resapphealth.com.au",
    "zipcode": "4000"
  },
  "RCE.AX": {
    "city": "Sydney",
    "country": "Australia",
    "currency": "AUD",
    "exchange": "ASX",
    "industry": "Biotechnology",
    "long_name": "Recce Pharmaceuticals Ltd",
    "market": "au_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "RECCE LTD FPO",
    "state": "NSW",
    "summary": "Recce Pharmaceuticals Ltd, a biotechnology company, engages in the research, development, and commercialization of synthetic antibiotics in Australia, the United States, and the United Kingdom. The company's lead candidate is RECCE 327 to treat blood infections and sepsis derived from E. coli and S. aureus bacteria, including their superbug forms. It also develops RECCE 529, a synthetic anti-infective for viral infections; and RECCE 435, a synthetic polymer antibiotics. The company was formerly known as Recce Limited and changed its name to Recce Pharmaceuticals Ltd in November 2017. Recce Pharmaceuticals Ltd was incorporated in 2007 and is headquartered in Sydney, Australia.",
    "website": "http://www.recce.com.au",
    "zipcode": "2000"
  },
  "REG.AX": {
    "city": "Armadale",
    "country": "Australia",
    "currency": "AUD",
    "exchange": "ASX",
    "industry": "Medical Care Facilities",
    "long_name": "Regis Healthcare Limited",
    "market": "au_market",
    "market_cap": "Small Cap",
    "sector": "Healthcare",
    "short_name": "REG HEALTH FPO",
    "state": "VIC",
    "summary": "Regis Healthcare Limited provides residential aged care services in Australia. The company offers home care services, including personal hygiene, dressing and undressing, and mobility and transportation; home help services, such as cooking and cleaning, shopping and transportation, and facilitating social outings; aged care facilities; owns and operates specialist retirement and independent living villages, which provides laundry, meals, cleaning, and allied health services consist of physiotherapy, podiatry, diversional therapy, and therapeutic activities. It also offers companionship and government-funded and private home care services; aged care services, including ageing-in-place, respite care, specialist dementia care, and palliative care services; Day Respite Programs for carers; and therapeutic services to people living in the community, in retirement villages, and aged care facilities. As of June 30, 2020, the company owned and operated 65 aged care facilities. The company was formerly known as Fairway Investment Holdings Pty Ltd. and changed its name to Regis Healthcare Limited in September 2014. Regis Healthcare Limited was incorporated in 2007 and is based in Armadale, Australia.",
    "website": "http://www.regis.com.au",
    "zipcode": "3143"
  },
  "RGS.AX": {
    "city": "Paddington",
    "country": "Australia",
    "currency": "AUD",
    "exchange": "ASX",
    "industry": "Biotechnology",
    "long_name": "Regeneus Ltd",
    "market": "au_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "REGENEUS FPO",
    "state": "NSW",
    "summary": "Regeneus Ltd, a clinical-stage regenerative medicine company, engages in developing cell-based therapies for the human health markets with a focus on osteoarthritis and other musculoskeletal disorders, and neuropathic pain and dermatology diseases. Its lead platform technology includes Progenza, a cryopreserved multi-synergistic therapy for the treatment of osteoarthritis and neuropathic pain. The company also develops Sygenus for the treatment of skin wound healing. Regeneus Ltd was founded in 2007 and is headquartered in Paddington, Australia.",
    "website": "http://regeneus.com.au",
    "zipcode": "2021"
  },
  "RHC.AX": {
    "city": "Sydney",
    "country": "Australia",
    "currency": "AUD",
    "exchange": "ASX",
    "industry": "Medical Care Facilities",
    "long_name": "Ramsay Health Care Limited",
    "market": "au_market",
    "market_cap": "Large Cap",
    "sector": "Healthcare",
    "short_name": "RAMSAY FPO",
    "state": "NSW",
    "summary": "Ramsay Health Care Limited provides health care services to public and private patients. The company's health care services comprise day surgery procedures and other surgeries, as well as psychiatric care and rehabilitation services. It operates through approximately 500 locations across Australia, the United Kingdom, France, Sweden, Norway, Denmark, Germany, Indonesia, Malaysia, Hong Kong, and Italy. The company was founded in 1964 and is based in Sydney, Australia.",
    "website": "http://www.ramsayhealth.com",
    "zipcode": "2000"
  },
  "RHCPA.AX": {
    "city": "Sydney",
    "country": "Australia",
    "currency": "AUD",
    "exchange": "ASX",
    "industry": "Medical Care Facilities",
    "long_name": "Ramsay Health Care Limited",
    "market": "au_market",
    "market_cap": "Mid Cap",
    "sector": "Healthcare",
    "short_name": "RAMSAY KPYR6QT",
    "state": "NSW",
    "summary": "Ramsay Health Care Limited provides health care services to public and private patients. The company's health care services comprise day surgery procedures and other surgeries, as well as psychiatric care and rehabilitation services. It operates through approximately 500 locations across Australia, the United Kingdom, France, Sweden, Norway, Denmark, Germany, Indonesia, Malaysia, Hong Kong, and Italy. The company was founded in 1964 and is based in Sydney, Australia.",
    "website": "http://www.ramsayhealth.com",
    "zipcode": "2000"
  },
  "RHNMF": {
    "city": "Richmond",
    "country": "Australia",
    "currency": "USD",
    "exchange": "PNK",
    "industry": "Medical Devices",
    "long_name": "Rhinomed Limited",
    "market": "us_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "RHINOMED LIMITED",
    "state": "VIC",
    "summary": "Rhinomed Limited engages in the research, development, and commercialization of consumer and medical devices worldwide. It identifies, acquires, and commercializes nasal stent delivery technologies. The company's product portfolio includes Turbine for enhanced breathing in sports; Mute, an anti-snoring device; and Pronto for nasal congestion and sleep disturbance issues. It also engages in developing applications for the delivery of medical cannabis and conditions, including anxiety, pain, allergies, nausea, anxiety, and coughs and colds; and nasal swab to test the presence of upper respiratory tract diseases, including influenza, and coronavirus strains. The company was formerly known as Consegna Group Limited and changed its name to Rhinomed Limited in November 2013. Rhinomed Limited was incorporated in 2004 and is based in Richmond, Australia.",
    "website": "http://www.rhinomed.global",
    "zipcode": "3121"
  },
  "RHT.AX": {
    "city": "Burswood",
    "country": "Australia",
    "currency": "AUD",
    "exchange": "ASX",
    "industry": "Medical Devices",
    "long_name": "Resonance Health Limited",
    "market": "au_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "RESONANCE FPO",
    "state": "WA",
    "summary": "Resonance Health Limited, a healthcare company, develops and delivers non-invasive medical imaging software and services worldwide. Its flagship products include FerriScan, a non-invasive liver diagnostic technology used for the measurement of liver iron concentration; and FerriSmart, an automated software medical device to manage patients with iron overload disorders, such as thalassemia, sickle cell disease, hereditary haemochromatosis, anaemias, and cancers. The company also offers Cardiac T2, a dual analysis service with FerriScan to provide information regarding body iron stores; HepaFat-Scan, a magnetic resonance imaging (MRI) based tool for the measurement of volumetric liver fat fraction; HepaFat-AI, an artificial intelligence software tool, which is used for the automated assessment of liver fat from MRI data; and Bone Marrow R2-MRI for the assessment of iron levels in the bone marrow. It also provides imaging core laboratory and support services for clinical trials. The company serves clinicians for the diagnosis and management of human diseases; researchers; and pharmaceutical companies for their clinical trials. Resonance Health Limited was incorporated in 1987 and is headquartered in Burswood, Australia.",
    "website": "http://www.resonancehealth.com",
    "zipcode": "6100"
  },
  "RHY.AX": {
    "city": "Parkville",
    "country": "Australia",
    "currency": "AUD",
    "exchange": "ASX",
    "industry": "Diagnostics & Research",
    "long_name": "Rhythm Biosciences Limited",
    "market": "au_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "RHYTHM BIO FPO",
    "state": "VIC",
    "summary": "Rhythm Biosciences Limited engages in developing and commercializing medical diagnostics technology in Australia and internationally. It is developing ColoSTAT, a blood test for the early detection of colorectal cancer. The company was incorporated in 2017 and is headquartered in Parkville, Australia.",
    "website": "http://www.rhythmbio.com",
    "zipcode": "3010"
  },
  "RJV.F": {
    "city": "Crows Nest",
    "country": "Australia",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Medical Devices",
    "long_name": "SomnoMed Limited",
    "market": "dr_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "SOMNOMED LTD.",
    "state": "NSW",
    "summary": "SomnoMed Limited, together with its subsidiaries, produces and sells devices for the oral treatment of sleep related disorders in Europe, North America, and the Asia Pacific Region. Its products include SomnoDent, an oral appliance for obstructive sleep apnea; and SomnoBrux, a mouthguard for the treatment of teeth grinding damage, as well as SomTabs for cleaning its devices. The company was founded in 2004 and is based in Crows Nest, Australia.",
    "website": "http://somnomed.com/au/",
    "zipcode": "2065"
  },
  "RMSYF": {
    "city": "Sydney",
    "country": "Australia",
    "currency": "USD",
    "exchange": "PNK",
    "industry": "Medical Care Facilities",
    "long_name": "Ramsay Health Care Limited",
    "market": "us_market",
    "market_cap": "Large Cap",
    "sector": "Healthcare",
    "short_name": "RAMSAY HEALTH CARE",
    "state": "NSW",
    "summary": "Ramsay Health Care Limited provides health care services to public and private patients. The company's health care services comprise day surgery procedures and other surgeries, as well as psychiatric care and rehabilitation services. It operates through approximately 500 locations across Australia, the United Kingdom, France, Sweden, Norway, Denmark, Germany, Indonesia, Malaysia, Hong Kong, and Italy. The company was founded in 1964 and is based in Sydney, Australia.",
    "website": "http://www.ramsayhealth.com",
    "zipcode": "2000"
  },
  "RMY.F": {
    "city": "Sydney",
    "country": "Australia",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Medical Care Facilities",
    "long_name": "Ramsay Health Care Limited",
    "market": "dr_market",
    "market_cap": "Large Cap",
    "sector": "Healthcare",
    "short_name": "RAMSAY HEALTH",
    "state": "NSW",
    "summary": "Ramsay Health Care Limited provides health care services to public and private patients. The company's health care services comprise day surgery procedures and other surgeries, as well as psychiatric care and rehabilitation services. It operates through approximately 500 locations across Australia, the United Kingdom, France, Sweden, Norway, Denmark, Germany, Indonesia, Malaysia, Hong Kong, and Italy. The company was founded in 1964 and is based in Sydney, Australia.",
    "website": "http://www.ramsayhealth.com",
    "zipcode": "2000"
  },
  "RMYHY": {
    "city": "Sydney",
    "country": "Australia",
    "currency": "USD",
    "exchange": "PNK",
    "industry": "Medical Care Facilities",
    "long_name": "Ramsay Health Care Limited",
    "market": "us_market",
    "market_cap": "Large Cap",
    "sector": "Healthcare",
    "short_name": "RAMSAY HEALTH CARE",
    "state": "NSW",
    "summary": "Ramsay Health Care Limited provides health care services to public and private patients. The company's health care services comprise day surgery procedures and other surgeries, as well as psychiatric care and rehabilitation services. It operates through approximately 500 locations across Australia, the United Kingdom, France, Sweden, Norway, Denmark, Germany, Indonesia, Malaysia, Hong Kong, and Italy. The company was founded in 1964 and is based in Sydney, Australia.",
    "website": "http://www.ramsayhealth.com",
    "zipcode": "2000"
  },
  "RNO.AX": {
    "city": "Richmond",
    "country": "Australia",
    "currency": "AUD",
    "exchange": "ASX",
    "industry": "Medical Devices",
    "long_name": "Rhinomed Limited",
    "market": "au_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "RHINOMED FPO",
    "state": "VIC",
    "summary": "Rhinomed Limited engages in the research, development, and commercialization of consumer and medical devices worldwide. It identifies, acquires, and commercializes nasal stent delivery technologies. The company's product portfolio includes Turbine for enhanced breathing in sports; Mute, an anti-snoring device; and Pronto for nasal congestion and sleep disturbance issues. It also engages in developing applications for the delivery of medical cannabis and conditions, including anxiety, pain, allergies, nausea, anxiety, and coughs and colds; and nasal swab to test the presence of upper respiratory tract diseases, including influenza, and coronavirus strains. The company was formerly known as Consegna Group Limited and changed its name to Rhinomed Limited in November 2013. Rhinomed Limited was incorporated in 2004 and is based in Richmond, Australia.",
    "website": "http://www.rhinomed.global",
    "zipcode": "3121"
  },
  "RSH.AX": {
    "city": "Melbourne",
    "country": "Australia",
    "currency": "AUD",
    "exchange": "ASX",
    "industry": "Medical Devices",
    "long_name": "Respiri Limited",
    "market": "au_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "RESPIRI FPO",
    "state": "VIC",
    "summary": "Respiri Limited, an e-health SaaS company, researches, develops, and commercializes, medical devices in Australia and Israel. The company produces and sells mobile health applications. Its products include Wheezo, a mobile app, which has asthma management diary, medication usage and reminders, and symptoms and triggers to help asthma sufferers; and Wholter, a device for home ambulatory recording of nocturnal wheeze and cough. The company also offers PulmoTrack, a computerized wheeze detection product designed for hospital/clinical based real-time monitoring of wheeze and cough in the management of acute asthma in the ER and ICU, and for pediatric pulmonary function testing and sleep labs. The company was formerly known as iSonea Limited and changed its name to Respiri Limited in December 2015. Respiri Limited is based in Melbourne, Australia.",
    "website": "http://www.respiri.co",
    "zipcode": "3004"
  },
  "RSN.SG": {
    "city": "Burswood",
    "country": "Australia",
    "currency": "EUR",
    "exchange": "STU",
    "industry": "Medical Devices",
    "long_name": "Resonance Health Limited",
    "market": "dr_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "Resonance Health Ltd. Registere",
    "state": "WA",
    "summary": "Resonance Health Limited, a healthcare company, develops and delivers non-invasive medical imaging software and services worldwide. Its flagship products include FerriScan, a non-invasive liver diagnostic technology used for the measurement of liver iron concentration; and FerriSmart, an automated software medical device to manage patients with iron overload disorders, such as thalassemia, sickle cell disease, hereditary haemochromatosis, anaemias, and cancers. The company also offers Cardiac T2, a dual analysis service with FerriScan to provide information regarding body iron stores; HepaFat-Scan, a magnetic resonance imaging (MRI) based tool for the measurement of volumetric liver fat fraction; HepaFat-AI, an artificial intelligence software tool, which is used for the automated assessment of liver fat from MRI data; and Bone Marrow R2-MRI for the assessment of iron levels in the bone marrow. It also provides imaging core laboratory and support services for clinical trials. The company serves clinicians for the diagnosis and management of human diseases; researchers; and pharmaceutical companies for their clinical trials. Resonance Health Limited was incorporated in 1987 and is headquartered in Burswood, Australia.",
    "website": "http://www.resonancehealth.com",
    "zipcode": "6100"
  },
  "S5YA.F": {
    "city": "Rowville",
    "country": "Australia",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Medical Distribution",
    "long_name": "Sigma Healthcare Limited",
    "market": "dr_market",
    "market_cap": "Small Cap",
    "sector": "Healthcare",
    "short_name": "SIGMA HEALTHCARE LTD",
    "state": "VIC",
    "summary": "Sigma Healthcare Limited, together with its subsidiaries, engages in the wholesale and distribution of pharmaceutical products primarily in Australia. It operates a network of branded and independent stores under the Amcal+, Chemist King, Discount Drug Stores, Guardian, WholeLife, and PharmaSave brands. The company also develops and support a range of private label products. In addition, it provides hospital pharmacy services, including data and programs supporting specialty medication services; dose administration aid and related services to the residential, aged care, and community pharmacy sectors; technology solutions and data analytics; and product development and support services for a range of private and exclusive label products, as well as supplies medical consumables and devices to aged care facilities, hospitals, and clinics. Further, the company provides third party and fourth party logistics services to pharmaceutical manufacturers and other supplier partners. Sigma Healthcare Limited was founded in 1912 and is headquartered in Rowville, Australia.",
    "website": "http://www.sigmahealthcare.com.au",
    "zipcode": "3178"
  },
  "SAB.F": {
    "city": "Sydney",
    "country": "Australia",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Medical Care Facilities",
    "long_name": "Sonic Healthcare Limited",
    "market": "dr_market",
    "market_cap": "Large Cap",
    "sector": "Healthcare",
    "short_name": "SONIC HEALTHCARE",
    "state": "NSW",
    "summary": "Sonic Healthcare Limited, a healthcare company, provides medical diagnostic services, and administrative services and facilities to medical practitioners. The company operates through Laboratory, Imaging, and Other segments. It offers laboratory medicine/pathology and radiology/diagnostic imaging services to clinicians, hospitals, community health services, and their patients. The company also provides general practice, occupational health services, remote health services, community and home nursing services, primary care research programs, health assessment technologies, hospital avoidance programs, and clinical trials and chronic disease management programs. In addition, it offers Phase I-IV clinical trials, safety testing, and patient monitoring services to the pharmaceutical, biotechnology, and research organizations. The company operates 233 primary care clinics. Sonic Healthcare Limited operates in Australia, the United States, Germany, and internationally. The company was formerly known as Sonic Technology Australia Limited and changed its name to Sonic Healthcare Limited in November 1995. Sonic Healthcare Limited was incorporated in 1934 and is headquartered in Sydney, Australia.",
    "website": "http://www.sonichealthcare.com",
    "zipcode": "2000"
  },
  "SCU.AX": {
    "city": "Sydney",
    "country": "Australia",
    "currency": "AUD",
    "exchange": "ASX",
    "industry": "Drug Manufacturers - Specialty & Generic",
    "long_name": "Stemcell United Limited",
    "market": "au_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "STEMCELL FPO",
    "state": "NSW",
    "summary": "Stemcell United Limited, together with its subsidiaries, engages in the sourcing, producing, marketing, and selling of traditional medicine in Australia, Singapore, Greater China, and Malaysia. The company's products include Cannabis Sativa, an industrial hemp; Dendrobium Officinale Kimura et Migo, an orchid extract; Resina, a Daemonorops Draco Blume extract; and Caulerpa Lentillifera, a sea grape extract. The company has a collaboration agreement with Temasek Polytechnic of Singapore to conduct joint research on the application of plant stem cell technology to the cultivation and commercial farming of seagrapes in Singapore. The company was formerly known as On Q Group Limited and changed its name to Stemcell United Limited in September 2015. Stemcell United Limited was incorporated in 1984 and is headquartered in Sydney, Australia.",
    "website": "http://www.scu.com.sg",
    "zipcode": "2000"
  },
  "SDI.AX": {
    "city": "Bayswater",
    "country": "Australia",
    "currency": "AUD",
    "exchange": "ASX",
    "industry": "Medical Instruments & Supplies",
    "long_name": "SDI Limited",
    "market": "au_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "SDI FPO",
    "state": "VIC",
    "summary": "SDI Limited engages in the research, development, manufacture, and distribution of dental restorative materials, whitening systems, other dental materials in Australia, Europe, the United States, and Brazil. It offers alloys, adhesives, etchants, composites, glass ionomers, sealants, cements, tooth desensitizing agent and cavity cleansers, and tooth whitening products, as well as various equipment; and composite and glass ionomer accessories. The company serves dental distributors, dental dealers, and dentists. SDI Limited was founded in 1972 and is headquartered in Bayswater, Australia.",
    "website": "http://www.sdi.com.au",
    "zipcode": "3153"
  },
  "SHG.AX": {
    "city": "Subiaco",
    "country": "Australia",
    "currency": "AUD",
    "exchange": "ASX",
    "industry": "Health Information Services",
    "long_name": "Singular Health Group Ltd",
    "market": "au_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "SINGHEALTH FPO",
    "state": "WA",
    "summary": "Singular Health Group Ltd, a medical technology company, focuses on development of medical software for visualization, manipulation, and transfer of medical imaging data in 3D and virtual reality. It develops products based on its volume rendering platform (VRP) software. The company offers MedVR, a clinical 3D medical visualization software; Virtual Anatomy, a 3D medical education solution; and 3D Dicom Viewer, a cross-platform application that allows its users to interact with their medical scans in 3D. Singular Health Group Ltd was founded in 2017 and is headquartered in Subiaco, Australia.",
    "website": "http://singular.health",
    "zipcode": "6008"
  },
  "SHL.AX": {
    "city": "Sydney",
    "country": "Australia",
    "currency": "AUD",
    "exchange": "ASX",
    "industry": "Medical Care Facilities",
    "long_name": "Sonic Healthcare Limited",
    "market": "au_market",
    "market_cap": "Large Cap",
    "sector": "Healthcare",
    "short_name": "SONIC HLTH FPO",
    "state": "NSW",
    "summary": "Sonic Healthcare Limited, a healthcare company, provides medical diagnostic services, and administrative services and facilities to medical practitioners. The company operates through Laboratory, Imaging, and Other segments. It offers laboratory medicine/pathology and radiology/diagnostic imaging services to clinicians, hospitals, community health services, and their patients. The company also provides general practice, occupational health services, remote health services, community and home nursing services, primary care research programs, health assessment technologies, hospital avoidance programs, and clinical trials and chronic disease management programs. In addition, it offers Phase I-IV clinical trials, safety testing, and patient monitoring services to the pharmaceutical, biotechnology, and research organizations. The company operates 233 primary care clinics. Sonic Healthcare Limited operates in Australia, the United States, Germany, and internationally. The company was formerly known as Sonic Technology Australia Limited and changed its name to Sonic Healthcare Limited in November 1995. Sonic Healthcare Limited was incorporated in 1934 and is headquartered in Sydney, Australia.",
    "website": "http://www.sonichealthcare.com",
    "zipcode": "2000"
  },
  "SIG.AX": {
    "city": "Rowville",
    "country": "Australia",
    "currency": "AUD",
    "exchange": "ASX",
    "industry": "Medical Distribution",
    "long_name": "Sigma Healthcare Limited",
    "market": "au_market",
    "market_cap": "Small Cap",
    "sector": "Healthcare",
    "short_name": "SIGMAHEALT FPO",
    "state": "VIC",
    "summary": "Sigma Healthcare Limited, together with its subsidiaries, engages in the wholesale and distribution of pharmaceutical products primarily in Australia. It operates a network of branded and independent stores under the Amcal+, Chemist King, Discount Drug Stores, Guardian, WholeLife, and PharmaSave brands. The company also develops and support a range of private label products. In addition, it provides hospital pharmacy services, including data and programs supporting specialty medication services; dose administration aid and related services to the residential, aged care, and community pharmacy sectors; technology solutions and data analytics; and product development and support services for a range of private and exclusive label products, as well as supplies medical consumables and devices to aged care facilities, hospitals, and clinics. Further, the company provides third party and fourth party logistics services to pharmaceutical manufacturers and other supplier partners. Sigma Healthcare Limited was founded in 1912 and is headquartered in Rowville, Australia.",
    "website": "http://www.sigmahealthcare.com.au",
    "zipcode": "3178"
  },
  "SKHCF": {
    "city": "Sydney",
    "country": "Australia",
    "currency": "USD",
    "exchange": "PNK",
    "industry": "Medical Care Facilities",
    "long_name": "Sonic Healthcare Limited",
    "market": "us_market",
    "market_cap": "Large Cap",
    "sector": "Healthcare",
    "short_name": "SONIC HEALTHCARE",
    "state": "NSW",
    "summary": "Sonic Healthcare Limited, a healthcare company, provides medical diagnostic services, and administrative services and facilities to medical practitioners. The company operates through Laboratory, Imaging, and Other segments. It offers laboratory medicine/pathology and radiology/diagnostic imaging services to clinicians, hospitals, community health services, and their patients. The company also provides general practice, occupational health services, remote health services, community and home nursing services, primary care research programs, health assessment technologies, hospital avoidance programs, and clinical trials and chronic disease management programs. In addition, it offers Phase I-IV clinical trials, safety testing, and patient monitoring services to the pharmaceutical, biotechnology, and research organizations. The company operates 233 primary care clinics. Sonic Healthcare Limited operates in Australia, the United States, Germany, and internationally. The company was formerly known as Sonic Technology Australia Limited and changed its name to Sonic Healthcare Limited in November 1995. Sonic Healthcare Limited was incorporated in 1934 and is headquartered in Sydney, Australia.",
    "website": "http://www.sonichealthcare.com",
    "zipcode": "2000"
  },
  "SKHHY": {
    "city": "Sydney",
    "country": "Australia",
    "currency": "USD",
    "exchange": "PNK",
    "industry": "Medical Care Facilities",
    "long_name": "Sonic Healthcare Limited",
    "market": "us_market",
    "market_cap": "Large Cap",
    "sector": "Healthcare",
    "short_name": "SONIC HEALTHCARE",
    "state": "NSW",
    "summary": "Sonic Healthcare Limited, a healthcare company, provides medical diagnostic services, and administrative services and facilities to medical practitioners. The company operates through Laboratory, Imaging, and Other segments. It offers laboratory medicine/pathology and radiology/diagnostic imaging services to clinicians, hospitals, community health services, and their patients. The company also provides general practice, occupational health services, remote health services, community and home nursing services, primary care research programs, health assessment technologies, hospital avoidance programs, and clinical trials and chronic disease management programs. In addition, it offers Phase I-IV clinical trials, safety testing, and patient monitoring services to the pharmaceutical, biotechnology, and research organizations. The company operates 233 primary care clinics. Sonic Healthcare Limited operates in Australia, the United States, Germany, and internationally. The company was formerly known as Sonic Technology Australia Limited and changed its name to Sonic Healthcare Limited in November 1995. Sonic Healthcare Limited was incorporated in 1934 and is headquartered in Sydney, Australia.",
    "website": "http://www.sonichealthcare.com",
    "zipcode": "2000"
  },
  "SLA.AX": {
    "city": "Parkside",
    "country": "Australia",
    "currency": "AUD",
    "exchange": "ASX",
    "industry": "Medical Care Facilities",
    "long_name": "SILK Laser Australia Limited",
    "market": "au_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "SILK LASER FPO",
    "state": "SA",
    "summary": "SILK Laser Australia Limited operates and franchises a network of specialist clinics that offer non-surgical aesthetic services in Australia. Its services include laser hair removal, cosmetic injectables, skin treatment, and body contouring. The company also manufactures and sells skincare products. As of December 31, 2020, the company had 28 corporate and owned stores, and 28 franchised stores, including 11 joint venture clinics. The company was formerly known as SILK Laser & Skin Holdings Pty Ltd. SILK Laser Australia Limited was founded in 2009 and is based in Parkside, Australia.",
    "website": "http://www.silklaser.com.au",
    "zipcode": "5063"
  },
  "SOM.AX": {
    "city": "Crows Nest",
    "country": "Australia",
    "currency": "AUD",
    "exchange": "ASX",
    "industry": "Medical Devices",
    "long_name": "SomnoMed Limited",
    "market": "au_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "SOMNOMED FPO",
    "state": "NSW",
    "summary": "SomnoMed Limited, together with its subsidiaries, produces and sells devices for the oral treatment of sleep related disorders in Europe, North America, and the Asia Pacific Region. Its products include SomnoDent, an oral appliance for obstructive sleep apnea; and SomnoBrux, a mouthguard for the treatment of teeth grinding damage, as well as SomTabs for cleaning its devices. The company was founded in 2004 and is based in Crows Nest, Australia.",
    "website": "http://somnomed.com/au/",
    "zipcode": "2065"
  },
  "SOMNF": {
    "city": "Crows Nest",
    "country": "Australia",
    "currency": "USD",
    "exchange": "PNK",
    "industry": "Medical Devices",
    "long_name": "SomnoMed Limited",
    "market": "us_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "SOMNOMED LIMITED",
    "state": "NSW",
    "summary": "SomnoMed Limited, together with its subsidiaries, produces and sells devices for the oral treatment of sleep related disorders in Europe, North America, and the Asia Pacific Region. Its products include SomnoDent, an oral appliance for obstructive sleep apnea; and SomnoBrux, a mouthguard for the treatment of teeth grinding damage, as well as SomTabs for cleaning its devices. The company was founded in 2004 and is based in Crows Nest, Australia.",
    "website": "http://somnomed.com/au/",
    "zipcode": "2065"
  },
  "SPHRF": {
    "city": "Abbotsford",
    "country": "Australia",
    "currency": "USD",
    "exchange": "PNK",
    "industry": "Biotechnology",
    "long_name": "Starpharma Holdings Limited",
    "market": "us_market",
    "market_cap": "Small Cap",
    "sector": "Healthcare",
    "short_name": "STARPHARMA HOLDINGS LIMITED",
    "state": "VIC",
    "summary": "Starpharma Holdings Limited engages in the research, development, and commercialization of dendrimer products for pharmaceutical, life-science, and other applications worldwide. The company offers VivaGel, a non-antibiotic therapy for the management and prevention of bacterial vaginosis. It also develops VivaGel condom, an antiviral condom; and DEP, a dendrimer drug delivery technology, including DEP docetaxel that is in Phase II clinical trials, DEP cabazitaxel that is in Phase 1 clinical trial, and DEP irinotecan that is in phase 1/2 clinical trials for the treatment of solid tumors. The company was founded in 1996 and is headquartered in Abbotsford, Australia.",
    "website": "http://starpharma.com",
    "zipcode": "3067"
  },
  "SPHRY": {
    "city": "Abbotsford",
    "country": "Australia",
    "currency": "USD",
    "exchange": "PNK",
    "industry": "Biotechnology",
    "long_name": "Starpharma Holdings Limited",
    "market": "us_market",
    "market_cap": "Small Cap",
    "sector": "Healthcare",
    "short_name": "STARPHARMA HOLDINGS LIMITED",
    "state": "VIC",
    "summary": "Starpharma Holdings Limited engages in the research, development, and commercialization of dendrimer products for pharmaceutical, life-science, and other applications worldwide. The company offers VivaGel, a non-antibiotic therapy for the management and prevention of bacterial vaginosis. It also develops VivaGel condom, an antiviral condom; and DEP, a dendrimer drug delivery technology, including DEP docetaxel that is in Phase II clinical trials, DEP cabazitaxel that is in Phase 1 clinical trial, and DEP irinotecan that is in phase 1/2 clinical trials for the treatment of solid tumors. The company was founded in 1996 and is headquartered in Abbotsford, Australia.",
    "website": "http://starpharma.com",
    "zipcode": "3067"
  },
  "SPL.AX": {
    "city": "Abbotsford",
    "country": "Australia",
    "currency": "AUD",
    "exchange": "ASX",
    "industry": "Biotechnology",
    "long_name": "Starpharma Holdings Limited",
    "market": "au_market",
    "market_cap": "Small Cap",
    "sector": "Healthcare",
    "short_name": "STARPHARMA FPO",
    "state": "VIC",
    "summary": "Starpharma Holdings Limited engages in the research, development, and commercialization of dendrimer products for pharmaceutical, life-science, and other applications worldwide. The company offers VivaGel, a non-antibiotic therapy for the management and prevention of bacterial vaginosis. It also develops VivaGel condom, an antiviral condom; and DEP, a dendrimer drug delivery technology, including DEP docetaxel that is in Phase II clinical trials, DEP cabazitaxel that is in Phase 1 clinical trial, and DEP irinotecan that is in phase 1/2 clinical trials for the treatment of solid tumors. The company was founded in 1996 and is headquartered in Abbotsford, Australia.",
    "website": "http://starpharma.com",
    "zipcode": "3067"
  },
  "SUD.AX": {
    "city": "Osborne Park",
    "country": "Australia",
    "currency": "AUD",
    "exchange": "ASX",
    "industry": "Biotechnology",
    "long_name": "Suda Pharmaceuticals Ltd",
    "market": "au_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "SUDA FPO",
    "state": "WA",
    "summary": "Suda Pharmaceuticals Ltd engages in the development of drug delivery technology in Australia, India, Europe and Korea. It offers ZolpiMist, an oro-mucosal spray formulation of zolpidem tartrate marketed under the brand name of Ambien or Stilnox, a non-benzodiazepine prescribed for the short-term treatment of insomnia. The company's product pipeline includes Sumatriptan, an oral spray formulation for the treatment of acute migraine; and anagrelide, a platelet lowering agent for use in thrombosis, which is used for the treatment of cancer. Suda Pharmaceuticals Ltd has license and supply agreement with Teva Pharmaceuticals International GmbH and Mitsubishi Tanabe Pharma Singapore for ZolpiMist oral spray; product development, licence, and supply agreement with Cann Pharmaceutical Australia Ltd for the development of novel oral spray of pharmaceutical-grade cannabinoid derivatives for the treatment of drug resistant epilepsy, melanoma, and motion sickness; and feasibility and option agreement with Zelira Therapeutics for the use of cannabinoids for a range of uses, including insomnia, autism, opioid reduction, anxiety, pain, and cancer. The company also has a feasibility study and option agreement with Laboratorios Ordesa, S.L. The company was formerly known as Suda Limited and changed its name to Suda Pharmaceuticals Ltd in November 2017. Suda Pharmaceuticals Ltd was incorporated in 1999 and is headquartered in Osborne Park, Australia.",
    "website": "http://sudapharma.com",
    "zipcode": "6017"
  },
  "TD1.AX": {
    "city": "Cremorne",
    "country": "Australia",
    "currency": "AUD",
    "exchange": "ASX",
    "industry": "Health Information Services",
    "long_name": "TALi Digital Limited",
    "market": "au_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "TALI DIGI FPO",
    "state": "VIC",
    "summary": "TALi Digital Limited engages in the research, development, and commercialization of medical technology in Australia. The company operates through Research and Development; and Investments segments. It offers TALi Train, a mobile software application used by clinicians, educators, and parents for strengthening of core attention in children between the development ages of 3-8; TALi Portal that allows healthcare professionals, educators, and parents to assess a child's daily performance and identify strengths and weaknesses to tailor the program to child's needs; and TALi Detect, which consists of seven tests to profile cognitive attention capabilities of a child. The company was formerly known as Novita Healthcare Limited and changed its name to TALI Digital Limited in December 2019. TALi Digital Limited was incorporated in 2004 and is based in Cremorne, Australia.",
    "website": "http://talidigital.com",
    "zipcode": "3121"
  },
  "TDLAF": {
    "city": "Greenslopes",
    "country": "Australia",
    "currency": "USD",
    "exchange": "PNK",
    "industry": "Diagnostics & Research",
    "long_name": "TBG Diagnostics Limited",
    "market": "us_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "TBG DIAGNOSTICS LTD",
    "state": "QLD",
    "summary": "TBG Diagnostics Limited, a molecular diagnostics company, develops, manufactures, and markets molecular diagnostics kits, instruments, and services in Taiwan and China. It provides ExProbe HLA and HPA kits for human leukocyte antigen (HLA) and human platelet antigens (HPA) allele genotyping, which uses real time polymerase chain reaction (PCR) techniques with sequence specific primers and probes; Morgan SSP HLA kits for determining HLA alleles using PCR techniques with sequence specific primers; HLAssure SBT HLA Kits for transplantation donor selection; and AccuType SBT analysis software to analyze sequences from all ab1 based files. The company also offers Morgan SSPal HLA Typing Analysis Software, a gel result interpretation software; HLA typing services that offer low to high resolution using PCR fragment analysis (SSP) and DNA sequencing (SBT); QPCR Q6000, a six-channel real time PCR instrument; QzNGS NGS that provides high resolution HLA genotyping; and COVID-19 testing kits. It serves clinical labs, blood centers, and bone marrow registry labs. The company was formerly known as Progen Pharmaceuticals Limited and changed its name to TBG Diagnostics Limited in December 2015. TBG Diagnostics Limited was incorporated in 1989 is based in Greenslopes, Australia.",
    "website": "http://www.tbgbio.com",
    "zipcode": "4120"
  },
  "TLPPF": {
    "city": "North Melbourne",
    "country": "Australia",
    "currency": "USD",
    "exchange": "PNK",
    "industry": "Biotechnology",
    "long_name": "Telix Pharmaceuticals Limited",
    "market": "us_market",
    "market_cap": "Small Cap",
    "sector": "Healthcare",
    "short_name": "TELIX PHARMACEUTIC",
    "state": "VIC",
    "summary": "Telix Pharmaceuticals Limited, a radiopharmaceutical company, develops molecularly targeted radiation products for unmet needs in cancer care in Australia, Belgium, Japan, and the United States. The company focuses on developing diagnostic and therapeutic products using molecularly targeted radiation (MTR). Its lead products include TLX250, which is in Phase II clinical trials for the diagnosis and treatment of renal (kidney) cancer; TLX250-CDx that is in Phase III clinical trials for the diagnosis and treatment of renal (kidney) cancer; TLX591, which is in pre-Phase 3 development for the diagnosis and treatment of metastatic castrate-resistant prostate cancer; TLX591-CDx that is in Phase III clinical trials for the diagnosis and treatment of metastatic castrate-resistant prostate cancer; and TLX101, which is in Phase I/II clinical trial for the treatment of glioblastoma (brain cancer). The company has a strategic collaboration with RefleXion Medical for the treatment of high-risk cancers; a strategic license and commercial partnership with China Grand Pharmaceutical and Healthcare Holdings Limited for developing a portfolio of MTR products; and scientific and clinical research collaboration with Mauna Kea Technologies. In addition, it has a collaboration with Kanazawa University to commence a Phase I trial of prostate cancer imaging product TLX591-CDxin Japan. The company was founded in 2015 and is headquartered in North Melbourne, Australia.",
    "website": "http://www.telixpharma.com",
    "zipcode": "3051"
  },
  "TLX.AX": {
    "city": "North Melbourne",
    "country": "Australia",
    "currency": "AUD",
    "exchange": "ASX",
    "industry": "Biotechnology",
    "long_name": "Telix Pharmaceuticals Limited",
    "market": "au_market",
    "market_cap": "Small Cap",
    "sector": "Healthcare",
    "short_name": "TELIXPHARM FPO",
    "state": "VIC",
    "summary": "Telix Pharmaceuticals Limited, a radiopharmaceutical company, develops molecularly targeted radiation products for unmet needs in cancer care in Australia, Belgium, Japan, and the United States. The company focuses on developing diagnostic and therapeutic products using molecularly targeted radiation (MTR). Its lead products include TLX250, which is in Phase II clinical trials for the diagnosis and treatment of renal (kidney) cancer; TLX250-CDx that is in Phase III clinical trials for the diagnosis and treatment of renal (kidney) cancer; TLX591, which is in pre-Phase 3 development for the diagnosis and treatment of metastatic castrate-resistant prostate cancer; TLX591-CDx that is in Phase III clinical trials for the diagnosis and treatment of metastatic castrate-resistant prostate cancer; and TLX101, which is in Phase I/II clinical trial for the treatment of glioblastoma (brain cancer). The company has a strategic collaboration with RefleXion Medical for the treatment of high-risk cancers; a strategic license and commercial partnership with China Grand Pharmaceutical and Healthcare Holdings Limited for developing a portfolio of MTR products; and scientific and clinical research collaboration with Mauna Kea Technologies. In addition, it has a collaboration with Kanazawa University to commence a Phase I trial of prostate cancer imaging product TLX591-CDxin Japan. The company was founded in 2015 and is headquartered in North Melbourne, Australia.",
    "website": "http://www.telixpharma.com",
    "zipcode": "3051"
  },
  "TTB.AX": {
    "city": "Surry Hills",
    "country": "Australia",
    "currency": "AUD",
    "exchange": "ASX",
    "industry": "Health Information Services",
    "long_name": "Total Brain Limited",
    "market": "au_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "TOTALBRAIN FPO",
    "state": "NSW",
    "summary": "Total Brain Limited, together with its subsidiaries, develops and sells brain health products in the United States. It offers Total Brain, a neuroscience-based mental health and brain performance app. Total Brain Limited has a partnership with the Center for Adolescent Research and Education to address growing youth mental health crisis. The company was formerly known as Brain Resource Limited and changed its name to Total Brain Limited in December 2018. Total Brain Limited was founded in 2000 and is based in Surry Hills, Australia.",
    "website": "http://www.totalbrain.com",
    "zipcode": "2010"
  },
  "TTBLF": {
    "city": "Surry Hills",
    "country": "Australia",
    "currency": "USD",
    "exchange": "PNK",
    "industry": "Health Information Services",
    "long_name": "Total Brain Limited",
    "market": "us_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "TOTAL BRAIN LTD",
    "state": "NSW",
    "summary": "Total Brain Limited, together with its subsidiaries, develops and sells brain health products in the United States. It offers Total Brain, a neuroscience-based mental health and brain performance app. Total Brain Limited has a partnership with the Center for Adolescent Research and Education to address growing youth mental health crisis. The company was formerly known as Brain Resource Limited and changed its name to Total Brain Limited in December 2018. Total Brain Limited was founded in 2000 and is based in Surry Hills, Australia.",
    "website": "http://www.totalbrain.com",
    "zipcode": "2010"
  },
  "U9O0.F": {
    "city": "Mile End South",
    "country": "Australia",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Health Information Services",
    "long_name": "Oakridge International Limited",
    "market": "dr_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "OAKRIDGE INTERNATIONAL",
    "state": "SA",
    "summary": "Oakridge International Limited develops Internet of Things technology solutions for consumer, commercial, industrial, and healthcare markets. It operates through Healthcare Technology, Technology Development, and Geothermal Projects segments. The company offers DiscoverBus wireless sensor network designed to create secure indoor wireless networks for smart office, smart building, industrial, and commercial applications; and DiscoverBus wired hub and node network primarily designed for wired networks for smart office, smart building, industrial, and commercial applications. It also provides Smart Home Gateway to automate, monitor, and control home; communication technology solutions, including the development and distribution of range of nurse call hardware and software solutions for use in hospitals, aged care, disability care, and supported independent living; and operates various geothermal projects. The company was formerly known as Xped Limited and changed its name to Oakridge International Limited in April 2021. Oakridge International Limited is based in Payneham, Australia.",
    "website": "http://www.xped.com",
    "zipcode": "5031"
  },
  "UBI.AX": {
    "city": "Rowville",
    "country": "Australia",
    "currency": "AUD",
    "exchange": "ASX",
    "industry": "Medical Devices",
    "long_name": "Universal Biosensors, Inc.",
    "market": "au_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "UNI BIOSEN CDI 1:1",
    "state": "VIC",
    "summary": "Universal Biosensors, Inc., through its subsidiary, Universal Biosensors Pty Ltd, operates as a biosensors company in Australia. The company focuses on the development, manufacture, and commercialization of point-of-use devices for measuring analytes across various industries. It offers SENTIA Wine Analyzer to test Free Sulphur Dioxide; prothrombin time international normalized ratio coagulation test strips; Sentia Free Sulphite test strips; and coagulation testing and calibration services, as well as distributes Siemens' Xprecia Stride Coagulation Analyzer. The company has a license agreement with LifeScan Global Corporation to develop a biosensor strip and a meter to be used for the detection and monitoring of diabetes in animals. Universal Biosensors, Inc. was incorporated in 2001 and is headquartered in Rowville, Australia.",
    "website": "http://www.universalbiosensors.com",
    "zipcode": "3178"
  },
  "UCM.AX": {
    "city": "Sydney",
    "country": "Australia",
    "currency": "AUD",
    "exchange": "ASX",
    "industry": "Medical Devices",
    "long_name": "Uscom Limited",
    "market": "au_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "USCOM FPO",
    "state": "NSW",
    "summary": "Uscom Limited designs, develops, manufactures, and markets non-invasive cardiovascular and pulmonary medical devices worldwide. It offers USCOM 1A, a non-invasive hemodynamic monitor that measures cardiovascular function using Doppler ultrasound; BP+, a supra-systolic oscillometric central blood pressure monitor that measures blood pressure and blood pressure waveforms at the heart, as well as in the arm; and SpiroSonic, a pulmonary function testing device based on multi-path ultrasound technology. The company provides Ventitest, a ventilator testing device; Ventitest sensor to test lung function; and The SpiroSonic AIR, a digital home care spirometer which feeds digital lung function signals through a phone app. It serves hospitals and other medical care locations through a network of distribution partners. The company was incorporated in 1999 and is headquartered in Sydney, Australia.",
    "website": "http://www.uscom.com.au",
    "zipcode": "2000"
  },
  "UKJ.F": {
    "city": "South Yarra",
    "country": "Australia",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Biotechnology",
    "long_name": "Opthea Limited",
    "market": "dr_market",
    "market_cap": "Small Cap",
    "sector": "Healthcare",
    "short_name": "OPTHEA LTD",
    "state": "VIC",
    "summary": "Opthea Limited, a biotechnology company, develops and commercializes therapies primarily for eye disease in Australia. The company's development activities are based on the intellectual property portfolio covering Vascular Endothelial Growth Factors (VEGF) VEGF-C, VEGF-D, and VEGF Receptor-3 for the treatment of diseases associated with blood and lymphatic vessel growth, as well as vascular leakage. Its lead molecule is OPT-302, a soluble form of VEGFR-3 for the treatment of wet age-related macular degeneration and diabetic macular edema. The company was formerly known as Circadian Technologies Limited and changed its name to Opthea Limited in December 2015. Opthea Limited was incorporated in 1984 and is based in South Yarra, Australia.",
    "website": "http://www.opthea.com",
    "zipcode": "3141"
  },
  "UKJ2.F": {
    "city": "South Yarra",
    "country": "Australia",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Biotechnology",
    "long_name": "Opthea Limited",
    "market": "dr_market",
    "market_cap": "Small Cap",
    "sector": "Healthcare",
    "short_name": "OPTHEA LTD (SP.ADR/8)",
    "state": "VIC",
    "summary": "Opthea Limited, a biotechnology company, develops and commercializes therapies primarily for eye disease in Australia. The company's development activities are based on the intellectual property portfolio covering Vascular Endothelial Growth Factors (VEGF) VEGF-C, VEGF-D, and VEGF Receptor-3 for the treatment of diseases associated with blood and lymphatic vessel growth, as well as vascular leakage. Its lead molecule is OPT-302, a soluble form of VEGFR-3 for the treatment of wet age-related macular degeneration and diabetic macular edema. The company was formerly known as Circadian Technologies Limited and changed its name to Opthea Limited in December 2015. Opthea Limited was incorporated in 1984 and is based in South Yarra, Australia.",
    "website": "http://www.opthea.com",
    "zipcode": "3141"
  },
  "UR9.F": {
    "city": "Melbourne",
    "country": "Australia",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Biotechnology",
    "long_name": "Clinuvel Pharmaceuticals Limited",
    "market": "dr_market",
    "market_cap": "Small Cap",
    "sector": "Healthcare",
    "short_name": "CLINUVEL PHARMACEUTICALS",
    "state": "VIC",
    "summary": "Clinuvel Pharmaceuticals Limited, a biopharmaceutical company, focuses on developing and delivering drugs for the treatment of patients with severe genetic and skin disorders worldwide. Its lead drug candidate is SCENESSE, a photoprotective drug for the prevention of phototoxicity in adult patients with erythropoietic protoporphyria (EPP). The company's pipeline products include CUV9900, an alpha-melanocyte stimulating hormone analogue; Parvysmelanotide (VLRX001), an addition to the family of melanocortin analogues, which provoke increased and prolonged cellular activity; and PRNUMBRA, a liquid injectable formulation of afamelanotide. Clinuvel Pharmaceuticals Limited has a collaboration agreement with HK Winhealth Pharma Group Co. Limited for launching SCENESSE under a named patient program for the treatment of patients with EPP in the People's Republic of China. The company was founded in 1987 and is headquartered in Melbourne, Australia.",
    "website": "http://www.clinuvel.com",
    "zipcode": "3000"
  },
  "UR9A.F": {
    "city": "Melbourne",
    "country": "Australia",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Biotechnology",
    "long_name": "Clinuvel Pharmaceuticals Limited",
    "market": "dr_market",
    "market_cap": "Small Cap",
    "sector": "Healthcare",
    "short_name": "CLINUVEL PHARMAC.ADRS1",
    "state": "VIC",
    "summary": "Clinuvel Pharmaceuticals Limited, a biopharmaceutical company, focuses on developing and delivering drugs for the treatment of patients with severe genetic and skin disorders worldwide. Its lead drug candidate is SCENESSE, a photoprotective drug for the prevention of phototoxicity in adult patients with erythropoietic protoporphyria (EPP). The company's pipeline products include CUV9900, an alpha-melanocyte stimulating hormone analogue; Parvysmelanotide (VLRX001), an addition to the family of melanocortin analogues, which provoke increased and prolonged cellular activity; and PRNUMBRA, a liquid injectable formulation of afamelanotide. Clinuvel Pharmaceuticals Limited has a collaboration agreement with HK Winhealth Pharma Group Co. Limited for launching SCENESSE under a named patient program for the treatment of patients with EPP in the People's Republic of China. The company was founded in 1987 and is headquartered in Melbourne, Australia.",
    "website": "http://www.clinuvel.com",
    "zipcode": "3000"
  },
  "USZ.F": {
    "city": "Sydney",
    "country": "Australia",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Drug Manufacturers - Specialty & Generic",
    "long_name": "Stemcell United Limited",
    "market": "dr_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "STEMCELL UNITED LTD",
    "state": "NSW",
    "summary": "Stemcell United Limited, together with its subsidiaries, engages in the sourcing, producing, marketing, and selling of traditional medicine in Australia, Singapore, Greater China, and Malaysia. The company's products include Cannabis Sativa, an industrial hemp; Dendrobium Officinale Kimura et Migo, an orchid extract; Resina, a Daemonorops Draco Blume extract; and Caulerpa Lentillifera, a sea grape extract. The company has a collaboration agreement with Temasek Polytechnic of Singapore to conduct joint research on the application of plant stem cell technology to the cultivation and commercial farming of seagrapes in Singapore. The company was formerly known as On Q Group Limited and changed its name to Stemcell United Limited in September 2015. Stemcell United Limited was incorporated in 1984 and is headquartered in Sydney, Australia.",
    "website": "http://www.scu.com.sg",
    "zipcode": "2000"
  },
  "UUD.F": {
    "city": "Frenchs Forest",
    "country": "Australia",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Drug Manufacturers - General",
    "long_name": "Pharmaxis Ltd",
    "market": "dr_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "PHARMAXIS LTD.",
    "state": "NSW",
    "summary": "Pharmaxis Ltd engages in the research, development, and commercialization of healthcare products for the treatment of fibrotic and inflammatory diseases worldwide. The company operates through two segments, Mannitol business, and New Drug Development. It offers Bronchitol, an inhaled dry powder for the treatment of cystic fibrosis; and Aridol, an airways inflammation test that is used to identify twitchy or hyper-responsive airways, as well as to assist in diagnosing and managing asthma. The company's product pipeline consists of amine oxidase inhibitors comprising semicarbazide-sensitive amine oxidase for diabetic retinopathy; selective lysyl oxidase like inhibitors targeting chronic fibrotic diseases, such as NASH, pulmonary fibrosis, kidney fibrosis, and cardiac fibrosis; and pan-lysyl oxidase inhibitors targeting severe fibrotic indications, which includes cancers and scarring. It is also developing Orbital, a dry powder inhaler to deliver high drug doses to lungs. Pharmaxis Ltd was founded in 1998 and is headquartered in Frenchs Forest, Australia.",
    "website": "http://www.pharmaxis.com.au",
    "zipcode": "2086"
  },
  "UV7.F": {
    "city": "Cremorne",
    "country": "Australia",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Health Information Services",
    "long_name": "TALi Digital Limited",
    "market": "dr_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "TALI DIGITAL LTD",
    "state": "VIC",
    "summary": "TALi Digital Limited engages in the research, development, and commercialization of medical technology in Australia. The company operates through Research and Development; and Investments segments. It offers TALi Train, a mobile software application used by clinicians, educators, and parents for strengthening of core attention in children between the development ages of 3-8; TALi Portal that allows healthcare professionals, educators, and parents to assess a child's daily performance and identify strengths and weaknesses to tailor the program to child's needs; and TALi Detect, which consists of seven tests to profile cognitive attention capabilities of a child. The company was formerly known as Novita Healthcare Limited and changed its name to TALI Digital Limited in December 2019. TALi Digital Limited was incorporated in 2004 and is based in Cremorne, Australia.",
    "website": "http://talidigital.com",
    "zipcode": "3121"
  },
  "UVP.F": {
    "city": "West Perth",
    "country": "Australia",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Drug Manufacturers - Specialty & Generic",
    "long_name": "AusCann Group Holdings Ltd",
    "market": "dr_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "AUSCANN GROUP HLDGS O.N.",
    "state": "WA",
    "summary": "AusCann Group Holdings Ltd, a pharmaceutical company, researches, develops, cultivates, produces, and distributes cannabinoid-based pharmaceuticals in Australia and internationally. It offers hard-shell capsules using Neuvis technology for the treatment of chronic neuropathic pain. The company is based in West Perth, Australia.",
    "website": "http://auscann.com.au",
    "zipcode": "6005"
  },
  "V6H.F": {
    "city": "Greenwich",
    "country": "Australia",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Medical Care Facilities",
    "long_name": "Virtus Health Limited",
    "market": "dr_market",
    "market_cap": "Small Cap",
    "sector": "Healthcare",
    "short_name": "VIRTUS HEALTH LTD",
    "state": "NSW",
    "summary": "Virtus Health Limited provides various healthcare services in Australia, Denmark, the United Kingdom, Ireland, and Singapore. The company operates through two segments, Healthcare Services Australia and Healthcare Services International. The company provides fertility clinics and diagnostics and pathology, as well as day hospital services. It offers in-vitro fertilization (IVF) services. In addition, it offers day hospital procedures, such as non-IVF elective surgery, laparoscopic gynecology procedure, endoscopy, and other surgery. As of August 12, 2020, the company operated through a network of 120 fertility specialists. Virtus Health Limited was founded in 2008 and is headquartered in Greenwich, Australia.",
    "website": "http://www.virtushealth.com.au",
    "zipcode": "2065"
  },
  "VBS.AX": {
    "city": "Rosebery",
    "country": "Australia",
    "currency": "AUD",
    "exchange": "ASX",
    "industry": "Biotechnology",
    "long_name": "Vectus Biosystems Limited",
    "market": "au_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "VECTUS BIO FPO",
    "state": "NSW",
    "summary": "Vectus Biosystems Limited engages in the medical research and development activities in Australia. The company develops treatment for fibrosis and high blood pressure. Its lead compound is VB0004, which has potent anti-hypertensive properties, as well as anti-fibrotic activity in the heart and kidneys. The company also intends to develop candidates for the treatment of fibrotic liver diseases, including non-alcoholic steatohepatitis and pulmonary fibrotic diseases. In addition, it develops AccuCal and RealCount software that improves speed and accuracy of measuring the amount of DNA and RNA in samples tested in laboratories. The company was founded in 2005 and is based in Rosebery, Australia.",
    "website": "http://www.vectusbiosystems.com.au",
    "zipcode": "2018"
  },
  "VLS.AX": {
    "city": "Kirrawee",
    "country": "Australia",
    "currency": "AUD",
    "exchange": "ASX",
    "industry": "Drug Manufacturers - Specialty & Generic",
    "long_name": "Vita Life Sciences Limited",
    "market": "au_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "VLSCIENCE FPO",
    "state": "NSW",
    "summary": "Vita Life Sciences Limited, a pharmaceutical and healthcare company, engages in formulation, packaging, distribution, and sale of vitamins and supplements. It offers a range of supplements, vitamins, minerals, herbs, and superfoods. The company markets its products through pharmacies and health food stores under the Herbs of Gold, VitaHealth, VitaScience, and VitaLife brands. It operates in Australia, Singapore, Malaysia, Thailand, Vietnam, Indonesia, China, and internationally. Vita Life Sciences Limited was founded in 1947 and is headquartered in Kirrawee, Australia.",
    "website": "http://www.vitalifesciences.com",
    "zipcode": "2232"
  },
  "VRT.AX": {
    "city": "Greenwich",
    "country": "Australia",
    "currency": "AUD",
    "exchange": "ASX",
    "industry": "Medical Care Facilities",
    "long_name": "Virtus Health Limited",
    "market": "au_market",
    "market_cap": "Small Cap",
    "sector": "Healthcare",
    "short_name": "VIRTUS FPO",
    "state": "NSW",
    "summary": "Virtus Health Limited provides various healthcare services in Australia, Denmark, the United Kingdom, Ireland, and Singapore. The company operates through two segments, Healthcare Services Australia and Healthcare Services International. The company provides fertility clinics and diagnostics and pathology, as well as day hospital services. It offers in-vitro fertilization (IVF) services. In addition, it offers day hospital procedures, such as non-IVF elective surgery, laparoscopic gynecology procedure, endoscopy, and other surgery. As of August 12, 2020, the company operated through a network of 120 fertility specialists. Virtus Health Limited was founded in 2008 and is headquartered in Greenwich, Australia.",
    "website": "http://www.virtushealth.com.au",
    "zipcode": "2065"
  },
  "WFL.AX": {
    "city": "Leederville",
    "country": "Australia",
    "currency": "AUD",
    "exchange": "ASX",
    "industry": "Diagnostics & Research",
    "long_name": "Wellfully Limited",
    "market": "au_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "WELLFULLYL FPO",
    "state": "WA",
    "summary": "Wellfully Limited develops dermaportation and enhanced transdermal polymer technologies for use in the pharmaceutical, cosmetic and skincare, and consumer healthcare sectors in Australia. The company provides partnering services and product solutions for technologies in transdermal and intra-dermal drug delivery; therapeutic and dermatological skincare; cosmetic and non-medicinal active ingredient; oral health; haircare solutions utilizing enhanced brushes and applicators; high penetration surface hygiene technologies; fabric and carpet cleaning technologies; and industrial surface interface systems. It offers various technology platforms, such as Static Micro-arrays, a film based micro-array technology for patches, masks, dressings, and other topical applications; and Field in Motion Micro-arrays, a magnetic micro-array film for use in brushes, applicators, and wipes; Dermaportation, a product development platform for a range of commercial applications; eSkin, a multi-product delivery system that offers a range of product-specific, time-varying magnetic fields for enhanced delivery of multiple formulations; and measured dose delivery devices and packaging solutions. The company was formerly known as OBJ Limited and changed its name to Wellfully Limited in September 2020. Wellfully Limited was founded in 2004 and is based in Leederville, Australia.",
    "website": "http://www.wellfully.net",
    "zipcode": "6007"
  },
  "YP1A.F": {
    "city": "Sydney",
    "country": "Australia",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Biotechnology",
    "long_name": "Immutep Limited",
    "market": "dr_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "IMMUTEP LTD ADRS II/10",
    "state": "NSW",
    "summary": "Immutep Limited, a biotech company, engages in the research and development of pharmaceutical product candidates. The company develops immunotherapeutic products for the treatment of cancer and autoimmune diseases. Its principal product candidate is IMP321, also known as eftilagimod alpha' or efti', which is a recombinant protein that is in Phase IIb clinical trial as a chemoimmunotherapy combination for metastatic breast cancer termed AIPAC and in a Phase I combination therapy trial in metastatic melanoma termed TACTI-mel; and is being evaluated as a combination therapy in head and neck squamous cell carcinoma and non-small cell lung carcinoma in a Phase II clinical trial called TACTI-002 and an investigator initiated Phase I trial called INSIGHT in advanced solid tumors. Its other products include IMP761, IMP701 and IMP731, all of which are related to lymphocyte activation gene 3, a gene linked to the regulation of T cells in immune responses. Immutep Limited has partnerships with GlaxoSmithKline, Novartis, CYTLIMIC Inc., INSIGHT, and EOC Pharma. The company was formerly known as Prima BioMed Ltd and changed its name to Immutep Limited in November 2017. Immutep Limited was incorporated in 1987 and is based in Sydney, Australia.",
    "website": "http://www.immutep.com",
    "zipcode": "2000"
  },
  "YP1B.F": {
    "city": "Sydney",
    "country": "Australia",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Biotechnology",
    "long_name": "Immutep Limited",
    "market": "dr_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "IMMUTEP LTD",
    "state": "NSW",
    "summary": "Immutep Limited, a biotech company, engages in the research and development of pharmaceutical product candidates. The company develops immunotherapeutic products for the treatment of cancer and autoimmune diseases. Its principal product candidate is IMP321, also known as eftilagimod alpha' or efti', which is a recombinant protein that is in Phase IIb clinical trial as a chemoimmunotherapy combination for metastatic breast cancer termed AIPAC and in a Phase I combination therapy trial in metastatic melanoma termed TACTI-mel; and is being evaluated as a combination therapy in head and neck squamous cell carcinoma and non-small cell lung carcinoma in a Phase II clinical trial called TACTI-002 and an investigator initiated Phase I trial called INSIGHT in advanced solid tumors. Its other products include IMP761, IMP701 and IMP731, all of which are related to lymphocyte activation gene 3, a gene linked to the regulation of T cells in immune responses. Immutep Limited has partnerships with GlaxoSmithKline, Novartis, CYTLIMIC Inc., INSIGHT, and EOC Pharma. The company was formerly known as Prima BioMed Ltd and changed its name to Immutep Limited in November 2017. Immutep Limited was incorporated in 1987 and is based in Sydney, Australia.",
    "website": "http://www.immutep.com",
    "zipcode": "2000"
  },
  "ZLD.AX": {
    "city": "Perth",
    "country": "Australia",
    "currency": "AUD",
    "exchange": "ASX",
    "industry": "Biotechnology",
    "long_name": "Zelira Therapeutics Limited",
    "market": "au_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "ZELIRATHER FPO",
    "state": "WA",
    "summary": "Zelira Therapeutics Limited, a bio-pharmaceutical company, engages in the development of cannabinoid-based formulations for the treatment of various medical conditions in Australia. It offers formulations under the HOPE brand in Pennsylvania and licenses in Louisiana, as well as develops Zenivol, a cannabinoid-based medicine for treatment of chronic insomnia. The company is also involved in a human clinical trial program focused on insomnia, autism, and opioid reduction; and a pre-clinical research program to examine the effect of cannabinoids in breast, brain, and pancreatic cancer, as well as the potential for cannabinoid formulations to treat diabetes-associated cognitive decline. It has a strategic partnership with CannPal Pty Ltd; and St Vincent's Hospital on opioid reduction study. The company was formerly known as Zelda Therapeutics Limited and changed its name to Zelira Therapeutics Limited in December 2019. Zelira Therapeutics Limited is based in Perth, Australia.",
    "website": "http://www.zeliratx.com",
    "zipcode": "6000"
  },
  "ZLDAF": {
    "city": "Perth",
    "country": "Australia",
    "currency": "USD",
    "exchange": "PNK",
    "industry": "Biotechnology",
    "long_name": "Zelira Therapeutics Limited",
    "market": "us_market",
    "market_cap": "Nano Cap",
    "sector": "Healthcare",
    "short_name": "ZELIRA THERAPEUTICS LTD",
    "state": "WA",
    "summary": "Zelira Therapeutics Limited, a bio-pharmaceutical company, engages in the development of cannabinoid-based formulations for the treatment of various medical conditions in Australia. It offers formulations under the HOPE brand in Pennsylvania and licenses in Louisiana, as well as develops Zenivol, a cannabinoid-based medicine for treatment of chronic insomnia. The company is also involved in a human clinical trial program focused on insomnia, autism, and opioid reduction; and a pre-clinical research program to examine the effect of cannabinoids in breast, brain, and pancreatic cancer, as well as the potential for cannabinoid formulations to treat diabetes-associated cognitive decline. It has a strategic partnership with CannPal Pty Ltd; and St Vincent's Hospital on opioid reduction study. The company was formerly known as Zelda Therapeutics Limited and changed its name to Zelira Therapeutics Limited in December 2019. Zelira Therapeutics Limited is based in Perth, Australia.",
    "website": "http://www.zeliratx.com",
    "zipcode": "6000"
  }
}
